\contentsline {chapter}{\numberline {1}Foreword}{13}{chapter.1}%
\contentsline {chapter}{\numberline {2}Rapid Reference}{17}{chapter.2}%
\contentsline {section}{\numberline {2.1}Calling for Help}{17}{section.2.1}%
\contentsline {section}{\numberline {2.2}PALS}{18}{section.2.2}%
\contentsline {subsection}{\numberline {2.2.1}Shock}{28}{subsection.2.2.1}%
\contentsline {subsubsection}{\numberline {2.2.1.1}Distributive Shock}{28}{subsubsection.2.2.1.1}%
\contentsline {subsubsection}{\numberline {2.2.1.2}Cardiogenic Shock}{29}{subsubsection.2.2.1.2}%
\contentsline {subsubsection}{\numberline {2.2.1.3}Obstructive Shock}{29}{subsubsection.2.2.1.3}%
\contentsline {subsection}{\numberline {2.2.2}Respiratory Emergencies}{30}{subsection.2.2.2}%
\contentsline {section}{\numberline {2.3}Infectious Disease}{31}{section.2.3}%
\contentsline {subsection}{\numberline {2.3.1}Sepsis Huddle}{31}{subsection.2.3.1}%
\contentsline {subsection}{\numberline {2.3.2}CSF Analysis}{32}{subsection.2.3.2}%
\contentsline {subsubsection}{\numberline {2.3.2.1}General Heuristics for CSF Interpretation"}{32}{subsubsection.2.3.2.1}%
\contentsline {section}{\numberline {2.4}Respiratory}{33}{section.2.4}%
\contentsline {subsection}{\numberline {2.4.1}Status Asthmaticus}{33}{subsection.2.4.1}%
\contentsline {subsubsection}{\numberline {2.4.1.1}A-B-C}{33}{subsubsection.2.4.1.1}%
\contentsline {subsubsection}{\numberline {2.4.1.2}Initial treatment}{33}{subsubsection.2.4.1.2}%
\contentsline {subsubsection}{\numberline {2.4.1.3}If poor response, add}{34}{subsubsection.2.4.1.3}%
\contentsline {subsubsection}{\numberline {2.4.1.4}If poor response continues, add}{34}{subsubsection.2.4.1.4}%
\contentsline {subsubsection}{\numberline {2.4.1.5}If impending respiratory failure}{34}{subsubsection.2.4.1.5}%
\contentsline {subsubsection}{\numberline {2.4.1.6}As patient improves}{34}{subsubsection.2.4.1.6}%
\contentsline {subsection}{\numberline {2.4.2}ABGs \& VBGs}{34}{subsection.2.4.2}%
\contentsline {subsubsection}{\numberline {2.4.2.1}Stepwise Approach to ABG/VBG Interpretation}{35}{subsubsection.2.4.2.1}%
\contentsline {subsubsection}{\numberline {2.4.2.2}Normal Blood Gas Values}{35}{subsubsection.2.4.2.2}%
\contentsline {subsubsection}{\numberline {2.4.2.3}Compensation}{35}{subsubsection.2.4.2.3}%
\contentsline {subsection}{\numberline {2.4.3}Respiratory Support for Spontaneously Breathing Patients}{36}{subsection.2.4.3}%
\contentsline {subsection}{\numberline {2.4.4}Trach Troubleshooting}{38}{subsection.2.4.4}%
\contentsline {subsubsection}{\numberline {2.4.4.1}Tracheostomy Basics}{38}{subsubsection.2.4.4.1}%
\contentsline {section}{\numberline {2.5}Status Epilepticus (SE)}{39}{section.2.5}%
\contentsline {subsection}{\numberline {2.5.1}PowerPlans \& Order Sets}{39}{subsection.2.5.1}%
\contentsline {subsection}{\numberline {2.5.2}Definition}{39}{subsection.2.5.2}%
\contentsline {subsection}{\numberline {2.5.3}Presentation}{40}{subsection.2.5.3}%
\contentsline {subsection}{\numberline {2.5.4}Differential}{40}{subsection.2.5.4}%
\contentsline {subsection}{\numberline {2.5.5}Management}{40}{subsection.2.5.5}%
\contentsline {section}{\numberline {2.6}Psychiatric}{40}{section.2.6}%
\contentsline {subsection}{\numberline {2.6.1}Anxiety, Agitation \& Delirium}{40}{subsection.2.6.1}%
\contentsline {subsubsection}{\numberline {2.6.1.1}Definition}{40}{subsubsection.2.6.1.1}%
\contentsline {subsubsection}{\numberline {2.6.1.2}Anxiety}{41}{subsubsection.2.6.1.2}%
\contentsline {subsubsection}{\numberline {2.6.1.3}Agitation}{41}{subsubsection.2.6.1.3}%
\contentsline {subsubsection}{\numberline {2.6.1.4}Delirium}{41}{subsubsection.2.6.1.4}%
\contentsline {subsubsection}{\numberline {2.6.1.5}Management}{41}{subsubsection.2.6.1.5}%
\contentsline {subsection}{\numberline {2.6.2}Overnight Behavioral Plan}{42}{subsection.2.6.2}%
\contentsline {chapter}{\numberline {3}Adolescent Medicine}{43}{chapter.3}%
\contentsline {section}{\numberline {3.1}BCH Wards Tips}{43}{section.3.1}%
\contentsline {subsubsection}{\numberline {3.1.0.1}Primary diagnoses}{43}{subsubsection.3.1.0.1}%
\contentsline {subsubsection}{\numberline {3.1.0.2}Format}{43}{subsubsection.3.1.0.2}%
\contentsline {section}{\numberline {3.2}Adolescent Clinic Tips}{43}{section.3.2}%
\contentsline {subsection}{\numberline {3.2.1}Overview}{43}{subsection.3.2.1}%
\contentsline {subsection}{\numberline {3.2.2}BCH Adolescent Clinic Specifics}{44}{subsection.3.2.2}%
\contentsline {subsection}{\numberline {3.2.3}BMC Adolescent Clinic Specifics}{44}{subsection.3.2.3}%
\contentsline {section}{\numberline {3.3}HEEADSSS Assessment}{44}{section.3.3}%
\contentsline {subsection}{\numberline {3.3.1}Home}{45}{subsection.3.3.1}%
\contentsline {subsection}{\numberline {3.3.2}Education and/or Employment}{45}{subsection.3.3.2}%
\contentsline {subsection}{\numberline {3.3.3}Eating}{46}{subsection.3.3.3}%
\contentsline {subsection}{\numberline {3.3.4}Activities}{46}{subsection.3.3.4}%
\contentsline {subsection}{\numberline {3.3.5}Drugs}{46}{subsection.3.3.5}%
\contentsline {subsection}{\numberline {3.3.6}Sexuality}{46}{subsection.3.3.6}%
\contentsline {subsection}{\numberline {3.3.7}Suicide \& Depression/Mood}{47}{subsection.3.3.7}%
\contentsline {subsection}{\numberline {3.3.8}Safety}{47}{subsection.3.3.8}%
\contentsline {section}{\numberline {3.4}Adolescent Screening Tools}{48}{section.3.4}%
\contentsline {section}{\numberline {3.5}Contraception}{48}{section.3.5}%
\contentsline {subsection}{\numberline {3.5.1}Emergency Contraception (EC)}{48}{subsection.3.5.1}%
\contentsline {subsection}{\numberline {3.5.2}Shared Decision Making (SDM)}{51}{subsection.3.5.2}%
\contentsline {subsection}{\numberline {3.5.3}Applying SDM Principles to Contraceptive Counseling Visits}{51}{subsection.3.5.3}%
\contentsline {subsubsection}{\numberline {3.5.3.1}Establish rapport}{51}{subsubsection.3.5.3.1}%
\contentsline {subsubsection}{\numberline {3.5.3.2}Assess patient readiness}{52}{subsubsection.3.5.3.2}%
\contentsline {subsubsection}{\numberline {3.5.3.3}Tailor information and discussion to patient preferences/needs}{52}{subsubsection.3.5.3.3}%
\contentsline {subsubsection}{\numberline {3.5.3.4}Discuss contraception side effects}{52}{subsubsection.3.5.3.4}%
\contentsline {subsubsection}{\numberline {3.5.3.5}Identify misconceptions about specific contraception methods}{53}{subsubsection.3.5.3.5}%
\contentsline {subsubsection}{\numberline {3.5.3.6}Ensure access to method discontinuation at any time}{53}{subsubsection.3.5.3.6}%
\contentsline {section}{\numberline {3.6}Tanner Staging}{55}{section.3.6}%
\contentsline {section}{\numberline {3.7}Vaginal Discharge and Infections}{56}{section.3.7}%
\contentsline {section}{\numberline {3.8}HIV}{60}{section.3.8}%
\contentsline {subsection}{\numberline {3.8.1}Signs \& Symptoms}{60}{subsection.3.8.1}%
\contentsline {subsection}{\numberline {3.8.2}Diagnosis}{61}{subsection.3.8.2}%
\contentsline {subsection}{\numberline {3.8.3}PEP vs.\nobreakspace {}PrEP}{61}{subsection.3.8.3}%
\contentsline {section}{\numberline {3.9}Genital Ulcers and Warts}{62}{section.3.9}%
\contentsline {section}{\numberline {3.10}Pelvic Inflammatory Disease (PID)}{66}{section.3.10}%
\contentsline {subsection}{\numberline {3.10.1}PowerPlans / Order Sets / EBGs}{66}{subsection.3.10.1}%
\contentsline {subsection}{\numberline {3.10.2}Pathophysiology}{66}{subsection.3.10.2}%
\contentsline {subsection}{\numberline {3.10.3}Etiology}{66}{subsection.3.10.3}%
\contentsline {subsection}{\numberline {3.10.4}Clinical Manifestations}{66}{subsection.3.10.4}%
\contentsline {subsection}{\numberline {3.10.5}Physical Exam}{67}{subsection.3.10.5}%
\contentsline {subsection}{\numberline {3.10.6}Evaluation}{67}{subsection.3.10.6}%
\contentsline {subsection}{\numberline {3.10.7}Management}{67}{subsection.3.10.7}%
\contentsline {subsubsection}{\numberline {3.10.7.1}Outpatient}{67}{subsubsection.3.10.7.1}%
\contentsline {subsubsection}{\numberline {3.10.7.2}Inpatient}{67}{subsubsection.3.10.7.2}%
\contentsline {section}{\numberline {3.11}Heavy or Irregular Menstrual Bleeding}{67}{section.3.11}%
\contentsline {subsection}{\numberline {3.11.1}PowerPlans / Order Sets / EBGs}{67}{subsection.3.11.1}%
\contentsline {subsection}{\numberline {3.11.2}Definition}{67}{subsection.3.11.2}%
\contentsline {subsection}{\numberline {3.11.3}Differential Diagnosis}{67}{subsection.3.11.3}%
\contentsline {subsection}{\numberline {3.11.4}Clinical Manifestations}{68}{subsection.3.11.4}%
\contentsline {subsection}{\numberline {3.11.5}Evaluation}{68}{subsection.3.11.5}%
\contentsline {subsection}{\numberline {3.11.6}Management}{68}{subsection.3.11.6}%
\contentsline {section}{\numberline {3.12}Amenorrhea}{68}{section.3.12}%
\contentsline {subsection}{\numberline {3.12.1}Definition}{68}{subsection.3.12.1}%
\contentsline {subsection}{\numberline {3.12.2}Pathophysiology}{68}{subsection.3.12.2}%
\contentsline {subsection}{\numberline {3.12.3}Clinical Manifestations}{69}{subsection.3.12.3}%
\contentsline {subsection}{\numberline {3.12.4}Physical Exam}{69}{subsection.3.12.4}%
\contentsline {subsection}{\numberline {3.12.5}Evaluation}{69}{subsection.3.12.5}%
\contentsline {subsection}{\numberline {3.12.6}Management}{70}{subsection.3.12.6}%
\contentsline {section}{\numberline {3.13}Gender Affirming Care}{70}{section.3.13}%
\contentsline {subsection}{\numberline {3.13.1}Why}{70}{subsection.3.13.1}%
\contentsline {subsection}{\numberline {3.13.2}How}{70}{subsection.3.13.2}%
\contentsline {subsection}{\numberline {3.13.3}Gender Affirming Care Clinics}{70}{subsection.3.13.3}%
\contentsline {subsection}{\numberline {3.13.4}\href {https://www.genderbread.org/}{The Genderbread Person}}{72}{subsection.3.13.4}%
\contentsline {section}{\numberline {3.14}Eating Disorders (ED)}{73}{section.3.14}%
\contentsline {subsection}{\numberline {3.14.1}Anorexia Nervosa (AN)}{73}{subsection.3.14.1}%
\contentsline {subsubsection}{\numberline {3.14.1.1}PowerPlans / Order Sets / EBGs}{73}{subsubsection.3.14.1.1}%
\contentsline {subsubsection}{\numberline {3.14.1.2}Definition}{73}{subsubsection.3.14.1.2}%
\contentsline {subsubsection}{\numberline {3.14.1.3}Clinical Manifestations}{73}{subsubsection.3.14.1.3}%
\contentsline {subsubsection}{\numberline {3.14.1.4}Physical Exam}{73}{subsubsection.3.14.1.4}%
\contentsline {subsubsection}{\numberline {3.14.1.5}Evaluation}{73}{subsubsection.3.14.1.5}%
\contentsline {subsubsection}{\numberline {3.14.1.6}Inpatient Management}{73}{subsubsection.3.14.1.6}%
\contentsline {subsection}{\numberline {3.14.2}Bulimia Nervosa (BN)}{74}{subsection.3.14.2}%
\contentsline {subsubsection}{\numberline {3.14.2.1}Definition}{74}{subsubsection.3.14.2.1}%
\contentsline {subsubsection}{\numberline {3.14.2.2}Clinical Manifestations}{74}{subsubsection.3.14.2.2}%
\contentsline {subsubsection}{\numberline {3.14.2.3}Physical Exam}{74}{subsubsection.3.14.2.3}%
\contentsline {subsubsection}{\numberline {3.14.2.4}Evaluation}{74}{subsubsection.3.14.2.4}%
\contentsline {subsubsection}{\numberline {3.14.2.5}Inpatient Management}{74}{subsubsection.3.14.2.5}%
\contentsline {subsection}{\numberline {3.14.3}Acute Refusal of Food Intake Disorder (ARFID)}{75}{subsection.3.14.3}%
\contentsline {subsubsection}{\numberline {3.14.3.1}PowerPlans / Order Sets / EBGs}{75}{subsubsection.3.14.3.1}%
\contentsline {subsubsection}{\numberline {3.14.3.2}Definition}{75}{subsubsection.3.14.3.2}%
\contentsline {subsubsection}{\numberline {3.14.3.3}Pathophysiology}{75}{subsubsection.3.14.3.3}%
\contentsline {subsubsection}{\numberline {3.14.3.4}Clinical Manifestations}{75}{subsubsection.3.14.3.4}%
\contentsline {subsubsection}{\numberline {3.14.3.5}Evaluation}{75}{subsubsection.3.14.3.5}%
\contentsline {subsubsection}{\numberline {3.14.3.6}Inpatient Management}{75}{subsubsection.3.14.3.6}%
\contentsline {section}{\numberline {3.15}References}{75}{section.3.15}%
\contentsline {chapter}{\numberline {4}Allergy and Immunology}{77}{chapter.4}%
\contentsline {section}{\numberline {4.1}Adverse Drug Reactions}{77}{section.4.1}%
\contentsline {subsection}{\numberline {4.1.1}Type A}{77}{subsection.4.1.1}%
\contentsline {subsection}{\numberline {4.1.2}Type B}{77}{subsection.4.1.2}%
\contentsline {subsection}{\numberline {4.1.3}Organ-specific ADRs}{78}{subsection.4.1.3}%
\contentsline {subsection}{\numberline {4.1.4}Multiorgan ADRs}{78}{subsection.4.1.4}%
\contentsline {section}{\numberline {4.2}Anaphylaxis}{79}{section.4.2}%
\contentsline {subsection}{\numberline {4.2.1}Allergens}{79}{subsection.4.2.1}%
\contentsline {subsection}{\numberline {4.2.2}Clinical}{80}{subsection.4.2.2}%
\contentsline {subsection}{\numberline {4.2.3}Severe Reaction}{80}{subsection.4.2.3}%
\contentsline {subsection}{\numberline {4.2.4}Management \textbf {Emergent}}{82}{subsection.4.2.4}%
\contentsline {subsection}{\numberline {4.2.5}Med Dosing}{85}{subsection.4.2.5}%
\contentsline {subsection}{\numberline {4.2.6}ED Discharge Criteria}{85}{subsection.4.2.6}%
\contentsline {subsection}{\numberline {4.2.7}Post-discharge Treatment}{85}{subsection.4.2.7}%
\contentsline {section}{\numberline {4.3}Primary Immunodeficiencies}{85}{section.4.3}%
\contentsline {subsection}{\numberline {4.3.1}Pathophysiology}{85}{subsection.4.3.1}%
\contentsline {subsection}{\numberline {4.3.2}Epidemiology}{85}{subsection.4.3.2}%
\contentsline {subsection}{\numberline {4.3.3}\textbf {Physical Exam}}{85}{subsection.4.3.3}%
\contentsline {subsection}{\numberline {4.3.4}Diagnosis}{86}{subsection.4.3.4}%
\contentsline {subsection}{\numberline {4.3.5}Treatment}{86}{subsection.4.3.5}%
\contentsline {section}{\numberline {4.4}Indications for a Primary Immunodeficiency Evaluation}{87}{section.4.4}%
\contentsline {section}{\numberline {4.5}Diagnostic Approach to Primary Immunodeficiencies}{87}{section.4.5}%
\contentsline {subsection}{\numberline {4.5.1}Initial Labs (most cases)}{87}{subsection.4.5.1}%
\contentsline {subsection}{\numberline {4.5.2}Next Step}{87}{subsection.4.5.2}%
\contentsline {subsection}{\numberline {4.5.3}Advanced (Depending on specific history)}{87}{subsection.4.5.3}%
\contentsline {section}{\numberline {4.6}Classification of Primary Immunodeficiencies}{88}{section.4.6}%
\contentsline {subsection}{\numberline {4.6.1}B-cell (Humoral): decreased B-cell numbers and/or impaired antibody production}{88}{subsection.4.6.1}%
\contentsline {subsection}{\numberline {4.6.2}T-cell Defects}{88}{subsection.4.6.2}%
\contentsline {subsection}{\numberline {4.6.3}Combined B/T Cell Defect}{89}{subsection.4.6.3}%
\contentsline {subsubsection}{\numberline {4.6.3.1}Diseases}{89}{subsubsection.4.6.3.1}%
\contentsline {subsubsection}{\numberline {4.6.3.2}Clinical Manifestations}{89}{subsubsection.4.6.3.2}%
\contentsline {subsection}{\numberline {4.6.4}Phagocytic Defects}{89}{subsection.4.6.4}%
\contentsline {subsubsection}{\numberline {4.6.4.1}Diseases}{89}{subsubsection.4.6.4.1}%
\contentsline {subsubsection}{\numberline {4.6.4.2}Clinical Manifestations}{89}{subsubsection.4.6.4.2}%
\contentsline {subsubsection}{\numberline {4.6.4.3}Organisms}{90}{subsubsection.4.6.4.3}%
\contentsline {subsubsection}{\numberline {4.6.4.4}Vaccine Issues}{90}{subsubsection.4.6.4.4}%
\contentsline {subsection}{\numberline {4.6.5}Complement Defects}{90}{subsection.4.6.5}%
\contentsline {subsubsection}{\numberline {4.6.5.1}Diseases Classical pathway:}{90}{subsubsection.4.6.5.1}%
\contentsline {subsubsection}{\numberline {4.6.5.2}Clinical Manifestations}{90}{subsubsection.4.6.5.2}%
\contentsline {subsubsection}{\numberline {4.6.5.3}Organisms Encapsulated bacteria, Neisseria}{91}{subsubsection.4.6.5.3}%
\contentsline {subsubsection}{\numberline {4.6.5.4}Vaccine Issues}{91}{subsubsection.4.6.5.4}%
\contentsline {section}{\numberline {4.7}Selected Primary Immunodeficiencies}{91}{section.4.7}%
\contentsline {section}{\numberline {4.8}Selected Immunodeficiencies}{96}{section.4.8}%
\contentsline {section}{\numberline {4.9}Specific Antibody Deficiencies}{98}{section.4.9}%
\contentsline {section}{\numberline {4.10}Characteristics of Selected SCID disorders}{98}{section.4.10}%
\contentsline {subsection}{\numberline {4.10.1}T-, B+, SCID}{98}{subsection.4.10.1}%
\contentsline {subsubsection}{\numberline {4.10.1.1}Gene defects}{98}{subsubsection.4.10.1.1}%
\contentsline {subsubsection}{\numberline {4.10.1.2}Treatment Bone marrow transplant or gene therapy (IL2RG)}{98}{subsubsection.4.10.1.2}%
\contentsline {subsection}{\numberline {4.10.2}T-, B-, SCID}{98}{subsection.4.10.2}%
\contentsline {subsubsection}{\numberline {4.10.2.1}Gene defects}{99}{subsubsection.4.10.2.1}%
\contentsline {subsubsection}{\numberline {4.10.2.2}Treatment}{99}{subsubsection.4.10.2.2}%
\contentsline {section}{\numberline {4.11}General Approach to the Immunodeficient Patient}{99}{section.4.11}%
\contentsline {chapter}{\numberline {5}Cardiology}{101}{chapter.5}%
\contentsline {section}{\numberline {5.1}Cardiology Rotation Tips}{101}{section.5.1}%
\contentsline {subsubsection}{\numberline {5.1.0.1}Team Structure}{101}{subsubsection.5.1.0.1}%
\contentsline {subsubsection}{\numberline {5.1.0.2}Admissions}{101}{subsubsection.5.1.0.2}%
\contentsline {subsubsection}{\numberline {5.1.0.3}Resources}{102}{subsubsection.5.1.0.3}%
\contentsline {section}{\numberline {5.2}Disaster Planning}{102}{section.5.2}%
\contentsline {subsubsection}{\numberline {5.2.0.1}Know and use your resources!!!}{102}{subsubsection.5.2.0.1}%
\contentsline {section}{\numberline {5.3}EKG Approach}{103}{section.5.3}%
\contentsline {subsection}{\numberline {5.3.1}Ventricular Rate}{103}{subsection.5.3.1}%
\contentsline {subsection}{\numberline {5.3.2}Rhythm}{103}{subsection.5.3.2}%
\contentsline {subsection}{\numberline {5.3.3}QRS Axis}{103}{subsection.5.3.3}%
\contentsline {subsection}{\numberline {5.3.4}Intervals \& Segments}{104}{subsection.5.3.4}%
\contentsline {subsubsection}{\numberline {5.3.4.1}PR interval}{104}{subsubsection.5.3.4.1}%
\contentsline {subsubsection}{\numberline {5.3.4.2}QRS interval}{104}{subsubsection.5.3.4.2}%
\contentsline {subsubsection}{\numberline {5.3.4.3}QT interval}{104}{subsubsection.5.3.4.3}%
\contentsline {subsubsection}{\numberline {5.3.4.4}Q wave}{104}{subsubsection.5.3.4.4}%
\contentsline {subsubsection}{\numberline {5.3.4.5}U wave}{105}{subsubsection.5.3.4.5}%
\contentsline {subsubsection}{\numberline {5.3.4.6}ST segment}{105}{subsubsection.5.3.4.6}%
\contentsline {subsubsection}{\numberline {5.3.4.7}R/S progression}{105}{subsubsection.5.3.4.7}%
\contentsline {subsubsection}{\numberline {5.3.4.8}T waves}{106}{subsubsection.5.3.4.8}%
\contentsline {subsection}{\numberline {5.3.5}Chamber Size}{106}{subsection.5.3.5}%
\contentsline {subsubsection}{\numberline {5.3.5.1}R atrial enlargement (RAE)}{106}{subsubsection.5.3.5.1}%
\contentsline {subsubsection}{\numberline {5.3.5.2}L atrial enlargement (LAE)}{106}{subsubsection.5.3.5.2}%
\contentsline {subsubsection}{\numberline {5.3.5.3}L ventricular hypertrophy (LVH)}{106}{subsubsection.5.3.5.3}%
\contentsline {subsubsection}{\numberline {5.3.5.4}R ventricular hypertrophy (RVH)}{106}{subsubsection.5.3.5.4}%
\contentsline {subsubsection}{\numberline {5.3.5.5}Strain}{107}{subsubsection.5.3.5.5}%
\contentsline {subsection}{\numberline {5.3.6}Normal EKG values by age}{107}{subsection.5.3.6}%
\contentsline {section}{\numberline {5.4}Other Cardiac Work-Up}{107}{section.5.4}%
\contentsline {subsection}{\numberline {5.4.1}Chest X-Ray (CXR)}{107}{subsection.5.4.1}%
\contentsline {subsection}{\numberline {5.4.2}What to do next\ldots {}}{108}{subsection.5.4.2}%
\contentsline {subsection}{\numberline {5.4.3}When to start prostaglandins}{108}{subsection.5.4.3}%
\contentsline {section}{\numberline {5.5}Common Cardiology Concerns}{108}{section.5.5}%
\contentsline {subsection}{\numberline {5.5.1}Hyperlipidemia (HLD)}{108}{subsection.5.5.1}%
\contentsline {subsubsection}{\numberline {5.5.1.1}Screening}{108}{subsubsection.5.5.1.1}%
\contentsline {subsubsection}{\numberline {5.5.1.2}Diagnosis}{108}{subsubsection.5.5.1.2}%
\contentsline {subsubsection}{\numberline {5.5.1.3}Management}{109}{subsubsection.5.5.1.3}%
\contentsline {subsection}{\numberline {5.5.2}Hypertension (HTN)}{109}{subsection.5.5.2}%
\contentsline {subsubsection}{\numberline {5.5.2.1}Screening}{109}{subsubsection.5.5.2.1}%
\contentsline {subsubsection}{\numberline {5.5.2.2}Diagnosis}{109}{subsubsection.5.5.2.2}%
\contentsline {subsubsection}{\numberline {5.5.2.3}Management}{109}{subsubsection.5.5.2.3}%
\contentsline {subsubsection}{\numberline {5.5.2.4}Work-up}{109}{subsubsection.5.5.2.4}%
\contentsline {subsection}{\numberline {5.5.3}Evaluating Murmurs (including in a newborn)}{110}{subsection.5.5.3}%
\contentsline {subsubsection}{\numberline {5.5.3.1}History}{110}{subsubsection.5.5.3.1}%
\contentsline {subsubsection}{\numberline {5.5.3.2}Physical Exam}{110}{subsubsection.5.5.3.2}%
\contentsline {subsubsection}{\numberline {5.5.3.3}Is it innocent or pathologic?}{110}{subsubsection.5.5.3.3}%
\contentsline {subsubsection}{\numberline {5.5.3.4}Work-up}{110}{subsubsection.5.5.3.4}%
\contentsline {subsubsection}{\numberline {5.5.3.5}Common Innocent Murmurs}{110}{subsubsection.5.5.3.5}%
\contentsline {section}{\numberline {5.6}Arrhythmias \& Pacemakers}{111}{section.5.6}%
\contentsline {subsection}{\numberline {5.6.1}Causes of Palpitations}{111}{subsection.5.6.1}%
\contentsline {subsubsection}{\numberline {5.6.1.1}Cardiac}{111}{subsubsection.5.6.1.1}%
\contentsline {subsubsection}{\numberline {5.6.1.2}Non-cardiac}{111}{subsubsection.5.6.1.2}%
\contentsline {subsection}{\numberline {5.6.2}Premature Ventricular Contractions (PVCs)}{111}{subsection.5.6.2}%
\contentsline {subsubsection}{\numberline {5.6.2.1}Presentation}{111}{subsubsection.5.6.2.1}%
\contentsline {subsubsection}{\numberline {5.6.2.2}Presentation}{111}{subsubsection.5.6.2.2}%
\contentsline {subsubsection}{\numberline {5.6.2.3}Pathophysiology}{111}{subsubsection.5.6.2.3}%
\contentsline {subsubsection}{\numberline {5.6.2.4}Work-up}{111}{subsubsection.5.6.2.4}%
\contentsline {subsubsection}{\numberline {5.6.2.5}Treatment}{111}{subsubsection.5.6.2.5}%
\contentsline {subsection}{\numberline {5.6.3}Premature Atrial Contractions (PACs)}{112}{subsection.5.6.3}%
\contentsline {subsubsection}{\numberline {5.6.3.1}Presentation}{112}{subsubsection.5.6.3.1}%
\contentsline {subsubsection}{\numberline {5.6.3.2}Pathophysiology}{112}{subsubsection.5.6.3.2}%
\contentsline {subsubsection}{\numberline {5.6.3.3}Work-up}{112}{subsubsection.5.6.3.3}%
\contentsline {subsubsection}{\numberline {5.6.3.4}Treatment}{112}{subsubsection.5.6.3.4}%
\contentsline {subsection}{\numberline {5.6.4}Sinus Bradycardia}{112}{subsection.5.6.4}%
\contentsline {subsubsection}{\numberline {5.6.4.1}Presentation}{112}{subsubsection.5.6.4.1}%
\contentsline {subsubsection}{\numberline {5.6.4.2}Pathophysiology}{112}{subsubsection.5.6.4.2}%
\contentsline {subsubsection}{\numberline {5.6.4.3}Work-up}{112}{subsubsection.5.6.4.3}%
\contentsline {subsubsection}{\numberline {5.6.4.4}Treatment}{113}{subsubsection.5.6.4.4}%
\contentsline {subsection}{\numberline {5.6.5}AV Block}{113}{subsection.5.6.5}%
\contentsline {subsection}{\numberline {5.6.6}Supraventricular Tachycardia (SVT)}{113}{subsection.5.6.6}%
\contentsline {subsubsection}{\numberline {5.6.6.1}Presentation}{113}{subsubsection.5.6.6.1}%
\contentsline {subsubsection}{\numberline {5.6.6.2}Work-up}{114}{subsubsection.5.6.6.2}%
\contentsline {subsubsection}{\numberline {5.6.6.3}Treatment}{114}{subsubsection.5.6.6.3}%
\contentsline {subsection}{\numberline {5.6.7}Wolff-Parkinson-White Syndrome}{114}{subsection.5.6.7}%
\contentsline {subsubsection}{\numberline {5.6.7.1}Presentation}{114}{subsubsection.5.6.7.1}%
\contentsline {subsubsection}{\numberline {5.6.7.2}Pathophysiology}{114}{subsubsection.5.6.7.2}%
\contentsline {subsubsection}{\numberline {5.6.7.3}Work-up}{114}{subsubsection.5.6.7.3}%
\contentsline {subsubsection}{\numberline {5.6.7.4}Treatment}{114}{subsubsection.5.6.7.4}%
\contentsline {subsection}{\numberline {5.6.8}Ventricular Tachycardia (VT/VTach) and Ventricular Fibrillation (VF/VFib)}{114}{subsection.5.6.8}%
\contentsline {subsubsection}{\numberline {5.6.8.1}Presentation}{114}{subsubsection.5.6.8.1}%
\contentsline {subsubsection}{\numberline {5.6.8.2}Pathophysiology}{114}{subsubsection.5.6.8.2}%
\contentsline {subsubsection}{\numberline {5.6.8.3}Work-up}{115}{subsubsection.5.6.8.3}%
\contentsline {subsubsection}{\numberline {5.6.8.4}Treatment}{115}{subsubsection.5.6.8.4}%
\contentsline {subsection}{\numberline {5.6.9}Long QT Syndrome}{115}{subsection.5.6.9}%
\contentsline {subsubsection}{\numberline {5.6.9.1}Presentation}{115}{subsubsection.5.6.9.1}%
\contentsline {subsubsection}{\numberline {5.6.9.2}Pathophysiology}{115}{subsubsection.5.6.9.2}%
\contentsline {subsubsection}{\numberline {5.6.9.3}Work-up}{116}{subsubsection.5.6.9.3}%
\contentsline {subsubsection}{\numberline {5.6.9.4}Treatment}{116}{subsubsection.5.6.9.4}%
\contentsline {subsection}{\numberline {5.6.10}Pacemakers}{116}{subsection.5.6.10}%
\contentsline {subsubsection}{\numberline {5.6.10.1}Positions}{116}{subsubsection.5.6.10.1}%
\contentsline {subsubsection}{\numberline {5.6.10.2}Settings}{116}{subsubsection.5.6.10.2}%
\contentsline {section}{\numberline {5.7}Acyanotic Congenital Heart Disease (CHD)}{117}{section.5.7}%
\contentsline {subsection}{\numberline {5.7.1}Atrial Septal Defect (ASD)}{117}{subsection.5.7.1}%
\contentsline {subsubsection}{\numberline {5.7.1.1}Lesion}{117}{subsubsection.5.7.1.1}%
\contentsline {subsubsection}{\numberline {5.7.1.2}Basics}{117}{subsubsection.5.7.1.2}%
\contentsline {subsubsection}{\numberline {5.7.1.3}Presentation}{118}{subsubsection.5.7.1.3}%
\contentsline {subsubsection}{\numberline {5.7.1.4}Studies}{118}{subsubsection.5.7.1.4}%
\contentsline {subsubsection}{\numberline {5.7.1.5}Treatment}{118}{subsubsection.5.7.1.5}%
\contentsline {subsection}{\numberline {5.7.2}Ventricular Septal Defect (VSD)}{118}{subsection.5.7.2}%
\contentsline {subsubsection}{\numberline {5.7.2.1}Lesion}{119}{subsubsection.5.7.2.1}%
\contentsline {subsubsection}{\numberline {5.7.2.2}Basics}{119}{subsubsection.5.7.2.2}%
\contentsline {subsubsection}{\numberline {5.7.2.3}Presentation}{120}{subsubsection.5.7.2.3}%
\contentsline {subsubsection}{\numberline {5.7.2.4}Studies}{120}{subsubsection.5.7.2.4}%
\contentsline {subsubsection}{\numberline {5.7.2.5}Treatment}{120}{subsubsection.5.7.2.5}%
\contentsline {subsection}{\numberline {5.7.3}Patent Ductus Arteriosis (PDA)}{120}{subsection.5.7.3}%
\contentsline {subsubsection}{\numberline {5.7.3.1}Lesion}{121}{subsubsection.5.7.3.1}%
\contentsline {subsubsection}{\numberline {5.7.3.2}Basics}{121}{subsubsection.5.7.3.2}%
\contentsline {subsubsection}{\numberline {5.7.3.3}Presentation}{121}{subsubsection.5.7.3.3}%
\contentsline {subsubsection}{\numberline {5.7.3.4}Studies}{121}{subsubsection.5.7.3.4}%
\contentsline {subsubsection}{\numberline {5.7.3.5}Treatment}{122}{subsubsection.5.7.3.5}%
\contentsline {subsection}{\numberline {5.7.4}AV Canal Defects (AVCD)}{122}{subsection.5.7.4}%
\contentsline {subsubsection}{\numberline {5.7.4.1}Lesion}{122}{subsubsection.5.7.4.1}%
\contentsline {subsubsection}{\numberline {5.7.4.2}Basics}{122}{subsubsection.5.7.4.2}%
\contentsline {subsubsection}{\numberline {5.7.4.3}Presentation}{123}{subsubsection.5.7.4.3}%
\contentsline {subsubsection}{\numberline {5.7.4.4}Studies}{123}{subsubsection.5.7.4.4}%
\contentsline {subsubsection}{\numberline {5.7.4.5}Treatment}{123}{subsubsection.5.7.4.5}%
\contentsline {subsection}{\numberline {5.7.5}Congenital Corrected TGA}{123}{subsection.5.7.5}%
\contentsline {subsubsection}{\numberline {5.7.5.1}Lesion}{124}{subsubsection.5.7.5.1}%
\contentsline {subsubsection}{\numberline {5.7.5.2}Basics}{124}{subsubsection.5.7.5.2}%
\contentsline {subsubsection}{\numberline {5.7.5.3}Presentation}{125}{subsubsection.5.7.5.3}%
\contentsline {subsubsection}{\numberline {5.7.5.4}Studies}{125}{subsubsection.5.7.5.4}%
\contentsline {subsubsection}{\numberline {5.7.5.5}Treatment}{125}{subsubsection.5.7.5.5}%
\contentsline {subsection}{\numberline {5.7.6}Valvar Pulmonary Stenosis}{125}{subsection.5.7.6}%
\contentsline {subsubsection}{\numberline {5.7.6.1}Lesion}{126}{subsubsection.5.7.6.1}%
\contentsline {subsubsection}{\numberline {5.7.6.2}Basics}{126}{subsubsection.5.7.6.2}%
\contentsline {subsubsection}{\numberline {5.7.6.3}Presentation}{126}{subsubsection.5.7.6.3}%
\contentsline {subsubsection}{\numberline {5.7.6.4}Studies}{126}{subsubsection.5.7.6.4}%
\contentsline {subsubsection}{\numberline {5.7.6.5}Treatment}{127}{subsubsection.5.7.6.5}%
\contentsline {subsection}{\numberline {5.7.7}Valvar Aortic Stenosis}{127}{subsection.5.7.7}%
\contentsline {subsubsection}{\numberline {5.7.7.1}Lesion}{127}{subsubsection.5.7.7.1}%
\contentsline {subsubsection}{\numberline {5.7.7.2}Basics}{127}{subsubsection.5.7.7.2}%
\contentsline {subsubsection}{\numberline {5.7.7.3}Presentation}{128}{subsubsection.5.7.7.3}%
\contentsline {subsubsection}{\numberline {5.7.7.4}Studies}{128}{subsubsection.5.7.7.4}%
\contentsline {subsubsection}{\numberline {5.7.7.5}Treatment}{128}{subsubsection.5.7.7.5}%
\contentsline {subsection}{\numberline {5.7.8}Coarctation of the Aorta}{128}{subsection.5.7.8}%
\contentsline {subsubsection}{\numberline {5.7.8.1}Lesion}{128}{subsubsection.5.7.8.1}%
\contentsline {subsubsection}{\numberline {5.7.8.2}Basics}{129}{subsubsection.5.7.8.2}%
\contentsline {subsubsection}{\numberline {5.7.8.3}Presentation}{129}{subsubsection.5.7.8.3}%
\contentsline {subsubsection}{\numberline {5.7.8.4}Studies}{129}{subsubsection.5.7.8.4}%
\contentsline {subsubsection}{\numberline {5.7.8.5}Treatment}{129}{subsubsection.5.7.8.5}%
\contentsline {section}{\numberline {5.8}Cyanotic Congenital Heart Disease (CHD)}{129}{section.5.8}%
\contentsline {subsection}{\numberline {5.8.1}Tetralogy of Fallot (ToF)}{129}{subsection.5.8.1}%
\contentsline {subsubsection}{\numberline {5.8.1.1}Lesion}{130}{subsubsection.5.8.1.1}%
\contentsline {subsubsection}{\numberline {5.8.1.2}Basics}{130}{subsubsection.5.8.1.2}%
\contentsline {subsubsection}{\numberline {5.8.1.3}Presentation}{131}{subsubsection.5.8.1.3}%
\contentsline {subsubsection}{\numberline {5.8.1.4}Studies}{131}{subsubsection.5.8.1.4}%
\contentsline {subsubsection}{\numberline {5.8.1.5}Treatment}{131}{subsubsection.5.8.1.5}%
\contentsline {subsection}{\numberline {5.8.2}Transposition of the Great Arteries (TGA)}{131}{subsection.5.8.2}%
\contentsline {subsubsection}{\numberline {5.8.2.1}Lesion}{132}{subsubsection.5.8.2.1}%
\contentsline {subsubsection}{\numberline {5.8.2.2}Basics}{132}{subsubsection.5.8.2.2}%
\contentsline {subsubsection}{\numberline {5.8.2.3}Presentation}{133}{subsubsection.5.8.2.3}%
\contentsline {subsubsection}{\numberline {5.8.2.4}Studies}{133}{subsubsection.5.8.2.4}%
\contentsline {subsubsection}{\numberline {5.8.2.5}Treatment}{133}{subsubsection.5.8.2.5}%
\contentsline {subsection}{\numberline {5.8.3}Total Anomalous Pulmonary Venous Return (TAPVR)}{133}{subsection.5.8.3}%
\contentsline {subsubsection}{\numberline {5.8.3.1}Lesion}{134}{subsubsection.5.8.3.1}%
\contentsline {subsubsection}{\numberline {5.8.3.2}Basics}{134}{subsubsection.5.8.3.2}%
\contentsline {subsubsection}{\numberline {5.8.3.3}Presentation}{135}{subsubsection.5.8.3.3}%
\contentsline {subsubsection}{\numberline {5.8.3.4}Studies}{135}{subsubsection.5.8.3.4}%
\contentsline {subsubsection}{\numberline {5.8.3.5}Treatment}{135}{subsubsection.5.8.3.5}%
\contentsline {subsection}{\numberline {5.8.4}Tricuspid Atresia}{135}{subsection.5.8.4}%
\contentsline {subsubsection}{\numberline {5.8.4.1}Lesion}{136}{subsubsection.5.8.4.1}%
\contentsline {subsubsection}{\numberline {5.8.4.2}Basics}{136}{subsubsection.5.8.4.2}%
\contentsline {subsubsection}{\numberline {5.8.4.3}Presentation}{137}{subsubsection.5.8.4.3}%
\contentsline {subsubsection}{\numberline {5.8.4.4}Studies}{137}{subsubsection.5.8.4.4}%
\contentsline {subsubsection}{\numberline {5.8.4.5}Treatment}{137}{subsubsection.5.8.4.5}%
\contentsline {subsection}{\numberline {5.8.5}Ebstein's Anomaly}{137}{subsection.5.8.5}%
\contentsline {subsubsection}{\numberline {5.8.5.1}Lesion}{138}{subsubsection.5.8.5.1}%
\contentsline {subsubsection}{\numberline {5.8.5.2}Basics}{138}{subsubsection.5.8.5.2}%
\contentsline {subsubsection}{\numberline {5.8.5.3}Presentation}{139}{subsubsection.5.8.5.3}%
\contentsline {subsubsection}{\numberline {5.8.5.4}Studies}{139}{subsubsection.5.8.5.4}%
\contentsline {subsubsection}{\numberline {5.8.5.5}Treatment}{139}{subsubsection.5.8.5.5}%
\contentsline {subsection}{\numberline {5.8.6}Hypoplastic Left Heart Syndrome (HLHS)}{139}{subsection.5.8.6}%
\contentsline {subsubsection}{\numberline {5.8.6.1}Lesion}{140}{subsubsection.5.8.6.1}%
\contentsline {subsubsection}{\numberline {5.8.6.2}Basics}{140}{subsubsection.5.8.6.2}%
\contentsline {subsubsection}{\numberline {5.8.6.3}Presentation}{141}{subsubsection.5.8.6.3}%
\contentsline {subsubsection}{\numberline {5.8.6.4}Studies}{141}{subsubsection.5.8.6.4}%
\contentsline {subsubsection}{\numberline {5.8.6.5}Treatment}{141}{subsubsection.5.8.6.5}%
\contentsline {subsection}{\numberline {5.8.7}Double Outlet Right Ventricle (DORV)}{141}{subsection.5.8.7}%
\contentsline {subsubsection}{\numberline {5.8.7.1}Lesion}{142}{subsubsection.5.8.7.1}%
\contentsline {subsubsection}{\numberline {5.8.7.2}Basics}{142}{subsubsection.5.8.7.2}%
\contentsline {subsubsection}{\numberline {5.8.7.3}Presentation}{143}{subsubsection.5.8.7.3}%
\contentsline {subsubsection}{\numberline {5.8.7.4}Studies}{143}{subsubsection.5.8.7.4}%
\contentsline {subsubsection}{\numberline {5.8.7.5}Treatment}{143}{subsubsection.5.8.7.5}%
\contentsline {subsection}{\numberline {5.8.8}Truncus arteriosus}{143}{subsection.5.8.8}%
\contentsline {subsubsection}{\numberline {5.8.8.1}Lesion}{144}{subsubsection.5.8.8.1}%
\contentsline {subsubsection}{\numberline {5.8.8.2}Basics}{144}{subsubsection.5.8.8.2}%
\contentsline {subsubsection}{\numberline {5.8.8.3}Presentation}{144}{subsubsection.5.8.8.3}%
\contentsline {subsubsection}{\numberline {5.8.8.4}Studies}{145}{subsubsection.5.8.8.4}%
\contentsline {subsubsection}{\numberline {5.8.8.5}Treatment}{145}{subsubsection.5.8.8.5}%
\contentsline {subsection}{\numberline {5.8.9}Pulmonary atresia with IVS}{145}{subsection.5.8.9}%
\contentsline {subsubsection}{\numberline {5.8.9.1}Lesion}{145}{subsubsection.5.8.9.1}%
\contentsline {subsubsection}{\numberline {5.8.9.2}Basics}{146}{subsubsection.5.8.9.2}%
\contentsline {subsubsection}{\numberline {5.8.9.3}Presentation}{146}{subsubsection.5.8.9.3}%
\contentsline {subsubsection}{\numberline {5.8.9.4}Studies}{146}{subsubsection.5.8.9.4}%
\contentsline {subsubsection}{\numberline {5.8.9.5}Treatment}{146}{subsubsection.5.8.9.5}%
\contentsline {section}{\numberline {5.9}Surgical Repair of CHD}{146}{section.5.9}%
\contentsline {subsection}{\numberline {5.9.1}Stage 1 Operation (aka Norwood Operation)}{146}{subsection.5.9.1}%
\contentsline {subsubsection}{\numberline {5.9.1.1}Indications}{146}{subsubsection.5.9.1.1}%
\contentsline {subsubsection}{\numberline {5.9.1.2}Goals}{146}{subsubsection.5.9.1.2}%
\contentsline {subsubsection}{\numberline {5.9.1.3}Post-op Sats}{147}{subsubsection.5.9.1.3}%
\contentsline {subsection}{\numberline {5.9.2}Bidirectional Glenn}{147}{subsection.5.9.2}%
\contentsline {subsubsection}{\numberline {5.9.2.1}Indications}{147}{subsubsection.5.9.2.1}%
\contentsline {subsubsection}{\numberline {5.9.2.2}Goals}{147}{subsubsection.5.9.2.2}%
\contentsline {subsubsection}{\numberline {5.9.2.3}Post-op Sats}{148}{subsubsection.5.9.2.3}%
\contentsline {subsubsection}{\numberline {5.9.2.4}Complications}{148}{subsubsection.5.9.2.4}%
\contentsline {subsection}{\numberline {5.9.3}Fontan}{148}{subsection.5.9.3}%
\contentsline {subsubsection}{\numberline {5.9.3.1}Description}{148}{subsubsection.5.9.3.1}%
\contentsline {subsubsection}{\numberline {5.9.3.2}Indications}{148}{subsubsection.5.9.3.2}%
\contentsline {subsubsection}{\numberline {5.9.3.3}Goals}{149}{subsubsection.5.9.3.3}%
\contentsline {subsubsection}{\numberline {5.9.3.4}Post-op Sats}{149}{subsubsection.5.9.3.4}%
\contentsline {subsubsection}{\numberline {5.9.3.5}Complications}{149}{subsubsection.5.9.3.5}%
\contentsline {subsection}{\numberline {5.9.4}Arterial Switch Operation}{149}{subsection.5.9.4}%
\contentsline {subsubsection}{\numberline {5.9.4.1}Indications}{150}{subsubsection.5.9.4.1}%
\contentsline {subsubsection}{\numberline {5.9.4.2}Goals}{150}{subsubsection.5.9.4.2}%
\contentsline {subsubsection}{\numberline {5.9.4.3}Complications}{150}{subsubsection.5.9.4.3}%
\contentsline {section}{\numberline {5.10}Catheterization \& Caring for the Post-Cath Child}{153}{section.5.10}%
\contentsline {subsubsection}{\numberline {5.10.0.1}Complications}{153}{subsubsection.5.10.0.1}%
\contentsline {section}{\numberline {5.11}Cardiomyopathy}{153}{section.5.11}%
\contentsline {subsection}{\numberline {5.11.1}Hypertrophic Cardiomyopathy (HCM)}{153}{subsection.5.11.1}%
\contentsline {subsubsection}{\numberline {5.11.1.1}Presentation}{153}{subsubsection.5.11.1.1}%
\contentsline {subsubsection}{\numberline {5.11.1.2}Physical Exam}{153}{subsubsection.5.11.1.2}%
\contentsline {subsubsection}{\numberline {5.11.1.3}Pathophysiology}{153}{subsubsection.5.11.1.3}%
\contentsline {subsubsection}{\numberline {5.11.1.4}Work-up}{155}{subsubsection.5.11.1.4}%
\contentsline {subsubsection}{\numberline {5.11.1.5}Treatment}{155}{subsubsection.5.11.1.5}%
\contentsline {subsection}{\numberline {5.11.2}Dilated Cardiomyopathy}{155}{subsection.5.11.2}%
\contentsline {subsubsection}{\numberline {5.11.2.1}Presentation}{155}{subsubsection.5.11.2.1}%
\contentsline {subsubsection}{\numberline {5.11.2.2}Physical Exam}{155}{subsubsection.5.11.2.2}%
\contentsline {subsubsection}{\numberline {5.11.2.3}Pathophysiology}{155}{subsubsection.5.11.2.3}%
\contentsline {subsubsection}{\numberline {5.11.2.4}Work-up}{155}{subsubsection.5.11.2.4}%
\contentsline {subsubsection}{\numberline {5.11.2.5}Treatment}{156}{subsubsection.5.11.2.5}%
\contentsline {subsection}{\numberline {5.11.3}Arrhythmogenic Cardiomyopathy}{156}{subsection.5.11.3}%
\contentsline {subsubsection}{\numberline {5.11.3.1}Presentation}{156}{subsubsection.5.11.3.1}%
\contentsline {subsubsection}{\numberline {5.11.3.2}Pathophysiology}{156}{subsubsection.5.11.3.2}%
\contentsline {subsubsection}{\numberline {5.11.3.3}Work-up}{156}{subsubsection.5.11.3.3}%
\contentsline {subsubsection}{\numberline {5.11.3.4}Treatment}{156}{subsubsection.5.11.3.4}%
\contentsline {subsection}{\numberline {5.11.4}Restrictive Cardiomyopathy}{156}{subsection.5.11.4}%
\contentsline {subsubsection}{\numberline {5.11.4.1}Presentation}{156}{subsubsection.5.11.4.1}%
\contentsline {subsubsection}{\numberline {5.11.4.2}Pathophysiology}{156}{subsubsection.5.11.4.2}%
\contentsline {subsubsection}{\numberline {5.11.4.3}Work-up}{156}{subsubsection.5.11.4.3}%
\contentsline {subsubsection}{\numberline {5.11.4.4}Treatment}{156}{subsubsection.5.11.4.4}%
\contentsline {subsection}{\numberline {5.11.5}Left Ventricular Non-Compaction Cardiomyopathy (LVNC)}{157}{subsection.5.11.5}%
\contentsline {subsubsection}{\numberline {5.11.5.1}Presentation}{157}{subsubsection.5.11.5.1}%
\contentsline {subsubsection}{\numberline {5.11.5.2}Pathophysiology}{157}{subsubsection.5.11.5.2}%
\contentsline {subsubsection}{\numberline {5.11.5.3}Work-up}{157}{subsubsection.5.11.5.3}%
\contentsline {subsubsection}{\numberline {5.11.5.4}Treatment}{157}{subsubsection.5.11.5.4}%
\contentsline {section}{\numberline {5.12}Congestive Heart Failure (CHF)}{157}{section.5.12}%
\contentsline {subsubsection}{\numberline {5.12.0.1}Presentation}{157}{subsubsection.5.12.0.1}%
\contentsline {subsubsection}{\numberline {5.12.0.2}Physical Exam}{157}{subsubsection.5.12.0.2}%
\contentsline {subsubsection}{\numberline {5.12.0.3}Pathophysiology}{157}{subsubsection.5.12.0.3}%
\contentsline {subsubsection}{\numberline {5.12.0.4}Work-up}{157}{subsubsection.5.12.0.4}%
\contentsline {subsubsection}{\numberline {5.12.0.5}Treatment}{158}{subsubsection.5.12.0.5}%
\contentsline {section}{\numberline {5.13}Coronary Artery Anomalies}{158}{section.5.13}%
\contentsline {subsection}{\numberline {5.13.1}Anomalous Left Coronary Artery off the Pulmonary Artery (ALCAPA)}{158}{subsection.5.13.1}%
\contentsline {subsubsection}{\numberline {5.13.1.1}Presentation}{158}{subsubsection.5.13.1.1}%
\contentsline {subsubsection}{\numberline {5.13.1.2}Pathophysiology}{158}{subsubsection.5.13.1.2}%
\contentsline {subsubsection}{\numberline {5.13.1.3}Work-up}{159}{subsubsection.5.13.1.3}%
\contentsline {subsubsection}{\numberline {5.13.1.4}Treatment}{159}{subsubsection.5.13.1.4}%
\contentsline {subsection}{\numberline {5.13.2}Anomalous Aortic Origin of a Coronary Artery (AAOCA)}{159}{subsection.5.13.2}%
\contentsline {subsubsection}{\numberline {5.13.2.1}Presentation}{159}{subsubsection.5.13.2.1}%
\contentsline {subsubsection}{\numberline {5.13.2.2}Pathophysiology}{160}{subsubsection.5.13.2.2}%
\contentsline {subsubsection}{\numberline {5.13.2.3}Treatment}{160}{subsubsection.5.13.2.3}%
\contentsline {section}{\numberline {5.14}Pulmonary Hypertension (pHTN)}{160}{section.5.14}%
\contentsline {subsubsection}{\numberline {5.14.0.1}Presentation}{160}{subsubsection.5.14.0.1}%
\contentsline {subsubsection}{\numberline {5.14.0.2}Physical Exam}{160}{subsubsection.5.14.0.2}%
\contentsline {subsubsection}{\numberline {5.14.0.3}Pathophysiology}{161}{subsubsection.5.14.0.3}%
\contentsline {subsubsection}{\numberline {5.14.0.4}Work-up}{161}{subsubsection.5.14.0.4}%
\contentsline {subsubsection}{\numberline {5.14.0.5}Treatment}{161}{subsubsection.5.14.0.5}%
\contentsline {section}{\numberline {5.15}Cardiac Infections}{161}{section.5.15}%
\contentsline {subsection}{\numberline {5.15.1}Myocarditis}{161}{subsection.5.15.1}%
\contentsline {subsubsection}{\numberline {5.15.1.1}Presentation}{161}{subsubsection.5.15.1.1}%
\contentsline {subsubsection}{\numberline {5.15.1.2}Physical Exam}{162}{subsubsection.5.15.1.2}%
\contentsline {subsubsection}{\numberline {5.15.1.3}Pathophysiology}{162}{subsubsection.5.15.1.3}%
\contentsline {subsubsection}{\numberline {5.15.1.4}Work-up}{162}{subsubsection.5.15.1.4}%
\contentsline {subsubsection}{\numberline {5.15.1.5}Treatment}{162}{subsubsection.5.15.1.5}%
\contentsline {subsection}{\numberline {5.15.2}Endocarditis}{162}{subsection.5.15.2}%
\contentsline {subsubsection}{\numberline {5.15.2.1}Presentation}{162}{subsubsection.5.15.2.1}%
\contentsline {subsubsection}{\numberline {5.15.2.2}Physical Exam}{163}{subsubsection.5.15.2.2}%
\contentsline {subsubsection}{\numberline {5.15.2.3}Pathophysiology}{163}{subsubsection.5.15.2.3}%
\contentsline {subsubsection}{\numberline {5.15.2.4}Work-up}{163}{subsubsection.5.15.2.4}%
\contentsline {subsubsection}{\numberline {5.15.2.5}Diagnosis}{163}{subsubsection.5.15.2.5}%
\contentsline {subsubsection}{\numberline {5.15.2.6}Treatment}{163}{subsubsection.5.15.2.6}%
\contentsline {subsubsection}{\numberline {5.15.2.7}Complications}{164}{subsubsection.5.15.2.7}%
\contentsline {subsection}{\numberline {5.15.3}Pericarditis}{164}{subsection.5.15.3}%
\contentsline {subsubsection}{\numberline {5.15.3.1}Presentation}{164}{subsubsection.5.15.3.1}%
\contentsline {subsubsection}{\numberline {5.15.3.2}Physical Exam}{164}{subsubsection.5.15.3.2}%
\contentsline {subsubsection}{\numberline {5.15.3.3}Pathophysiology}{164}{subsubsection.5.15.3.3}%
\contentsline {subsubsection}{\numberline {5.15.3.4}Work-up}{164}{subsubsection.5.15.3.4}%
\contentsline {subsubsection}{\numberline {5.15.3.5}Treatment}{164}{subsubsection.5.15.3.5}%
\contentsline {section}{\numberline {5.16}References}{164}{section.5.16}%
\contentsline {chapter}{\numberline {6}Cellular Therapy}{165}{chapter.6}%
\contentsline {section}{\numberline {6.1}Introduction}{165}{section.6.1}%
\contentsline {section}{\numberline {6.2}Hematopoietic Cell Transplantation (HCT)}{166}{section.6.2}%
\contentsline {subsection}{\numberline {6.2.1}Graft}{166}{subsection.6.2.1}%
\contentsline {subsection}{\numberline {6.2.2}Donor Types}{166}{subsection.6.2.2}%
\contentsline {subsection}{\numberline {6.2.3}Conditioning Regimens}{167}{subsection.6.2.3}%
\contentsline {subsection}{\numberline {6.2.4}Timeline}{167}{subsection.6.2.4}%
\contentsline {subsection}{\numberline {6.2.5}Complications}{167}{subsection.6.2.5}%
\contentsline {section}{\numberline {6.3}Cytotoxic T Lymphocytes (CTLs)}{169}{section.6.3}%
\contentsline {subsection}{\numberline {6.3.1}Concept}{169}{subsection.6.3.1}%
\contentsline {section}{\numberline {6.4}Chimeric Antigen Receptor (CAR) T-cells}{170}{section.6.4}%
\contentsline {subsection}{\numberline {6.4.1}Concept}{170}{subsection.6.4.1}%
\contentsline {subsection}{\numberline {6.4.2}Complications}{170}{subsection.6.4.2}%
\contentsline {section}{\numberline {6.5}Emerging Cellular Therapies}{171}{section.6.5}%
\contentsline {subsection}{\numberline {6.5.1}Currently in Clinical Trials}{171}{subsection.6.5.1}%
\contentsline {chapter}{\numberline {7}Critical Care \& ICP}{173}{chapter.7}%
\contentsline {section}{\numberline {7.1}Vasopressors \& Inotropes}{173}{section.7.1}%
\contentsline {section}{\numberline {7.2}Shock}{174}{section.7.2}%
\contentsline {subsubsection}{\numberline {7.2.0.1}Definition}{174}{subsubsection.7.2.0.1}%
\contentsline {subsubsection}{\numberline {7.2.0.2}Labs}{174}{subsubsection.7.2.0.2}%
\contentsline {subsection}{\numberline {7.2.1}Types of Shock}{175}{subsection.7.2.1}%
\contentsline {subsection}{\numberline {7.2.2}Septic Shock Treatment Algorithm}{178}{subsection.7.2.2}%
\contentsline {section}{\numberline {7.3}Analgesia, Sedation \& Paralysis}{179}{section.7.3}%
\contentsline {subsection}{\numberline {7.3.1}Analgesics}{179}{subsection.7.3.1}%
\contentsline {subsection}{\numberline {7.3.2}Sedatives}{179}{subsection.7.3.2}%
\contentsline {subsection}{\numberline {7.3.3}Paralytics}{180}{subsection.7.3.3}%
\contentsline {section}{\numberline {7.4}Rapid Sequence Intubation (RSI)}{181}{section.7.4}%
\contentsline {subsection}{\numberline {7.4.1}Pre-Med (``Appetizer'' ü•ó)}{181}{subsection.7.4.1}%
\contentsline {subsection}{\numberline {7.4.2}Induction (``Main Course'' üçî)}{182}{subsection.7.4.2}%
\contentsline {subsection}{\numberline {7.4.3}Paralysis (``Dessert'' üç∞)}{183}{subsection.7.4.3}%
\contentsline {section}{\numberline {7.5}Respiratory Support: Ventilation \& Oxygenation}{183}{section.7.5}%
\contentsline {subsection}{\numberline {7.5.1}High-Flow Nasal Cannula (HFNC)}{183}{subsection.7.5.1}%
\contentsline {subsubsection}{\numberline {7.5.1.1}Definition}{184}{subsubsection.7.5.1.1}%
\contentsline {subsubsection}{\numberline {7.5.1.2}Indications \& Contraindications}{184}{subsubsection.7.5.1.2}%
\contentsline {subsubsection}{\numberline {7.5.1.3}Bronchiolitis HFNC Pathway}{184}{subsubsection.7.5.1.3}%
\contentsline {subsection}{\numberline {7.5.2}Non-Invasive Positive Pressure Ventilaion (NIPPV)}{184}{subsection.7.5.2}%
\contentsline {subsubsection}{\numberline {7.5.2.1}Interface}{185}{subsubsection.7.5.2.1}%
\contentsline {subsubsection}{\numberline {7.5.2.2}Continuous Positive Airway Pressure (CPAP)}{185}{subsubsection.7.5.2.2}%
\contentsline {subsubsection}{\numberline {7.5.2.3}Bilevel Positive Airway Pressure (BiPAP)}{185}{subsubsection.7.5.2.3}%
\contentsline {subsubsection}{\numberline {7.5.2.4}Weaning NIV Support}{185}{subsubsection.7.5.2.4}%
\contentsline {subsection}{\numberline {7.5.3}Mechanical Ventilation (MV)}{186}{subsection.7.5.3}%
\contentsline {subsubsection}{\numberline {7.5.3.1}Glossary}{186}{subsubsection.7.5.3.1}%
\contentsline {subsubsection}{\numberline {7.5.3.2}General Principles of Mechanical Ventilation}{186}{subsubsection.7.5.3.2}%
\contentsline {subsubsection}{\numberline {7.5.3.3}Modes of Ventilation}{186}{subsubsection.7.5.3.3}%
\contentsline {subsubsection}{\numberline {7.5.3.4}Troubleshooting Desaturations on a Ventilator (``DOPE'')}{187}{subsubsection.7.5.3.4}%
\contentsline {section}{\numberline {7.6}Extracorporeal Membrane Oxygenation (ECMO)}{187}{section.7.6}%
\contentsline {subsubsection}{\numberline {7.6.0.1}Definition}{188}{subsubsection.7.6.0.1}%
\contentsline {subsubsection}{\numberline {7.6.0.2}Indications \& Contraindications}{188}{subsubsection.7.6.0.2}%
\contentsline {subsubsection}{\numberline {7.6.0.3}Pre-ECMO Initiation}{189}{subsubsection.7.6.0.3}%
\contentsline {subsubsection}{\numberline {7.6.0.4}Titration}{189}{subsubsection.7.6.0.4}%
\contentsline {subsubsection}{\numberline {7.6.0.5}Complications}{189}{subsubsection.7.6.0.5}%
\contentsline {section}{\numberline {7.7}Acute Respiratory Distress Syndrome (ARDS)}{189}{section.7.7}%
\contentsline {subsubsection}{\numberline {7.7.0.1}Definition}{189}{subsubsection.7.7.0.1}%
\contentsline {subsubsection}{\numberline {7.7.0.2}Pathophysiology}{189}{subsubsection.7.7.0.2}%
\contentsline {subsubsection}{\numberline {7.7.0.3}Clinical Manifestations}{190}{subsubsection.7.7.0.3}%
\contentsline {subsubsection}{\numberline {7.7.0.4}Diagnostic Studies}{190}{subsubsection.7.7.0.4}%
\contentsline {subsubsection}{\numberline {7.7.0.5}Management}{190}{subsubsection.7.7.0.5}%
\contentsline {section}{\numberline {7.8}Hypertensive Crisis}{190}{section.7.8}%
\contentsline {subsubsection}{\numberline {7.8.0.1}Definitions}{190}{subsubsection.7.8.0.1}%
\contentsline {subsubsection}{\numberline {7.8.0.2}Etiology}{190}{subsubsection.7.8.0.2}%
\contentsline {subsubsection}{\numberline {7.8.0.3}Clinical Manifestations}{190}{subsubsection.7.8.0.3}%
\contentsline {subsubsection}{\numberline {7.8.0.4}Diagnostic Studies}{191}{subsubsection.7.8.0.4}%
\contentsline {subsubsection}{\numberline {7.8.0.5}Management}{191}{subsubsection.7.8.0.5}%
\contentsline {paragraph}{\numberline {7.8.0.5.1}Medications for Management of Hypertensive Crisis}{191}{paragraph.7.8.0.5.1}%
\contentsline {section}{\numberline {7.9}Diabetic Ketoacidosis (DKA)}{192}{section.7.9}%
\contentsline {subsubsection}{\numberline {7.9.0.1}Order Set}{192}{subsubsection.7.9.0.1}%
\contentsline {subsubsection}{\numberline {7.9.0.2}Definition}{192}{subsubsection.7.9.0.2}%
\contentsline {subsubsection}{\numberline {7.9.0.3}Clinical Manifestations}{192}{subsubsection.7.9.0.3}%
\contentsline {subsubsection}{\numberline {7.9.0.4}Diagnostic Studies}{192}{subsubsection.7.9.0.4}%
\contentsline {subsubsection}{\numberline {7.9.0.5}Management}{193}{subsubsection.7.9.0.5}%
\contentsline {subsubsection}{\numberline {7.9.0.6}Complications}{193}{subsubsection.7.9.0.6}%
\contentsline {section}{\numberline {7.10}References}{194}{section.7.10}%
\contentsline {chapter}{\numberline {8}Dermatology}{195}{chapter.8}%
\contentsline {section}{\numberline {8.1}Key Questions for Taking a Dermatologic HIstory}{195}{section.8.1}%
\contentsline {section}{\numberline {8.2}Describing Dermatologic Lesions}{195}{section.8.2}%
\contentsline {subsection}{\numberline {8.2.1}Primary Lesion}{195}{subsection.8.2.1}%
\contentsline {subsection}{\numberline {8.2.2}Secondary Changes}{197}{subsection.8.2.2}%
\contentsline {subsection}{\numberline {8.2.3}Color Descriptor}{197}{subsection.8.2.3}%
\contentsline {subsection}{\numberline {8.2.4}Lesion Shapes}{197}{subsection.8.2.4}%
\contentsline {subsection}{\numberline {8.2.5}Distribution}{199}{subsection.8.2.5}%
\contentsline {section}{\numberline {8.3}Newborn Derm}{199}{section.8.3}%
\contentsline {subsection}{\numberline {8.3.1}Neonatal Rashes}{199}{subsection.8.3.1}%
\contentsline {subsection}{\numberline {8.3.2}Neonatal Birthmarks}{201}{subsection.8.3.2}%
\contentsline {subsection}{\numberline {8.3.3}Diaper Dermatitis}{204}{subsection.8.3.3}%
\contentsline {section}{\numberline {8.4}Dermatologic Emergencies}{205}{section.8.4}%
\contentsline {subsection}{\numberline {8.4.1}Stevens Johnson Syndrome (SJS)}{205}{subsection.8.4.1}%
\contentsline {subsubsection}{\numberline {8.4.1.1}Definition}{205}{subsubsection.8.4.1.1}%
\contentsline {subsubsection}{\numberline {8.4.1.2}Etiology}{205}{subsubsection.8.4.1.2}%
\contentsline {subsubsection}{\numberline {8.4.1.3}Presentation}{205}{subsubsection.8.4.1.3}%
\contentsline {subsubsection}{\numberline {8.4.1.4}Management}{205}{subsubsection.8.4.1.4}%
\contentsline {subsection}{\numberline {8.4.2}Toxic Epidermal Necrolysis (TEN)}{205}{subsection.8.4.2}%
\contentsline {subsubsection}{\numberline {8.4.2.1}Definition}{205}{subsubsection.8.4.2.1}%
\contentsline {subsubsection}{\numberline {8.4.2.2}Etiology}{206}{subsubsection.8.4.2.2}%
\contentsline {subsubsection}{\numberline {8.4.2.3}Presentation}{206}{subsubsection.8.4.2.3}%
\contentsline {subsubsection}{\numberline {8.4.2.4}Management}{206}{subsubsection.8.4.2.4}%
\contentsline {subsection}{\numberline {8.4.3}Drug Reaction with Eosinophilis and Systemic Symptoms (DRESS)}{206}{subsection.8.4.3}%
\contentsline {subsubsection}{\numberline {8.4.3.1}Definition}{206}{subsubsection.8.4.3.1}%
\contentsline {subsubsection}{\numberline {8.4.3.2}Etiology}{206}{subsubsection.8.4.3.2}%
\contentsline {subsubsection}{\numberline {8.4.3.3}Presentation}{206}{subsubsection.8.4.3.3}%
\contentsline {subsubsection}{\numberline {8.4.3.4}Management}{207}{subsubsection.8.4.3.4}%
\contentsline {subsection}{\numberline {8.4.4}Staph Scalded Skin Syndrome (SSSS)}{207}{subsection.8.4.4}%
\contentsline {subsubsection}{\numberline {8.4.4.1}Definition}{207}{subsubsection.8.4.4.1}%
\contentsline {subsubsection}{\numberline {8.4.4.2}Presentation}{207}{subsubsection.8.4.4.2}%
\contentsline {subsubsection}{\numberline {8.4.4.3}Management}{208}{subsubsection.8.4.4.3}%
\contentsline {section}{\numberline {8.5}Common Dermatologic Conditions}{208}{section.8.5}%
\contentsline {subsection}{\numberline {8.5.1}Acne}{208}{subsection.8.5.1}%
\contentsline {subsubsection}{\numberline {8.5.1.1}Pathophysiology}{208}{subsubsection.8.5.1.1}%
\contentsline {subsubsection}{\numberline {8.5.1.2}Management}{208}{subsubsection.8.5.1.2}%
\contentsline {subsection}{\numberline {8.5.2}Atopic Dermatitis (Eczema)}{209}{subsection.8.5.2}%
\contentsline {subsubsection}{\numberline {8.5.2.1}Definition}{209}{subsubsection.8.5.2.1}%
\contentsline {subsubsection}{\numberline {8.5.2.2}Presentation}{209}{subsubsection.8.5.2.2}%
\contentsline {subsubsection}{\numberline {8.5.2.3}Complications}{209}{subsubsection.8.5.2.3}%
\contentsline {subsubsection}{\numberline {8.5.2.4}Management}{209}{subsubsection.8.5.2.4}%
\contentsline {subsection}{\numberline {8.5.3}Erythema Multiforme}{209}{subsection.8.5.3}%
\contentsline {subsubsection}{\numberline {8.5.3.1}Definition}{209}{subsubsection.8.5.3.1}%
\contentsline {subsubsection}{\numberline {8.5.3.2}Etiology}{210}{subsubsection.8.5.3.2}%
\contentsline {subsubsection}{\numberline {8.5.3.3}Presentation}{210}{subsubsection.8.5.3.3}%
\contentsline {subsubsection}{\numberline {8.5.3.4}Management}{210}{subsubsection.8.5.3.4}%
\contentsline {subsection}{\numberline {8.5.4}Impetigo}{210}{subsection.8.5.4}%
\contentsline {subsubsection}{\numberline {8.5.4.1}Definition}{210}{subsubsection.8.5.4.1}%
\contentsline {subsubsection}{\numberline {8.5.4.2}Presentation}{210}{subsubsection.8.5.4.2}%
\contentsline {subsubsection}{\numberline {8.5.4.3}Management}{211}{subsubsection.8.5.4.3}%
\contentsline {subsection}{\numberline {8.5.5}Erysipelas}{211}{subsection.8.5.5}%
\contentsline {subsubsection}{\numberline {8.5.5.1}Definition}{211}{subsubsection.8.5.5.1}%
\contentsline {subsubsection}{\numberline {8.5.5.2}Presentation}{211}{subsubsection.8.5.5.2}%
\contentsline {subsubsection}{\numberline {8.5.5.3}Management}{212}{subsubsection.8.5.5.3}%
\contentsline {subsection}{\numberline {8.5.6}Molluscum Contagiosum}{212}{subsection.8.5.6}%
\contentsline {subsubsection}{\numberline {8.5.6.1}Definition}{212}{subsubsection.8.5.6.1}%
\contentsline {subsubsection}{\numberline {8.5.6.2}Presentation}{212}{subsubsection.8.5.6.2}%
\contentsline {subsubsection}{\numberline {8.5.6.3}Management}{213}{subsubsection.8.5.6.3}%
\contentsline {subsection}{\numberline {8.5.7}Pityriasis Rosea}{213}{subsection.8.5.7}%
\contentsline {subsubsection}{\numberline {8.5.7.1}Presentation}{213}{subsubsection.8.5.7.1}%
\contentsline {subsubsection}{\numberline {8.5.7.2}Management}{213}{subsubsection.8.5.7.2}%
\contentsline {subsection}{\numberline {8.5.8}Scabies}{213}{subsection.8.5.8}%
\contentsline {subsubsection}{\numberline {8.5.8.1}Definition}{213}{subsubsection.8.5.8.1}%
\contentsline {subsubsection}{\numberline {8.5.8.2}Presentation}{214}{subsubsection.8.5.8.2}%
\contentsline {subsubsection}{\numberline {8.5.8.3}Management}{214}{subsubsection.8.5.8.3}%
\contentsline {subsection}{\numberline {8.5.9}Lice}{214}{subsection.8.5.9}%
\contentsline {subsubsection}{\numberline {8.5.9.1}Presentation}{214}{subsubsection.8.5.9.1}%
\contentsline {subsubsection}{\numberline {8.5.9.2}Management}{214}{subsubsection.8.5.9.2}%
\contentsline {subsection}{\numberline {8.5.10}Tinea Corporis}{214}{subsection.8.5.10}%
\contentsline {subsubsection}{\numberline {8.5.10.1}Definition}{214}{subsubsection.8.5.10.1}%
\contentsline {subsubsection}{\numberline {8.5.10.2}Presentation}{215}{subsubsection.8.5.10.2}%
\contentsline {subsubsection}{\numberline {8.5.10.3}Management}{215}{subsubsection.8.5.10.3}%
\contentsline {subsection}{\numberline {8.5.11}Tinea Capitis}{215}{subsection.8.5.11}%
\contentsline {subsubsection}{\numberline {8.5.11.1}Definition}{215}{subsubsection.8.5.11.1}%
\contentsline {subsubsection}{\numberline {8.5.11.2}Presentation}{215}{subsubsection.8.5.11.2}%
\contentsline {subsubsection}{\numberline {8.5.11.3}Management}{216}{subsubsection.8.5.11.3}%
\contentsline {section}{\numberline {8.6}Cutaneous Signs of Systemic Disease}{216}{section.8.6}%
\contentsline {section}{\numberline {8.7}Drug Eruptions}{216}{section.8.7}%
\contentsline {section}{\numberline {8.8}Principles of Dermatologic Therapy}{216}{section.8.8}%
\contentsline {subsection}{\numberline {8.8.1}Quantities of Topicals to Prescribe}{217}{subsection.8.8.1}%
\contentsline {section}{\numberline {8.9}Topical Steroids}{218}{section.8.9}%
\contentsline {subsection}{\numberline {8.9.1}Classes of Topical Steroids}{218}{subsection.8.9.1}%
\contentsline {subsection}{\numberline {8.9.2}Side Effects of Topical Steroids}{219}{subsection.8.9.2}%
\contentsline {section}{\numberline {8.10}Sun Protection}{219}{section.8.10}%
\contentsline {subsection}{\numberline {8.10.1}Types of Sunscreen}{219}{subsection.8.10.1}%
\contentsline {subsection}{\numberline {8.10.2}Choosing Sunscreen}{219}{subsection.8.10.2}%
\contentsline {section}{\numberline {8.11}References}{220}{section.8.11}%
\contentsline {subsection}{\numberline {8.11.1}Additional Dermatology Resources}{220}{subsection.8.11.1}%
\contentsline {chapter}{\numberline {9}Emergency Medicine}{221}{chapter.9}%
\contentsline {section}{\numberline {9.1}Acute Abdominal Pain}{221}{section.9.1}%
\contentsline {subsection}{\numberline {9.1.1}Differential}{221}{subsection.9.1.1}%
\contentsline {subsection}{\numberline {9.1.2}Workup}{221}{subsection.9.1.2}%
\contentsline {section}{\numberline {9.2}Altered Mental Status}{222}{section.9.2}%
\contentsline {section}{\numberline {9.3}Blunt Abdominal Trauma}{224}{section.9.3}%
\contentsline {subsection}{\numberline {9.3.1}Treatment}{224}{subsection.9.3.1}%
\contentsline {section}{\numberline {9.4}Appendicitis}{225}{section.9.4}%
\contentsline {subsection}{\numberline {9.4.1}Definition}{225}{subsection.9.4.1}%
\contentsline {subsection}{\numberline {9.4.2}Pathophysiology}{225}{subsection.9.4.2}%
\contentsline {subsection}{\numberline {9.4.3}Clinical}{225}{subsection.9.4.3}%
\contentsline {subsection}{\numberline {9.4.4}Physical Exam}{225}{subsection.9.4.4}%
\contentsline {subsection}{\numberline {9.4.5}Studies}{226}{subsection.9.4.5}%
\contentsline {subsection}{\numberline {9.4.6}Treatment}{226}{subsection.9.4.6}%
\contentsline {section}{\numberline {9.5}Acute Chest Pain}{226}{section.9.5}%
\contentsline {subsection}{\numberline {9.5.1}Differential}{226}{subsection.9.5.1}%
\contentsline {subsection}{\numberline {9.5.2}History}{227}{subsection.9.5.2}%
\contentsline {subsection}{\numberline {9.5.3}Physical Exam}{227}{subsection.9.5.3}%
\contentsline {subsection}{\numberline {9.5.4}Studies}{228}{subsection.9.5.4}%
\contentsline {section}{\numberline {9.6}Acute Scrotal Pain}{228}{section.9.6}%
\contentsline {subsection}{\numberline {9.6.1}History}{228}{subsection.9.6.1}%
\contentsline {subsection}{\numberline {9.6.2}Physical Exam}{228}{subsection.9.6.2}%
\contentsline {subsection}{\numberline {9.6.3}Studies}{229}{subsection.9.6.3}%
\contentsline {section}{\numberline {9.7}Atraumatic Limp}{230}{section.9.7}%
\contentsline {subsection}{\numberline {9.7.1}Differential Diagnoses}{230}{subsection.9.7.1}%
\contentsline {subsection}{\numberline {9.7.2}Workup}{231}{subsection.9.7.2}%
\contentsline {subsection}{\numberline {9.7.3}Management}{232}{subsection.9.7.3}%
\contentsline {subsection}{\numberline {9.7.4}Discharge Criteria}{232}{subsection.9.7.4}%
\contentsline {section}{\numberline {9.8}Animal Bites}{233}{section.9.8}%
\contentsline {subsection}{\numberline {9.8.1}Bacteria}{233}{subsection.9.8.1}%
\contentsline {subsection}{\numberline {9.8.2}Clinical Presentation}{233}{subsection.9.8.2}%
\contentsline {subsection}{\numberline {9.8.3}Workup}{233}{subsection.9.8.3}%
\contentsline {subsection}{\numberline {9.8.4}Management and Treatment}{234}{subsection.9.8.4}%
\contentsline {section}{\numberline {9.9}Brief Resolved Unexplained Event (BRUE)}{234}{section.9.9}%
\contentsline {subsection}{\numberline {9.9.1}Presentation}{235}{subsection.9.9.1}%
\contentsline {subsection}{\numberline {9.9.2}Workup}{235}{subsection.9.9.2}%
\contentsline {subsection}{\numberline {9.9.3}Management and Treatment}{235}{subsection.9.9.3}%
\contentsline {section}{\numberline {9.10}Burns}{236}{section.9.10}%
\contentsline {subsection}{\numberline {9.10.1}Classification: 1st degree}{236}{subsection.9.10.1}%
\contentsline {subsection}{\numberline {9.10.2}Classification: 2nd degree}{236}{subsection.9.10.2}%
\contentsline {subsection}{\numberline {9.10.3}Classification: 3rd Degree}{236}{subsection.9.10.3}%
\contentsline {subsection}{\numberline {9.10.4}Pathogenesis}{236}{subsection.9.10.4}%
\contentsline {subsection}{\numberline {9.10.5}Estimating Burn Size}{237}{subsection.9.10.5}%
\contentsline {subsection}{\numberline {9.10.6}Workup}{239}{subsection.9.10.6}%
\contentsline {subsection}{\numberline {9.10.7}Treatment}{239}{subsection.9.10.7}%
\contentsline {section}{\numberline {9.11}Deep Space Neck Infections}{240}{section.9.11}%
\contentsline {subsection}{\numberline {9.11.1}Peritonsillar Abscess}{240}{subsection.9.11.1}%
\contentsline {subsubsection}{\numberline {9.11.1.1}Workup}{240}{subsubsection.9.11.1.1}%
\contentsline {subsubsection}{\numberline {9.11.1.2}Treatment}{240}{subsubsection.9.11.1.2}%
\contentsline {subsubsection}{\numberline {9.11.1.3}Complications}{241}{subsubsection.9.11.1.3}%
\contentsline {subsection}{\numberline {9.11.2}Parapharyngeal Abscess}{241}{subsection.9.11.2}%
\contentsline {subsubsection}{\numberline {9.11.2.1}Workup}{241}{subsubsection.9.11.2.1}%
\contentsline {subsubsection}{\numberline {9.11.2.2}Treatment}{241}{subsubsection.9.11.2.2}%
\contentsline {subsubsection}{\numberline {9.11.2.3}Complications}{241}{subsubsection.9.11.2.3}%
\contentsline {subsection}{\numberline {9.11.3}Retropharyngeal Abscess}{242}{subsection.9.11.3}%
\contentsline {subsubsection}{\numberline {9.11.3.1}Workup}{242}{subsubsection.9.11.3.1}%
\contentsline {subsubsection}{\numberline {9.11.3.2}Treatment}{242}{subsubsection.9.11.3.2}%
\contentsline {subsubsection}{\numberline {9.11.3.3}Complications}{242}{subsubsection.9.11.3.3}%
\contentsline {section}{\numberline {9.12}Dehydration}{242}{section.9.12}%
\contentsline {subsection}{\numberline {9.12.1}Definition}{243}{subsection.9.12.1}%
\contentsline {subsection}{\numberline {9.12.2}Presentation}{243}{subsection.9.12.2}%
\contentsline {subsection}{\numberline {9.12.3}Physical Findings of Volume Depletion}{243}{subsection.9.12.3}%
\contentsline {subsection}{\numberline {9.12.4}Differential}{243}{subsection.9.12.4}%
\contentsline {subsection}{\numberline {9.12.5}Workup}{243}{subsection.9.12.5}%
\contentsline {subsection}{\numberline {9.12.6}Treatment}{244}{subsection.9.12.6}%
\contentsline {subsubsection}{\numberline {9.12.6.1}Mild}{244}{subsubsection.9.12.6.1}%
\contentsline {subsubsection}{\numberline {9.12.6.2}Moderate}{244}{subsubsection.9.12.6.2}%
\contentsline {subsubsection}{\numberline {9.12.6.3}Severe}{245}{subsubsection.9.12.6.3}%
\contentsline {subsubsection}{\numberline {9.12.6.4}ORT failure}{245}{subsubsection.9.12.6.4}%
\contentsline {subsubsection}{\numberline {9.12.6.5}Ondansetron}{245}{subsubsection.9.12.6.5}%
\contentsline {subsubsection}{\numberline {9.12.6.6}Discahrge Criteria}{245}{subsubsection.9.12.6.6}%
\contentsline {section}{\numberline {9.13}Dental Emergencies}{246}{section.9.13}%
\contentsline {subsection}{\numberline {9.13.1}Avulsion}{249}{subsection.9.13.1}%
\contentsline {subsection}{\numberline {9.13.2}Fracture}{249}{subsection.9.13.2}%
\contentsline {subsection}{\numberline {9.13.3}Luxation Injuries}{250}{subsection.9.13.3}%
\contentsline {subsubsection}{\numberline {9.13.3.1}Concussion}{250}{subsubsection.9.13.3.1}%
\contentsline {subsubsection}{\numberline {9.13.3.2}Subluxation}{250}{subsubsection.9.13.3.2}%
\contentsline {subsubsection}{\numberline {9.13.3.3}Intrusion}{250}{subsubsection.9.13.3.3}%
\contentsline {subsubsection}{\numberline {9.13.3.4}Extrusion}{250}{subsubsection.9.13.3.4}%
\contentsline {subsubsection}{\numberline {9.13.3.5}Lateral luxation}{250}{subsubsection.9.13.3.5}%
\contentsline {subsection}{\numberline {9.13.4}Workup}{250}{subsection.9.13.4}%
\contentsline {subsection}{\numberline {9.13.5}Treatment}{251}{subsection.9.13.5}%
\contentsline {subsubsection}{\numberline {9.13.5.1}General aftercare}{251}{subsubsection.9.13.5.1}%
\contentsline {section}{\numberline {9.14}Epistaxis}{252}{section.9.14}%
\contentsline {subsection}{\numberline {9.14.1}Pathogenesis}{252}{subsection.9.14.1}%
\contentsline {subsection}{\numberline {9.14.2}Etiology}{252}{subsection.9.14.2}%
\contentsline {subsection}{\numberline {9.14.3}Clinical Presentation}{252}{subsection.9.14.3}%
\contentsline {subsection}{\numberline {9.14.4}Workup}{253}{subsection.9.14.4}%
\contentsline {subsection}{\numberline {9.14.5}Treatment}{253}{subsection.9.14.5}%
\contentsline {section}{\numberline {9.15}Febrile Infant}{253}{section.9.15}%
\contentsline {subsection}{\numberline {9.15.1}Definition}{253}{subsection.9.15.1}%
\contentsline {subsection}{\numberline {9.15.2}Etiology}{254}{subsection.9.15.2}%
\contentsline {subsection}{\numberline {9.15.3}Pathogenesis}{254}{subsection.9.15.3}%
\contentsline {subsection}{\numberline {9.15.4}Most Common Pathogens by Age}{254}{subsection.9.15.4}%
\contentsline {subsection}{\numberline {9.15.5}Clinical Presentation}{254}{subsection.9.15.5}%
\contentsline {subsubsection}{\numberline {9.15.5.1}History}{255}{subsubsection.9.15.5.1}%
\contentsline {subsubsection}{\numberline {9.15.5.2}Physical exam}{255}{subsubsection.9.15.5.2}%
\contentsline {subsection}{\numberline {9.15.6}Workup}{255}{subsection.9.15.6}%
\contentsline {subsubsection}{\numberline {9.15.6.1}Age 0- \textless 1 month (well-appearing)}{255}{subsubsection.9.15.6.1}%
\contentsline {subsubsection}{\numberline {9.15.6.2}Age 1- \textless 2 months (well-appearing)}{255}{subsubsection.9.15.6.2}%
\contentsline {subsection}{\numberline {9.15.7}Treatment}{256}{subsection.9.15.7}%
\contentsline {subsubsection}{\numberline {9.15.7.1}Emperic Antibiotic Treatment Based on Age}{256}{subsubsection.9.15.7.1}%
\contentsline {section}{\numberline {9.16}Foreign Body Aspiration}{256}{section.9.16}%
\contentsline {subsection}{\numberline {9.16.1}Presentation}{256}{subsection.9.16.1}%
\contentsline {subsection}{\numberline {9.16.2}Workup}{257}{subsection.9.16.2}%
\contentsline {subsubsection}{\numberline {9.16.2.1}Physical Exam}{257}{subsubsection.9.16.2.1}%
\contentsline {subsubsection}{\numberline {9.16.2.2}Diagnostic Studies}{257}{subsubsection.9.16.2.2}%
\contentsline {subsection}{\numberline {9.16.3}Management}{257}{subsection.9.16.3}%
\contentsline {section}{\numberline {9.17}Foreign Body Ingestion}{257}{section.9.17}%
\contentsline {subsection}{\numberline {9.17.1}Pathogenesis}{257}{subsection.9.17.1}%
\contentsline {subsection}{\numberline {9.17.2}Presentation}{258}{subsection.9.17.2}%
\contentsline {subsection}{\numberline {9.17.3}Workup}{258}{subsection.9.17.3}%
\contentsline {subsection}{\numberline {9.17.4}Treatment}{258}{subsection.9.17.4}%
\contentsline {subsubsection}{\numberline {9.17.4.1}Button batteries}{258}{subsubsection.9.17.4.1}%
\contentsline {subsubsection}{\numberline {9.17.4.2}Coins/Blunt objects}{258}{subsubsection.9.17.4.2}%
\contentsline {subsubsection}{\numberline {9.17.4.3}Sharp objects}{258}{subsubsection.9.17.4.3}%
\contentsline {subsubsection}{\numberline {9.17.4.4}Magnets}{258}{subsubsection.9.17.4.4}%
\contentsline {subsubsection}{\numberline {9.17.4.5}Food impaction}{259}{subsubsection.9.17.4.5}%
\contentsline {section}{\numberline {9.18}Suspected Child Abuse}{259}{section.9.18}%
\contentsline {subsection}{\numberline {9.18.1}Presentation}{259}{subsection.9.18.1}%
\contentsline {subsubsection}{\numberline {9.18.1.1}Skeletal injuries}{259}{subsubsection.9.18.1.1}%
\contentsline {subsubsection}{\numberline {9.18.1.2}Bruises}{259}{subsubsection.9.18.1.2}%
\contentsline {subsubsection}{\numberline {9.18.1.3}Burns}{259}{subsubsection.9.18.1.3}%
\contentsline {subsubsection}{\numberline {9.18.1.4}Head trauma}{260}{subsubsection.9.18.1.4}%
\contentsline {subsection}{\numberline {9.18.2}Workup}{260}{subsection.9.18.2}%
\contentsline {section}{\numberline {9.19}Sexual Assault}{260}{section.9.19}%
\contentsline {subsection}{\numberline {9.19.1}Workup (\textless 12yo)}{260}{subsection.9.19.1}%
\contentsline {subsubsection}{\numberline {9.19.1.1}Occurred \textless 72 hours:}{260}{subsubsection.9.19.1.1}%
\contentsline {subsubsection}{\numberline {9.19.1.2}Occurred \textgreater 72 hours:}{261}{subsubsection.9.19.1.2}%
\contentsline {subsection}{\numberline {9.19.2}Treatment (\textless 12yo)}{261}{subsection.9.19.2}%
\contentsline {subsection}{\numberline {9.19.3}Workup (\textgreater 12yo)}{261}{subsection.9.19.3}%
\contentsline {subsubsection}{\numberline {9.19.3.1}Occurred \textless 120 hours (5 days):}{262}{subsubsection.9.19.3.1}%
\contentsline {subsubsection}{\numberline {9.19.3.2}Occurred \textgreater 120 hours (5 days) ago:}{262}{subsubsection.9.19.3.2}%
\contentsline {subsection}{\numberline {9.19.4}Treatment (\textgreater 12yo)}{262}{subsection.9.19.4}%
\contentsline {subsection}{\numberline {9.19.5}Discharge planning (\textgreater 12yo)}{262}{subsection.9.19.5}%
\contentsline {section}{\numberline {9.20}Syncope}{262}{section.9.20}%
\contentsline {subsection}{\numberline {9.20.1}Differential}{263}{subsection.9.20.1}%
\contentsline {subsubsection}{\numberline {9.20.1.1}Common conditions}{263}{subsubsection.9.20.1.1}%
\contentsline {subsubsection}{\numberline {9.20.1.2}Life-threatening}{263}{subsubsection.9.20.1.2}%
\contentsline {subsubsection}{\numberline {9.20.1.3}Other}{263}{subsubsection.9.20.1.3}%
\contentsline {subsection}{\numberline {9.20.2}Workup}{263}{subsection.9.20.2}%
\contentsline {subsubsection}{\numberline {9.20.2.1}History and Physical Exam}{263}{subsubsection.9.20.2.1}%
\contentsline {subsubsection}{\numberline {9.20.2.2}Labs and Imaging}{264}{subsubsection.9.20.2.2}%
\contentsline {section}{\numberline {9.21}Trauma}{264}{section.9.21}%
\contentsline {subsection}{\numberline {9.21.1}ATLS}{264}{subsection.9.21.1}%
\contentsline {subsubsection}{\numberline {9.21.1.1}Primary Survey}{264}{subsubsection.9.21.1.1}%
\contentsline {subsubsection}{\numberline {9.21.1.2}Secondary Survey}{264}{subsubsection.9.21.1.2}%
\contentsline {paragraph}{\numberline {9.21.1.2.1}Head}{265}{paragraph.9.21.1.2.1}%
\contentsline {paragraph}{\numberline {9.21.1.2.2}Eye}{265}{paragraph.9.21.1.2.2}%
\contentsline {paragraph}{\numberline {9.21.1.2.3}Neck}{265}{paragraph.9.21.1.2.3}%
\contentsline {paragraph}{\numberline {9.21.1.2.4}Chest}{265}{paragraph.9.21.1.2.4}%
\contentsline {paragraph}{\numberline {9.21.1.2.5}Abdomen}{265}{paragraph.9.21.1.2.5}%
\contentsline {paragraph}{\numberline {9.21.1.2.6}Pelvis}{265}{paragraph.9.21.1.2.6}%
\contentsline {paragraph}{\numberline {9.21.1.2.7}GU}{265}{paragraph.9.21.1.2.7}%
\contentsline {paragraph}{\numberline {9.21.1.2.8}Back}{265}{paragraph.9.21.1.2.8}%
\contentsline {paragraph}{\numberline {9.21.1.2.9}Extremities}{266}{paragraph.9.21.1.2.9}%
\contentsline {paragraph}{\numberline {9.21.1.2.10}Neurologic}{266}{paragraph.9.21.1.2.10}%
\contentsline {paragraph}{\numberline {9.21.1.2.11}Skin}{266}{paragraph.9.21.1.2.11}%
\contentsline {section}{\numberline {9.22}Mild Traumatic Brain Injury (Contusion and Concussion)}{266}{section.9.22}%
\contentsline {subsection}{\numberline {9.22.1}Definition}{266}{subsection.9.22.1}%
\contentsline {subsection}{\numberline {9.22.2}Pathogenesis}{266}{subsection.9.22.2}%
\contentsline {subsection}{\numberline {9.22.3}Presentation}{266}{subsection.9.22.3}%
\contentsline {subsection}{\numberline {9.22.4}Workup}{267}{subsection.9.22.4}%
\contentsline {subsubsection}{\numberline {9.22.4.1}History}{267}{subsubsection.9.22.4.1}%
\contentsline {subsubsection}{\numberline {9.22.4.2}Physical}{267}{subsubsection.9.22.4.2}%
\contentsline {subsubsection}{\numberline {9.22.4.3}PECARN algorithm}{267}{subsubsection.9.22.4.3}%
\contentsline {subsection}{\numberline {9.22.5}Treatment}{268}{subsection.9.22.5}%
\contentsline {section}{\numberline {9.23}Cervical Spine Injury}{269}{section.9.23}%
\contentsline {subsection}{\numberline {9.23.1}Workup \& Treatment}{269}{subsection.9.23.1}%
\contentsline {section}{\numberline {9.24}Laceration Repair}{270}{section.9.24}%
\contentsline {subsection}{\numberline {9.24.1}Equipment}{270}{subsection.9.24.1}%
\contentsline {subsection}{\numberline {9.24.2}General Technique}{272}{subsection.9.24.2}%
\contentsline {chapter}{\numberline {10}Endocrinology}{275}{chapter.10}%
\contentsline {section}{\numberline {10.1}Adrenal Insufficiency}{275}{section.10.1}%
\contentsline {subsection}{\numberline {10.1.1}PowerPlan/Order sets}{275}{subsection.10.1.1}%
\contentsline {subsection}{\numberline {10.1.2}Definition}{275}{subsection.10.1.2}%
\contentsline {subsection}{\numberline {10.1.3}Presentation}{275}{subsection.10.1.3}%
\contentsline {subsection}{\numberline {10.1.4}Diagnostic Studies}{276}{subsection.10.1.4}%
\contentsline {subsection}{\numberline {10.1.5}Acute Treatment}{276}{subsection.10.1.5}%
\contentsline {subsection}{\numberline {10.1.6}Maintenance Therapy}{276}{subsection.10.1.6}%
\contentsline {section}{\numberline {10.2}Diabetic Ketoacidosis}{276}{section.10.2}%
\contentsline {subsection}{\numberline {10.2.1}PowerPlan/Order sets}{276}{subsection.10.2.1}%
\contentsline {subsection}{\numberline {10.2.2}Definition}{276}{subsection.10.2.2}%
\contentsline {subsection}{\numberline {10.2.3}Pathophysiology}{276}{subsection.10.2.3}%
\contentsline {subsection}{\numberline {10.2.4}Presentation}{277}{subsection.10.2.4}%
\contentsline {subsection}{\numberline {10.2.5}Diagnostic Studies}{277}{subsection.10.2.5}%
\contentsline {subsection}{\numberline {10.2.6}Treatment}{277}{subsection.10.2.6}%
\contentsline {subsection}{\numberline {10.2.7}Subcutaneous Insulin Regimen}{278}{subsection.10.2.7}%
\contentsline {section}{\numberline {10.3}Hypoglycemia}{278}{section.10.3}%
\contentsline {subsection}{\numberline {10.3.1}PowerPlan/Order sets}{278}{subsection.10.3.1}%
\contentsline {subsection}{\numberline {10.3.2}Definition}{279}{subsection.10.3.2}%
\contentsline {subsection}{\numberline {10.3.3}Etiology}{279}{subsection.10.3.3}%
\contentsline {subsection}{\numberline {10.3.4}Presentation}{279}{subsection.10.3.4}%
\contentsline {subsection}{\numberline {10.3.5}Diagnostic Approach}{279}{subsection.10.3.5}%
\contentsline {subsection}{\numberline {10.3.6}Diagnostic Studies}{279}{subsection.10.3.6}%
\contentsline {subsection}{\numberline {10.3.7}Treatment}{280}{subsection.10.3.7}%
\contentsline {section}{\numberline {10.4}Diabetes Insipidus}{280}{section.10.4}%
\contentsline {subsection}{\numberline {10.4.1}PowerPlan/Order sets}{280}{subsection.10.4.1}%
\contentsline {subsection}{\numberline {10.4.2}Definition}{280}{subsection.10.4.2}%
\contentsline {subsection}{\numberline {10.4.3}Etiology}{280}{subsection.10.4.3}%
\contentsline {subsection}{\numberline {10.4.4}Presentation}{281}{subsection.10.4.4}%
\contentsline {subsection}{\numberline {10.4.5}Diagnostic Studies}{281}{subsection.10.4.5}%
\contentsline {subsection}{\numberline {10.4.6}Treatment}{281}{subsection.10.4.6}%
\contentsline {section}{\numberline {10.5}Syndrome of Inappropriate ADH (SIADH)}{281}{section.10.5}%
\contentsline {subsection}{\numberline {10.5.1}Definition}{281}{subsection.10.5.1}%
\contentsline {subsection}{\numberline {10.5.2}Etiology}{281}{subsection.10.5.2}%
\contentsline {subsection}{\numberline {10.5.3}Pathophysiology}{282}{subsection.10.5.3}%
\contentsline {subsection}{\numberline {10.5.4}Presentation}{282}{subsection.10.5.4}%
\contentsline {subsection}{\numberline {10.5.5}Diagnostic Studies}{282}{subsection.10.5.5}%
\contentsline {subsection}{\numberline {10.5.6}Treatment}{282}{subsection.10.5.6}%
\contentsline {section}{\numberline {10.6}Calcium Homeostasis}{282}{section.10.6}%
\contentsline {section}{\numberline {10.7}Hypocalcemia}{283}{section.10.7}%
\contentsline {subsection}{\numberline {10.7.1}Definition}{283}{subsection.10.7.1}%
\contentsline {subsection}{\numberline {10.7.2}Etiology}{283}{subsection.10.7.2}%
\contentsline {subsubsection}{\numberline {10.7.2.1}Low PTH (Hypoparathyroidism)}{283}{subsubsection.10.7.2.1}%
\contentsline {subsubsection}{\numberline {10.7.2.2}High PTH}{283}{subsubsection.10.7.2.2}%
\contentsline {subsubsection}{\numberline {10.7.2.3}Other Causes}{284}{subsubsection.10.7.2.3}%
\contentsline {subsection}{\numberline {10.7.3}Clinical Manifestations}{284}{subsection.10.7.3}%
\contentsline {subsection}{\numberline {10.7.4}Diagnostic Studies}{285}{subsection.10.7.4}%
\contentsline {subsection}{\numberline {10.7.5}Treatment}{285}{subsection.10.7.5}%
\contentsline {section}{\numberline {10.8}Hypercalcemia}{285}{section.10.8}%
\contentsline {subsection}{\numberline {10.8.1}Definition}{285}{subsection.10.8.1}%
\contentsline {subsection}{\numberline {10.8.2}Etiology}{285}{subsection.10.8.2}%
\contentsline {subsubsection}{\numberline {10.8.2.1}Parathyroid Related}{285}{subsubsection.10.8.2.1}%
\contentsline {subsubsection}{\numberline {10.8.2.2}Increased Bone Reabsorption}{286}{subsubsection.10.8.2.2}%
\contentsline {subsubsection}{\numberline {10.8.2.3}Increased 1,25 OHD Production}{286}{subsubsection.10.8.2.3}%
\contentsline {subsubsection}{\numberline {10.8.2.4}Metabolic Disorders}{286}{subsubsection.10.8.2.4}%
\contentsline {subsubsection}{\numberline {10.8.2.5}Medications}{286}{subsubsection.10.8.2.5}%
\contentsline {subsubsection}{\numberline {10.8.2.6}Other}{286}{subsubsection.10.8.2.6}%
\contentsline {subsection}{\numberline {10.8.3}Clinical Manifestations}{286}{subsection.10.8.3}%
\contentsline {subsection}{\numberline {10.8.4}Diagnostic Algorithm}{286}{subsection.10.8.4}%
\contentsline {subsection}{\numberline {10.8.5}Treatment}{287}{subsection.10.8.5}%
\contentsline {chapter}{\numberline {11}Gastroenterology, Hepatology \& Nutrition}{289}{chapter.11}%
\contentsline {section}{\numberline {11.1}Constipation}{289}{section.11.1}%
\contentsline {subsection}{\numberline {11.1.1}Bristol Stool Chart}{289}{subsection.11.1.1}%
\contentsline {subsection}{\numberline {11.1.2}PowerPlans, Order Sets \& Clinical Pathways}{289}{subsection.11.1.2}%
\contentsline {subsection}{\numberline {11.1.3}Presentation}{290}{subsection.11.1.3}%
\contentsline {subsection}{\numberline {11.1.4}Differential}{290}{subsection.11.1.4}%
\contentsline {subsection}{\numberline {11.1.5}Red Flags}{290}{subsection.11.1.5}%
\contentsline {subsection}{\numberline {11.1.6}Work-up}{290}{subsection.11.1.6}%
\contentsline {subsection}{\numberline {11.1.7}Management}{290}{subsection.11.1.7}%
\contentsline {subsubsection}{\numberline {11.1.7.1}Clean Out (evidence of impaction)}{291}{subsubsection.11.1.7.1}%
\contentsline {subsubsection}{\numberline {11.1.7.2}Maintenance}{291}{subsubsection.11.1.7.2}%
\contentsline {section}{\numberline {11.2}Diarrhea}{291}{section.11.2}%
\contentsline {subsection}{\numberline {11.2.1}PowerPlans, Order Sets \& Clinical Pathways}{291}{subsection.11.2.1}%
\contentsline {subsection}{\numberline {11.2.2}Differential}{292}{subsection.11.2.2}%
\contentsline {subsubsection}{\numberline {11.2.2.1}Acute vs.\nobreakspace {}chronic}{292}{subsubsection.11.2.2.1}%
\contentsline {subsubsection}{\numberline {11.2.2.2}Most common vs.\nobreakspace {}can't miss}{292}{subsubsection.11.2.2.2}%
\contentsline {subsection}{\numberline {11.2.3}Work-up}{292}{subsection.11.2.3}%
\contentsline {subsection}{\numberline {11.2.4}Interpretation}{293}{subsection.11.2.4}%
\contentsline {subsubsection}{\numberline {11.2.4.1}Stool Studies}{293}{subsubsection.11.2.4.1}%
\contentsline {subsubsection}{\numberline {11.2.4.2}Differentiating osmotic vs.\nobreakspace {}secretory diarrhea}{293}{subsubsection.11.2.4.2}%
\contentsline {subsection}{\numberline {11.2.5}Acute Management}{293}{subsection.11.2.5}%
\contentsline {section}{\numberline {11.3}Acute Gastroenteritis}{293}{section.11.3}%
\contentsline {subsection}{\numberline {11.3.1}PowerPlans, Order Sets \& Clinical Pathways}{293}{subsection.11.3.1}%
\contentsline {subsection}{\numberline {11.3.2}Presentation}{293}{subsection.11.3.2}%
\contentsline {subsection}{\numberline {11.3.3}Pathophysiology}{294}{subsection.11.3.3}%
\contentsline {subsection}{\numberline {11.3.4}Management}{294}{subsection.11.3.4}%
\contentsline {subsection}{\numberline {11.3.5}Anticipatory Guidance}{294}{subsection.11.3.5}%
\contentsline {section}{\numberline {11.4}Clostridium Difficile (C. diff)}{294}{section.11.4}%
\contentsline {subsection}{\numberline {11.4.1}PowerPlans, Order Sets \& Clinical Pathways}{294}{subsection.11.4.1}%
\contentsline {subsection}{\numberline {11.4.2}Presentation}{294}{subsection.11.4.2}%
\contentsline {subsection}{\numberline {11.4.3}Pathophysiology}{295}{subsection.11.4.3}%
\contentsline {subsection}{\numberline {11.4.4}Work-up}{295}{subsection.11.4.4}%
\contentsline {subsection}{\numberline {11.4.5}Management}{295}{subsection.11.4.5}%
\contentsline {section}{\numberline {11.5}Inflammatory Bowel Disease (IBD)}{295}{section.11.5}%
\contentsline {subsection}{\numberline {11.5.1}PowerPlans, Order Sets \& Clinical Pathways}{295}{subsection.11.5.1}%
\contentsline {subsection}{\numberline {11.5.2}Crohn's Disease (CD)}{295}{subsection.11.5.2}%
\contentsline {subsubsection}{\numberline {11.5.2.1}Epidemiology}{295}{subsubsection.11.5.2.1}%
\contentsline {subsubsection}{\numberline {11.5.2.2}Risk Factors}{295}{subsubsection.11.5.2.2}%
\contentsline {subsubsection}{\numberline {11.5.2.3}Presentation}{296}{subsubsection.11.5.2.3}%
\contentsline {subsubsection}{\numberline {11.5.2.4}Work-up}{296}{subsubsection.11.5.2.4}%
\contentsline {subsubsection}{\numberline {11.5.2.5}Management}{296}{subsubsection.11.5.2.5}%
\contentsline {subsection}{\numberline {11.5.3}Ulcerative Colitis (UC)}{297}{subsection.11.5.3}%
\contentsline {subsubsection}{\numberline {11.5.3.1}Epidemiology}{297}{subsubsection.11.5.3.1}%
\contentsline {subsubsection}{\numberline {11.5.3.2}Risk Factors}{297}{subsubsection.11.5.3.2}%
\contentsline {subsubsection}{\numberline {11.5.3.3}Presentation}{297}{subsubsection.11.5.3.3}%
\contentsline {subsubsection}{\numberline {11.5.3.4}Work-up}{297}{subsubsection.11.5.3.4}%
\contentsline {subsubsection}{\numberline {11.5.3.5}Management}{297}{subsubsection.11.5.3.5}%
\contentsline {section}{\numberline {11.6}Malabsorption}{298}{section.11.6}%
\contentsline {subsection}{\numberline {11.6.1}Carbohydrates}{298}{subsection.11.6.1}%
\contentsline {subsubsection}{\numberline {11.6.1.1}Presentation}{298}{subsubsection.11.6.1.1}%
\contentsline {subsubsection}{\numberline {11.6.1.2}Pathophysiology}{298}{subsubsection.11.6.1.2}%
\contentsline {subsubsection}{\numberline {11.6.1.3}Work-up}{298}{subsubsection.11.6.1.3}%
\contentsline {subsection}{\numberline {11.6.2}Fat}{298}{subsection.11.6.2}%
\contentsline {subsubsection}{\numberline {11.6.2.1}Presentation}{298}{subsubsection.11.6.2.1}%
\contentsline {subsubsection}{\numberline {11.6.2.2}Pathophysiology}{298}{subsubsection.11.6.2.2}%
\contentsline {subsubsection}{\numberline {11.6.2.3}Work-up}{299}{subsubsection.11.6.2.3}%
\contentsline {subsection}{\numberline {11.6.3}Protein}{299}{subsection.11.6.3}%
\contentsline {subsubsection}{\numberline {11.6.3.1}Presentation}{299}{subsubsection.11.6.3.1}%
\contentsline {subsubsection}{\numberline {11.6.3.2}Pathophysiology}{299}{subsubsection.11.6.3.2}%
\contentsline {subsubsection}{\numberline {11.6.3.3}Work-up}{299}{subsubsection.11.6.3.3}%
\contentsline {section}{\numberline {11.7}Celiac Disease}{299}{section.11.7}%
\contentsline {subsection}{\numberline {11.7.1}PowerPlans, Order Sets \& Clinical Pathways}{299}{subsection.11.7.1}%
\contentsline {subsection}{\numberline {11.7.2}Presentation}{299}{subsection.11.7.2}%
\contentsline {subsection}{\numberline {11.7.3}Pathophysiology}{299}{subsection.11.7.3}%
\contentsline {subsection}{\numberline {11.7.4}Work-up}{300}{subsection.11.7.4}%
\contentsline {subsection}{\numberline {11.7.5}Management}{300}{subsection.11.7.5}%
\contentsline {section}{\numberline {11.8}Gastrointestinal Bleeding}{300}{section.11.8}%
\contentsline {subsection}{\numberline {11.8.1}PowerPlans, Order Sets \& Clinical Pathways}{300}{subsection.11.8.1}%
\contentsline {subsection}{\numberline {11.8.2}Presentation}{300}{subsection.11.8.2}%
\contentsline {subsection}{\numberline {11.8.3}Anatomy}{300}{subsection.11.8.3}%
\contentsline {subsection}{\numberline {11.8.4}Work-up}{301}{subsection.11.8.4}%
\contentsline {subsection}{\numberline {11.8.5}Differential Diagnosis}{301}{subsection.11.8.5}%
\contentsline {subsubsection}{\numberline {11.8.5.1}Upper GI Bleed (UGIB)}{301}{subsubsection.11.8.5.1}%
\contentsline {subsubsection}{\numberline {11.8.5.2}Lower GI Bleed (LGIB)}{302}{subsubsection.11.8.5.2}%
\contentsline {subsection}{\numberline {11.8.6}Management}{303}{subsection.11.8.6}%
\contentsline {section}{\numberline {11.9}Gastroesophageal Reflux Disease (GER/GERD)}{303}{section.11.9}%
\contentsline {subsection}{\numberline {11.9.1}PowerPlans, Order Sets \& Clinical Pathways}{303}{subsection.11.9.1}%
\contentsline {subsection}{\numberline {11.9.2}Definitions}{303}{subsection.11.9.2}%
\contentsline {subsection}{\numberline {11.9.3}Presentation}{303}{subsection.11.9.3}%
\contentsline {subsection}{\numberline {11.9.4}Management}{303}{subsection.11.9.4}%
\contentsline {section}{\numberline {11.10}Pancreatitis}{304}{section.11.10}%
\contentsline {subsection}{\numberline {11.10.1}PowerPlans, Order Sets \& Clinical Pathways}{304}{subsection.11.10.1}%
\contentsline {subsection}{\numberline {11.10.2}Presentation}{304}{subsection.11.10.2}%
\contentsline {subsection}{\numberline {11.10.3}Pathophysiology}{304}{subsection.11.10.3}%
\contentsline {subsection}{\numberline {11.10.4}Diagnostic Criteria}{305}{subsection.11.10.4}%
\contentsline {subsection}{\numberline {11.10.5}Work-up}{305}{subsection.11.10.5}%
\contentsline {subsection}{\numberline {11.10.6}Management}{305}{subsection.11.10.6}%
\contentsline {subsection}{\numberline {11.10.7}Complications}{305}{subsection.11.10.7}%
\contentsline {section}{\numberline {11.11}Functional Gastrointestinal Disorders (FGID)}{305}{section.11.11}%
\contentsline {subsection}{\numberline {11.11.1}Pathophysiology}{305}{subsection.11.11.1}%
\contentsline {subsection}{\numberline {11.11.2}Alarm Symptoms}{305}{subsection.11.11.2}%
\contentsline {subsection}{\numberline {11.11.3}Management}{306}{subsection.11.11.3}%
\contentsline {subsection}{\numberline {11.11.4}Irritable Bowel Syndrome (IBS)}{306}{subsection.11.11.4}%
\contentsline {subsubsection}{\numberline {11.11.4.1}Presentation (Rome IV Criteria)}{306}{subsubsection.11.11.4.1}%
\contentsline {subsubsection}{\numberline {11.11.4.2}Specific Management}{306}{subsubsection.11.11.4.2}%
\contentsline {subsection}{\numberline {11.11.5}Functional Dyspepsia (FD)}{306}{subsection.11.11.5}%
\contentsline {subsubsection}{\numberline {11.11.5.1}Presentation (Rome IV Criteria)}{306}{subsubsection.11.11.5.1}%
\contentsline {subsubsection}{\numberline {11.11.5.2}Specific Management}{307}{subsubsection.11.11.5.2}%
\contentsline {subsection}{\numberline {11.11.6}Abdominal Migraine}{307}{subsection.11.11.6}%
\contentsline {subsubsection}{\numberline {11.11.6.1}Presentation (Rome IV Criteria)}{307}{subsubsection.11.11.6.1}%
\contentsline {subsubsection}{\numberline {11.11.6.2}Specific Management}{307}{subsubsection.11.11.6.2}%
\contentsline {subsection}{\numberline {11.11.7}Functional Abdominal Pain (FAP)}{307}{subsection.11.11.7}%
\contentsline {subsubsection}{\numberline {11.11.7.1}Presentation (Rome IV Criteria)}{307}{subsubsection.11.11.7.1}%
\contentsline {subsubsection}{\numberline {11.11.7.2}Specific Management}{307}{subsubsection.11.11.7.2}%
\contentsline {subsection}{\numberline {11.11.8}Cyclic Vomiting Syndrome}{307}{subsection.11.11.8}%
\contentsline {subsubsection}{\numberline {11.11.8.1}Presentation (Rome IV Criteria)}{307}{subsubsection.11.11.8.1}%
\contentsline {subsubsection}{\numberline {11.11.8.2}Specific Management}{307}{subsubsection.11.11.8.2}%
\contentsline {subsection}{\numberline {11.11.9}Functional Nausea}{308}{subsection.11.11.9}%
\contentsline {subsubsection}{\numberline {11.11.9.1}Presentation (Rome IV Criteria)}{308}{subsubsection.11.11.9.1}%
\contentsline {subsection}{\numberline {11.11.10}Functional Vomiting}{308}{subsection.11.11.10}%
\contentsline {subsubsection}{\numberline {11.11.10.1}Presentation (Rome IV Criteria)}{308}{subsubsection.11.11.10.1}%
\contentsline {subsection}{\numberline {11.11.11}Rumination Syndrome}{308}{subsection.11.11.11}%
\contentsline {subsubsection}{\numberline {11.11.11.1}Presentation (Rome IV Criteria)}{308}{subsubsection.11.11.11.1}%
\contentsline {subsubsection}{\numberline {11.11.11.2}Specific Management}{308}{subsubsection.11.11.11.2}%
\contentsline {section}{\numberline {11.12}Newborn GI}{308}{section.11.12}%
\contentsline {subsection}{\numberline {11.12.1}Pyloric Stenosis}{308}{subsection.11.12.1}%
\contentsline {subsubsection}{\numberline {11.12.1.1}Presentation}{308}{subsubsection.11.12.1.1}%
\contentsline {subsubsection}{\numberline {11.12.1.2}Pathophysiology}{308}{subsubsection.11.12.1.2}%
\contentsline {subsubsection}{\numberline {11.12.1.3}Work-up}{308}{subsubsection.11.12.1.3}%
\contentsline {subsubsection}{\numberline {11.12.1.4}Management}{309}{subsubsection.11.12.1.4}%
\contentsline {subsection}{\numberline {11.12.2}Malrotation/Volvulus}{309}{subsection.11.12.2}%
\contentsline {subsubsection}{\numberline {11.12.2.1}Presentation}{309}{subsubsection.11.12.2.1}%
\contentsline {subsubsection}{\numberline {11.12.2.2}Pathophysiology}{309}{subsubsection.11.12.2.2}%
\contentsline {subsubsection}{\numberline {11.12.2.3}Work-up}{309}{subsubsection.11.12.2.3}%
\contentsline {subsubsection}{\numberline {11.12.2.4}Management}{310}{subsubsection.11.12.2.4}%
\contentsline {subsection}{\numberline {11.12.3}Biliary Atresia (BA)}{310}{subsection.11.12.3}%
\contentsline {subsubsection}{\numberline {11.12.3.1}Presentation}{310}{subsubsection.11.12.3.1}%
\contentsline {subsubsection}{\numberline {11.12.3.2}Pathophysiology}{310}{subsubsection.11.12.3.2}%
\contentsline {subsubsection}{\numberline {11.12.3.3}Work-up}{310}{subsubsection.11.12.3.3}%
\contentsline {subsubsection}{\numberline {11.12.3.4}Management}{310}{subsubsection.11.12.3.4}%
\contentsline {section}{\numberline {11.13}GI Imaging}{311}{section.11.13}%
\contentsline {subsection}{\numberline {11.13.1}Abdominal XR (KUB)}{311}{subsection.11.13.1}%
\contentsline {subsubsection}{\numberline {11.13.1.1}Description}{311}{subsubsection.11.13.1.1}%
\contentsline {subsubsection}{\numberline {11.13.1.2}Used to Evaluate}{311}{subsubsection.11.13.1.2}%
\contentsline {subsubsection}{\numberline {11.13.1.3}Potential Pathology Visualized}{311}{subsubsection.11.13.1.3}%
\contentsline {subsubsection}{\numberline {11.13.1.4}Patient Prep}{312}{subsubsection.11.13.1.4}%
\contentsline {subsection}{\numberline {11.13.2}Modified Barium Swallow (MBS)}{312}{subsection.11.13.2}%
\contentsline {subsubsection}{\numberline {11.13.2.1}Description}{312}{subsubsection.11.13.2.1}%
\contentsline {subsubsection}{\numberline {11.13.2.2}Used to Evaluate}{312}{subsubsection.11.13.2.2}%
\contentsline {subsubsection}{\numberline {11.13.2.3}Potential Pathology Visualized}{312}{subsubsection.11.13.2.3}%
\contentsline {subsubsection}{\numberline {11.13.2.4}Patient Prep}{312}{subsubsection.11.13.2.4}%
\contentsline {subsection}{\numberline {11.13.3}Upper GI (UGI) Series}{312}{subsection.11.13.3}%
\contentsline {subsubsection}{\numberline {11.13.3.1}Description}{312}{subsubsection.11.13.3.1}%
\contentsline {subsubsection}{\numberline {11.13.3.2}Used to Evaluate}{313}{subsubsection.11.13.3.2}%
\contentsline {subsubsection}{\numberline {11.13.3.3}Potential Pathology Visualized}{313}{subsubsection.11.13.3.3}%
\contentsline {subsubsection}{\numberline {11.13.3.4}Patient Prep}{313}{subsubsection.11.13.3.4}%
\contentsline {subsubsection}{\numberline {11.13.3.5}Considerations}{313}{subsubsection.11.13.3.5}%
\contentsline {subsection}{\numberline {11.13.4}Abdominal CT}{313}{subsection.11.13.4}%
\contentsline {subsubsection}{\numberline {11.13.4.1}Description}{313}{subsubsection.11.13.4.1}%
\contentsline {subsubsection}{\numberline {11.13.4.2}Used to Evaluate}{313}{subsubsection.11.13.4.2}%
\contentsline {subsubsection}{\numberline {11.13.4.3}Potential Pathology Visualized}{314}{subsubsection.11.13.4.3}%
\contentsline {subsubsection}{\numberline {11.13.4.4}Patient Prep}{314}{subsubsection.11.13.4.4}%
\contentsline {subsection}{\numberline {11.13.5}Contrast Enema}{314}{subsection.11.13.5}%
\contentsline {subsubsection}{\numberline {11.13.5.1}Description}{314}{subsubsection.11.13.5.1}%
\contentsline {subsubsection}{\numberline {11.13.5.2}Used to Evaluate}{314}{subsubsection.11.13.5.2}%
\contentsline {subsubsection}{\numberline {11.13.5.3}Potential Pathology Visualized}{314}{subsubsection.11.13.5.3}%
\contentsline {subsubsection}{\numberline {11.13.5.4}Patient Prep}{314}{subsubsection.11.13.5.4}%
\contentsline {section}{\numberline {11.14}G-Tubes \& J-Tubes}{314}{section.11.14}%
\contentsline {subsection}{\numberline {11.14.1}PowerPlans, Order Sets \& Clinical Pathways}{314}{subsection.11.14.1}%
\contentsline {subsection}{\numberline {11.14.2}Indications}{314}{subsection.11.14.2}%
\contentsline {subsection}{\numberline {11.14.3}Tube Troubleshooting}{315}{subsection.11.14.3}%
\contentsline {subsubsection}{\numberline {11.14.3.1}Tube Falls Out}{315}{subsubsection.11.14.3.1}%
\contentsline {subsubsection}{\numberline {11.14.3.2}Clogged Tube}{315}{subsubsection.11.14.3.2}%
\contentsline {subsubsection}{\numberline {11.14.3.3}Granulation Tissue}{315}{subsubsection.11.14.3.3}%
\contentsline {subsubsection}{\numberline {11.14.3.4}Contact Dermatitis}{315}{subsubsection.11.14.3.4}%
\contentsline {subsubsection}{\numberline {11.14.3.5}Cellulitis}{315}{subsubsection.11.14.3.5}%
\contentsline {subsection}{\numberline {11.14.4}Devices}{315}{subsection.11.14.4}%
\contentsline {subsubsection}{\numberline {11.14.4.1}Percutaneous Endoscopic Gastrostomy (PEG) Tube}{315}{subsubsection.11.14.4.1}%
\contentsline {subsubsection}{\numberline {11.14.4.2}Surgically Placed G-Tube}{316}{subsubsection.11.14.4.2}%
\contentsline {subsubsection}{\numberline {11.14.4.3}Jejunal Tube}{316}{subsubsection.11.14.4.3}%
\contentsline {section}{\numberline {11.15}Infant Formulas}{317}{section.11.15}%
\contentsline {subsection}{\numberline {11.15.1}Helpful Math}{317}{subsection.11.15.1}%
\contentsline {subsection}{\numberline {11.15.2}Types of Formula}{317}{subsection.11.15.2}%
\contentsline {subsubsection}{\numberline {11.15.2.1}Cow's Milk}{317}{subsubsection.11.15.2.1}%
\contentsline {subsubsection}{\numberline {11.15.2.2}Partially Hydrolyzed}{317}{subsubsection.11.15.2.2}%
\contentsline {subsubsection}{\numberline {11.15.2.3}Soy}{317}{subsubsection.11.15.2.3}%
\contentsline {subsubsection}{\numberline {11.15.2.4}Hydrolyzed, Semi-Elemental}{317}{subsubsection.11.15.2.4}%
\contentsline {subsubsection}{\numberline {11.15.2.5}Amino Acid-Based, Elemental}{317}{subsubsection.11.15.2.5}%
\contentsline {subsection}{\numberline {11.15.3}Caloric Supplements}{318}{subsection.11.15.3}%
\contentsline {section}{\numberline {11.16}Total Parenteral Nutrition (TPN)}{318}{section.11.16}%
\contentsline {subsection}{\numberline {11.16.1}PowerPlans, Order Sets \& Clinical Pathways}{318}{subsection.11.16.1}%
\contentsline {subsection}{\numberline {11.16.2}Indications}{318}{subsection.11.16.2}%
\contentsline {subsection}{\numberline {11.16.3}Access}{318}{subsection.11.16.3}%
\contentsline {subsection}{\numberline {11.16.4}Monitoring}{318}{subsection.11.16.4}%
\contentsline {section}{\numberline {11.17}Liver Enzymes}{318}{section.11.17}%
\contentsline {section}{\numberline {11.18}Infectious Hepatitis}{321}{section.11.18}%
\contentsline {subsection}{\numberline {11.18.1}Hep B Serologies}{323}{subsection.11.18.1}%
\contentsline {subsubsection}{\numberline {11.18.1.1}Timeline of Hep B Serologies}{324}{subsubsection.11.18.1.1}%
\contentsline {subsubsection}{\numberline {11.18.1.2}Interpretation of Hep B Serologies}{324}{subsubsection.11.18.1.2}%
\contentsline {section}{\numberline {11.19}Autoimmune Hepatitis}{324}{section.11.19}%
\contentsline {subsection}{\numberline {11.19.1}Presentation}{324}{subsection.11.19.1}%
\contentsline {subsection}{\numberline {11.19.2}Pathophysiology}{325}{subsection.11.19.2}%
\contentsline {subsection}{\numberline {11.19.3}Work-up}{325}{subsection.11.19.3}%
\contentsline {subsection}{\numberline {11.19.4}Management}{325}{subsection.11.19.4}%
\contentsline {section}{\numberline {11.20}Non-Alcoholic Fatty Liver Disease (NAFLD)}{325}{section.11.20}%
\contentsline {subsection}{\numberline {11.20.1}Presentation}{325}{subsection.11.20.1}%
\contentsline {subsection}{\numberline {11.20.2}Pathophysiology}{325}{subsection.11.20.2}%
\contentsline {subsection}{\numberline {11.20.3}Work-up}{325}{subsection.11.20.3}%
\contentsline {subsection}{\numberline {11.20.4}Management}{325}{subsection.11.20.4}%
\contentsline {section}{\numberline {11.21}References}{326}{section.11.21}%
\contentsline {chapter}{\numberline {12}Hematology}{327}{chapter.12}%
\contentsline {section}{\numberline {12.1}Anemia }{327}{section.12.1}%
\contentsline {subsection}{\numberline {12.1.1}Definition}{327}{subsection.12.1.1}%
\contentsline {subsection}{\numberline {12.1.2}Approach to Anemia (by MCV \& Retics)}{327}{subsection.12.1.2}%
\contentsline {subsection}{\numberline {12.1.3}Microcytic Anemias}{329}{subsection.12.1.3}%
\contentsline {subsubsection}{\numberline {12.1.3.1}Thalassemias}{330}{subsubsection.12.1.3.1}%
\contentsline {subsection}{\numberline {12.1.4}Sickle Cell Anemia}{331}{subsection.12.1.4}%
\contentsline {subsection}{\numberline {12.1.5}Hemolytic Anemias}{331}{subsection.12.1.5}%
\contentsline {subsection}{\numberline {12.1.6}Other Normocytic Anemias}{336}{subsection.12.1.6}%
\contentsline {subsection}{\numberline {12.1.7}Macrocytic Anemias}{337}{subsection.12.1.7}%
\contentsline {subsection}{\numberline {12.1.8}Pediatric-Specific Anemias}{337}{subsection.12.1.8}%
\contentsline {subsubsection}{\numberline {12.1.8.1}Newborn Anemia}{338}{subsubsection.12.1.8.1}%
\contentsline {section}{\numberline {12.2}Sickle Cell Anemia}{338}{section.12.2}%
\contentsline {subsubsection}{\numberline {12.2.0.1}Pathophysiology}{338}{subsubsection.12.2.0.1}%
\contentsline {subsubsection}{\numberline {12.2.0.2}Clinical manifestations}{338}{subsubsection.12.2.0.2}%
\contentsline {subsubsection}{\numberline {12.2.0.3}Diagnosis}{339}{subsubsection.12.2.0.3}%
\contentsline {subsubsection}{\numberline {12.2.0.4}Management}{339}{subsubsection.12.2.0.4}%
\contentsline {subsection}{\numberline {12.2.1}Vaso-Occlusive Episode (VOE)}{339}{subsection.12.2.1}%
\contentsline {subsubsection}{\numberline {12.2.1.1}Fluids, Monitoring, \& Labs}{340}{subsubsection.12.2.1.1}%
\contentsline {paragraph}{\numberline {12.2.1.1.1}Pain Management}{340}{paragraph.12.2.1.1.1}%
\contentsline {subsubsection}{\numberline {12.2.1.2}Discharge planning}{342}{subsubsection.12.2.1.2}%
\contentsline {subsection}{\numberline {12.2.2}Acute Chest Syndrome (ACS)}{342}{subsection.12.2.2}%
\contentsline {subsubsection}{\numberline {12.2.2.1}Optimize ventilation}{342}{subsubsection.12.2.2.1}%
\contentsline {subsubsection}{\numberline {12.2.2.2}Fluid balance}{343}{subsubsection.12.2.2.2}%
\contentsline {subsubsection}{\numberline {12.2.2.3}Other monitoring \& labs}{343}{subsubsection.12.2.2.3}%
\contentsline {subsubsection}{\numberline {12.2.2.4}Antibiotics}{343}{subsubsection.12.2.2.4}%
\contentsline {subsubsection}{\numberline {12.2.2.5}Transfusions}{343}{subsubsection.12.2.2.5}%
\contentsline {subsubsection}{\numberline {12.2.2.6}Discharge planning}{343}{subsubsection.12.2.2.6}%
\contentsline {subsection}{\numberline {12.2.3}Fever}{344}{subsection.12.2.3}%
\contentsline {subsubsection}{\numberline {12.2.3.1}Definition}{344}{subsubsection.12.2.3.1}%
\contentsline {subsubsection}{\numberline {12.2.3.2}Work-up}{344}{subsubsection.12.2.3.2}%
\contentsline {subsubsection}{\numberline {12.2.3.3}Management}{344}{subsubsection.12.2.3.3}%
\contentsline {subsection}{\numberline {12.2.4}Blood Transfusions in SCD}{345}{subsection.12.2.4}%
\contentsline {subsubsection}{\numberline {12.2.4.1}Potential indications for transfusion}{345}{subsubsection.12.2.4.1}%
\contentsline {subsubsection}{\numberline {12.2.4.2}Amount of blood to transfuse}{345}{subsubsection.12.2.4.2}%
\contentsline {subsubsection}{\numberline {12.2.4.3}Other considerations}{345}{subsubsection.12.2.4.3}%
\contentsline {section}{\numberline {12.3}Transfusion Medicine}{345}{section.12.3}%
\contentsline {subsection}{\numberline {12.3.1}Consenting a Patient for Blood Products}{345}{subsection.12.3.1}%
\contentsline {subsubsection}{\numberline {12.3.1.1}Risks}{345}{subsubsection.12.3.1.1}%
\contentsline {subsubsection}{\numberline {12.3.1.2}Benefits}{346}{subsubsection.12.3.1.2}%
\contentsline {subsubsection}{\numberline {12.3.1.3}Alternatives (may not work as quickly)}{346}{subsubsection.12.3.1.3}%
\contentsline {subsection}{\numberline {12.3.2}Acute Transfusion Reactions}{346}{subsection.12.3.2}%
\contentsline {subsubsection}{\numberline {12.3.2.1}Specialized RBCs}{347}{subsubsection.12.3.2.1}%
\contentsline {subsection}{\numberline {12.3.3}Transfusion Products}{347}{subsection.12.3.3}%
\contentsline {section}{\numberline {12.4}Pancytopenia}{349}{section.12.4}%
\contentsline {subsection}{\numberline {12.4.1}Marrow}{349}{subsection.12.4.1}%
\contentsline {subsection}{\numberline {12.4.2}Systemic}{349}{subsection.12.4.2}%
\contentsline {subsection}{\numberline {12.4.3}Meds}{349}{subsection.12.4.3}%
\contentsline {subsection}{\numberline {12.4.4}Infectious}{350}{subsection.12.4.4}%
\contentsline {section}{\numberline {12.5}Thrombocytopenia}{350}{section.12.5}%
\contentsline {subsubsection}{\numberline {12.5.0.1}Definition}{350}{subsubsection.12.5.0.1}%
\contentsline {subsubsection}{\numberline {12.5.0.2}Pathogenesis}{350}{subsubsection.12.5.0.2}%
\contentsline {subsubsection}{\numberline {12.5.0.3}Labs}{350}{subsubsection.12.5.0.3}%
\contentsline {subsection}{\numberline {12.5.1}Causes}{350}{subsection.12.5.1}%
\contentsline {section}{\numberline {12.6}Hematologic Disorders of the Newborn/Child}{352}{section.12.6}%
\contentsline {subsection}{\numberline {12.6.1}Anemia of Prematurity}{352}{subsection.12.6.1}%
\contentsline {subsubsection}{\numberline {12.6.1.1}Pathogenesis}{352}{subsubsection.12.6.1.1}%
\contentsline {subsubsection}{\numberline {12.6.1.2}Clinical manifestations}{352}{subsubsection.12.6.1.2}%
\contentsline {subsubsection}{\numberline {12.6.1.3}Diagnosis}{352}{subsubsection.12.6.1.3}%
\contentsline {subsubsection}{\numberline {12.6.1.4}Management}{352}{subsubsection.12.6.1.4}%
\contentsline {subsection}{\numberline {12.6.2}Transient Erythroblastopenia of Childhood}{352}{subsection.12.6.2}%
\contentsline {subsubsection}{\numberline {12.6.2.1}Pathogenesis}{352}{subsubsection.12.6.2.1}%
\contentsline {subsubsection}{\numberline {12.6.2.2}Clinical manifestations}{352}{subsubsection.12.6.2.2}%
\contentsline {subsubsection}{\numberline {12.6.2.3}Diagnosis}{353}{subsubsection.12.6.2.3}%
\contentsline {subsubsection}{\numberline {12.6.2.4}Management}{353}{subsubsection.12.6.2.4}%
\contentsline {subsection}{\numberline {12.6.3}Neonatal Polycythemia}{353}{subsection.12.6.3}%
\contentsline {subsubsection}{\numberline {12.6.3.1}Pathogenesis}{353}{subsubsection.12.6.3.1}%
\contentsline {subsubsection}{\numberline {12.6.3.2}Clinical manifestations}{353}{subsubsection.12.6.3.2}%
\contentsline {subsubsection}{\numberline {12.6.3.3}Diagnosis}{353}{subsubsection.12.6.3.3}%
\contentsline {subsubsection}{\numberline {12.6.3.4}Management}{353}{subsubsection.12.6.3.4}%
\contentsline {section}{\numberline {12.7}Coagulation Disorders}{353}{section.12.7}%
\contentsline {section}{\numberline {12.8}Antiplatelet / Anticoagulant Medications}{355}{section.12.8}%
\contentsline {section}{\numberline {12.9}References}{359}{section.12.9}%
\contentsline {chapter}{\numberline {13}Infectious Diseases}{361}{chapter.13}%
\contentsline {section}{\numberline {13.1}\href {https://bchfit.tch.harvard.edu/}{Antibiogram+}}{361}{section.13.1}%
\contentsline {section}{\numberline {13.2}\href {https://bchfit.tch.harvard.edu/susceptibilityMatrix}{Antibiotic Susceptibilities} for Common Pathogens}{361}{section.13.2}%
\contentsline {subsection}{\numberline {13.2.1}Gram Negative Susceptibilities}{362}{subsection.13.2.1}%
\contentsline {subsection}{\numberline {13.2.2}Gram Positive Susceptibilities}{362}{subsection.13.2.2}%
\contentsline {subsection}{\numberline {13.2.3}Anaerobe Susceptibilities}{363}{subsection.13.2.3}%
\contentsline {section}{\numberline {13.3}\href {https://bchfit.tch.harvard.edu/diagnoses}{Antibiotic Recommendations} (Dosing, Duration) for Common Infections}{363}{section.13.3}%
\contentsline {subsection}{\numberline {13.3.1}Bone \& Joint}{363}{subsection.13.3.1}%
\contentsline {subsection}{\numberline {13.3.2}Head \& Neck}{363}{subsection.13.3.2}%
\contentsline {subsection}{\numberline {13.3.3}Gastrointestinal}{363}{subsection.13.3.3}%
\contentsline {subsection}{\numberline {13.3.4}Genitourinary}{364}{subsection.13.3.4}%
\contentsline {subsection}{\numberline {13.3.5}Respiratory}{364}{subsection.13.3.5}%
\contentsline {subsection}{\numberline {13.3.6}Skin \& Soft Tissue}{364}{subsection.13.3.6}%
\contentsline {section}{\numberline {13.4}Cellulitis \& Abscess}{364}{section.13.4}%
\contentsline {subsection}{\numberline {13.4.1}PowerPlans, Order Sets \& Clinical Pathways}{364}{subsection.13.4.1}%
\contentsline {subsection}{\numberline {13.4.2}Etiology}{364}{subsection.13.4.2}%
\contentsline {subsection}{\numberline {13.4.3}Differential}{364}{subsection.13.4.3}%
\contentsline {subsection}{\numberline {13.4.4}Work-up}{365}{subsection.13.4.4}%
\contentsline {subsection}{\numberline {13.4.5}Managament}{365}{subsection.13.4.5}%
\contentsline {section}{\numberline {13.5}Osteomyelitis}{365}{section.13.5}%
\contentsline {subsection}{\numberline {13.5.1}PowerPlans, Order Sets \& Clinical Pathways}{365}{subsection.13.5.1}%
\contentsline {subsection}{\numberline {13.5.2}Etiology}{365}{subsection.13.5.2}%
\contentsline {subsection}{\numberline {13.5.3}Presentation}{365}{subsection.13.5.3}%
\contentsline {subsection}{\numberline {13.5.4}Differential}{365}{subsection.13.5.4}%
\contentsline {subsection}{\numberline {13.5.5}Work-up}{366}{subsection.13.5.5}%
\contentsline {subsection}{\numberline {13.5.6}Treatment}{366}{subsection.13.5.6}%
\contentsline {section}{\numberline {13.6}Septic Arthritis}{366}{section.13.6}%
\contentsline {subsection}{\numberline {13.6.1}PowerPlans, Order Sets \& Clinical Pathways}{366}{subsection.13.6.1}%
\contentsline {subsection}{\numberline {13.6.2}Etiology}{366}{subsection.13.6.2}%
\contentsline {subsection}{\numberline {13.6.3}Presentation}{366}{subsection.13.6.3}%
\contentsline {subsection}{\numberline {13.6.4}Differential}{366}{subsection.13.6.4}%
\contentsline {subsection}{\numberline {13.6.5}Work-up}{366}{subsection.13.6.5}%
\contentsline {subsection}{\numberline {13.6.6}Treatment}{367}{subsection.13.6.6}%
\contentsline {section}{\numberline {13.7}Infectious Mononucleosis}{367}{section.13.7}%
\contentsline {subsection}{\numberline {13.7.1}Etiology}{367}{subsection.13.7.1}%
\contentsline {subsection}{\numberline {13.7.2}Presentation}{367}{subsection.13.7.2}%
\contentsline {subsection}{\numberline {13.7.3}Differential}{367}{subsection.13.7.3}%
\contentsline {subsection}{\numberline {13.7.4}Work-up}{367}{subsection.13.7.4}%
\contentsline {subsection}{\numberline {13.7.5}Treatment}{367}{subsection.13.7.5}%
\contentsline {section}{\numberline {13.8}Acute Otitis Media (AOM)}{367}{section.13.8}%
\contentsline {subsection}{\numberline {13.8.1}PowerPlans, Order Sets \& Clinical Pathways}{367}{subsection.13.8.1}%
\contentsline {subsection}{\numberline {13.8.2}Etiology}{367}{subsection.13.8.2}%
\contentsline {subsection}{\numberline {13.8.3}Differential}{368}{subsection.13.8.3}%
\contentsline {subsection}{\numberline {13.8.4}Work-up}{368}{subsection.13.8.4}%
\contentsline {subsection}{\numberline {13.8.5}Treatment}{368}{subsection.13.8.5}%
\contentsline {section}{\numberline {13.9}Influenza}{368}{section.13.9}%
\contentsline {subsection}{\numberline {13.9.1}PowerPlans, Order Sets \& Clinical Pathways}{368}{subsection.13.9.1}%
\contentsline {subsection}{\numberline {13.9.2}Etiology}{368}{subsection.13.9.2}%
\contentsline {subsection}{\numberline {13.9.3}Presentation}{368}{subsection.13.9.3}%
\contentsline {subsection}{\numberline {13.9.4}Work-up}{368}{subsection.13.9.4}%
\contentsline {subsection}{\numberline {13.9.5}Treatment}{369}{subsection.13.9.5}%
\contentsline {subsection}{\numberline {13.9.6}Prophylaxis}{369}{subsection.13.9.6}%
\contentsline {subsection}{\numberline {13.9.7}Complications}{369}{subsection.13.9.7}%
\contentsline {section}{\numberline {13.10}Fever of Unknown Origin (FUO)}{369}{section.13.10}%
\contentsline {subsection}{\numberline {13.10.1}PowerPlans, Order Sets \& Clinical Pathways}{369}{subsection.13.10.1}%
\contentsline {subsection}{\numberline {13.10.2}Definition}{370}{subsection.13.10.2}%
\contentsline {subsection}{\numberline {13.10.3}Differential}{370}{subsection.13.10.3}%
\contentsline {subsection}{\numberline {13.10.4}Work-up}{370}{subsection.13.10.4}%
\contentsline {subsection}{\numberline {13.10.5}Treatment}{370}{subsection.13.10.5}%
\contentsline {section}{\numberline {13.11}Urinary Tract Infection (UTI), First Febrile}{371}{section.13.11}%
\contentsline {subsection}{\numberline {13.11.1}PowerPlans, Order Sets \& Clinical Pathways}{371}{subsection.13.11.1}%
\contentsline {subsection}{\numberline {13.11.2}Etiology}{371}{subsection.13.11.2}%
\contentsline {subsection}{\numberline {13.11.3}Work-up}{371}{subsection.13.11.3}%
\contentsline {subsection}{\numberline {13.11.4}Treatment}{371}{subsection.13.11.4}%
\contentsline {section}{\numberline {13.12}Bacterial Meningitis}{372}{section.13.12}%
\contentsline {subsection}{\numberline {13.12.1}PowerPlans, Order Sets \& Clinical Pathways}{372}{subsection.13.12.1}%
\contentsline {subsection}{\numberline {13.12.2}Presentation}{372}{subsection.13.12.2}%
\contentsline {subsection}{\numberline {13.12.3}Differential}{372}{subsection.13.12.3}%
\contentsline {subsection}{\numberline {13.12.4}Work-up}{372}{subsection.13.12.4}%
\contentsline {subsection}{\numberline {13.12.5}Etiology/Management}{372}{subsection.13.12.5}%
\contentsline {subsection}{\numberline {13.12.6}Complications}{373}{subsection.13.12.6}%
\contentsline {section}{\numberline {13.13}\href {https://docs.google.com/presentation/d/13P51MYLSvwFDnY2127Lyh69S-WSXdUu4TAyy-H7wr68/edit\#slide=id.p}{COVID-19}}{373}{section.13.13}%
\contentsline {subsection}{\numberline {13.13.1}PowerPlans, Order Sets \& Clinical Pathways}{373}{subsection.13.13.1}%
\contentsline {chapter}{\numberline {14}Metabolism}{375}{chapter.14}%
\contentsline {section}{\numberline {14.1}I think this might be metabolic\ldots {}}{375}{section.14.1}%
\contentsline {section}{\numberline {14.2}Management of Metabolic Crises}{375}{section.14.2}%
\contentsline {subsection}{\numberline {14.2.1}General Principles}{375}{subsection.14.2.1}%
\contentsline {subsection}{\numberline {14.2.2}Acute Metabolic Encephalopathy}{376}{subsection.14.2.2}%
\contentsline {subsubsection}{\numberline {14.2.2.1}Definition}{376}{subsubsection.14.2.2.1}%
\contentsline {subsubsection}{\numberline {14.2.2.2}Etiologies}{376}{subsubsection.14.2.2.2}%
\contentsline {subsubsection}{\numberline {14.2.2.3}Presentation}{376}{subsubsection.14.2.2.3}%
\contentsline {subsubsection}{\numberline {14.2.2.4}Management}{376}{subsubsection.14.2.2.4}%
\contentsline {subsubsection}{\numberline {14.2.2.5}Risks of therapy}{377}{subsubsection.14.2.2.5}%
\contentsline {subsection}{\numberline {14.2.3}Hyperammonemia}{378}{subsection.14.2.3}%
\contentsline {subsubsection}{\numberline {14.2.3.1}Definition}{378}{subsubsection.14.2.3.1}%
\contentsline {subsubsection}{\numberline {14.2.3.2}Underlying differential diagnosis}{378}{subsubsection.14.2.3.2}%
\contentsline {subsubsection}{\numberline {14.2.3.3}Pathophysiology}{378}{subsubsection.14.2.3.3}%
\contentsline {subsubsection}{\numberline {14.2.3.4}Presentation}{378}{subsubsection.14.2.3.4}%
\contentsline {subsubsection}{\numberline {14.2.3.5}Workup}{378}{subsubsection.14.2.3.5}%
\contentsline {subsubsection}{\numberline {14.2.3.6}Management}{378}{subsubsection.14.2.3.6}%
\contentsline {subsubsection}{\numberline {14.2.3.7}Approach to hyperammonemia in neonates}{379}{subsubsection.14.2.3.7}%
\contentsline {subsection}{\numberline {14.2.4}Metabolic Acidosis d/t suspected IEM}{379}{subsection.14.2.4}%
\contentsline {subsubsection}{\numberline {14.2.4.1}Definition}{380}{subsubsection.14.2.4.1}%
\contentsline {subsubsection}{\numberline {14.2.4.2}Etiologies}{380}{subsubsection.14.2.4.2}%
\contentsline {subsubsection}{\numberline {14.2.4.3}Presentation}{380}{subsubsection.14.2.4.3}%
\contentsline {subsubsection}{\numberline {14.2.4.4}Physical Exam}{380}{subsubsection.14.2.4.4}%
\contentsline {subsubsection}{\numberline {14.2.4.5}Management}{380}{subsubsection.14.2.4.5}%
\contentsline {subsection}{\numberline {14.2.5}Seizures d/t suspected IEM}{381}{subsection.14.2.5}%
\contentsline {subsubsection}{\numberline {14.2.5.1}Etiology}{381}{subsubsection.14.2.5.1}%
\contentsline {subsubsection}{\numberline {14.2.5.2}Underlying differential diagnosis}{381}{subsubsection.14.2.5.2}%
\contentsline {subsubsection}{\numberline {14.2.5.3}Management}{381}{subsubsection.14.2.5.3}%
\contentsline {subsection}{\numberline {14.2.6}Ketotic Hypoglycemia}{381}{subsection.14.2.6}%
\contentsline {subsubsection}{\numberline {14.2.6.1}Definition}{382}{subsubsection.14.2.6.1}%
\contentsline {subsubsection}{\numberline {14.2.6.2}Etiology}{382}{subsubsection.14.2.6.2}%
\contentsline {subsubsection}{\numberline {14.2.6.3}Presentation}{382}{subsubsection.14.2.6.3}%
\contentsline {subsubsection}{\numberline {14.2.6.4}Physical exam}{382}{subsubsection.14.2.6.4}%
\contentsline {subsubsection}{\numberline {14.2.6.5}Management}{382}{subsubsection.14.2.6.5}%
\contentsline {subsection}{\numberline {14.2.7}Access in a metabolic crisis}{382}{subsection.14.2.7}%
\contentsline {section}{\numberline {14.3}Differential Diagnosis by Clinical Manifestations}{383}{section.14.3}%
\contentsline {subsection}{\numberline {14.3.1}Presenting in \emph {Neonatal period} or \emph {early infancy}}{383}{subsection.14.3.1}%
\contentsline {subsubsection}{\numberline {14.3.1.1}History}{383}{subsubsection.14.3.1.1}%
\contentsline {subsubsection}{\numberline {14.3.1.2}Presentation}{383}{subsubsection.14.3.1.2}%
\contentsline {paragraph}{\numberline {14.3.1.2.1}Encephalopathy}{383}{paragraph.14.3.1.2.1}%
\contentsline {paragraph}{\numberline {14.3.1.2.2}Seizures}{383}{paragraph.14.3.1.2.2}%
\contentsline {paragraph}{\numberline {14.3.1.2.3}Hepatic}{384}{paragraph.14.3.1.2.3}%
\contentsline {paragraph}{\numberline {14.3.1.2.4}Cardiomyopathy}{384}{paragraph.14.3.1.2.4}%
\contentsline {paragraph}{\numberline {14.3.1.2.5}Hypoglycemia}{384}{paragraph.14.3.1.2.5}%
\contentsline {subsubsection}{\numberline {14.3.1.3}Physical exam}{384}{subsubsection.14.3.1.3}%
\contentsline {subsubsection}{\numberline {14.3.1.4}Initial lab workup}{385}{subsubsection.14.3.1.4}%
\contentsline {subsubsection}{\numberline {14.3.1.5}Secondary workup}{386}{subsubsection.14.3.1.5}%
\contentsline {subsection}{\numberline {14.3.2}Later onset}{386}{subsection.14.3.2}%
\contentsline {subsubsection}{\numberline {14.3.2.1}History}{386}{subsubsection.14.3.2.1}%
\contentsline {subsubsection}{\numberline {14.3.2.2}Presentation}{386}{subsubsection.14.3.2.2}%
\contentsline {section}{\numberline {14.4}Aminoacidopathies}{387}{section.14.4}%
\contentsline {subsubsection}{\numberline {14.4.0.1}Biochemical defect}{387}{subsubsection.14.4.0.1}%
\contentsline {subsubsection}{\numberline {14.4.0.2}Presentation}{388}{subsubsection.14.4.0.2}%
\contentsline {subsubsection}{\numberline {14.4.0.3}Workup}{388}{subsubsection.14.4.0.3}%
\contentsline {subsubsection}{\numberline {14.4.0.4}Management (general approach)}{388}{subsubsection.14.4.0.4}%
\contentsline {section}{\numberline {14.5}Carbohydrate Metabolism Defects}{389}{section.14.5}%
\contentsline {subsubsection}{\numberline {14.5.0.1}Biochemical defect}{389}{subsubsection.14.5.0.1}%
\contentsline {subsubsection}{\numberline {14.5.0.2}Presentation}{389}{subsubsection.14.5.0.2}%
\contentsline {subsubsection}{\numberline {14.5.0.3}Workup}{389}{subsubsection.14.5.0.3}%
\contentsline {subsubsection}{\numberline {14.5.0.4}Management (general approach)}{390}{subsubsection.14.5.0.4}%
\contentsline {section}{\numberline {14.6}Fatty Acid Oxidation Disorders}{392}{section.14.6}%
\contentsline {subsubsection}{\numberline {14.6.0.1}Biochemical defect}{392}{subsubsection.14.6.0.1}%
\contentsline {subsubsection}{\numberline {14.6.0.2}Presentation}{392}{subsubsection.14.6.0.2}%
\contentsline {subsubsection}{\numberline {14.6.0.3}Workup}{392}{subsubsection.14.6.0.3}%
\contentsline {section}{\numberline {14.7}Lysosomal Diseases}{393}{section.14.7}%
\contentsline {subsubsection}{\numberline {14.7.0.1}Biochemical defect}{393}{subsubsection.14.7.0.1}%
\contentsline {subsubsection}{\numberline {14.7.0.2}Presentation}{393}{subsubsection.14.7.0.2}%
\contentsline {subsubsection}{\numberline {14.7.0.3}Workup}{394}{subsubsection.14.7.0.3}%
\contentsline {section}{\numberline {14.8}Mitochondrial Disorders / Primary Lactic Acidemias}{396}{section.14.8}%
\contentsline {subsubsection}{\numberline {14.8.0.1}Biochemical defect}{396}{subsubsection.14.8.0.1}%
\contentsline {subsubsection}{\numberline {14.8.0.2}Presentation}{396}{subsubsection.14.8.0.2}%
\contentsline {subsubsection}{\numberline {14.8.0.3}Workup}{397}{subsubsection.14.8.0.3}%
\contentsline {section}{\numberline {14.9}Organic Acidemias}{398}{section.14.9}%
\contentsline {subsubsection}{\numberline {14.9.0.1}Biochemical defect}{398}{subsubsection.14.9.0.1}%
\contentsline {subsubsection}{\numberline {14.9.0.2}Presentation}{398}{subsubsection.14.9.0.2}%
\contentsline {subsubsection}{\numberline {14.9.0.3}Workup}{398}{subsubsection.14.9.0.3}%
\contentsline {subsubsection}{\numberline {14.9.0.4}Management (general approach)}{398}{subsubsection.14.9.0.4}%
\contentsline {section}{\numberline {14.10}Peroxisomal Disorders}{401}{section.14.10}%
\contentsline {subsubsection}{\numberline {14.10.0.1}Biochemical defect}{401}{subsubsection.14.10.0.1}%
\contentsline {subsubsection}{\numberline {14.10.0.2}Presentation}{401}{subsubsection.14.10.0.2}%
\contentsline {subsubsection}{\numberline {14.10.0.3}Workup}{402}{subsubsection.14.10.0.3}%
\contentsline {section}{\numberline {14.11}Urea Cycle Defects}{403}{section.14.11}%
\contentsline {subsubsection}{\numberline {14.11.0.1}Biochemical defect}{403}{subsubsection.14.11.0.1}%
\contentsline {subsubsection}{\numberline {14.11.0.2}Presentation}{403}{subsubsection.14.11.0.2}%
\contentsline {subsubsection}{\numberline {14.11.0.3}Workup}{403}{subsubsection.14.11.0.3}%
\contentsline {subsubsection}{\numberline {14.11.0.4}Management (general approach)}{404}{subsubsection.14.11.0.4}%
\contentsline {section}{\numberline {14.12}Glossary}{406}{section.14.12}%
\contentsline {section}{\numberline {14.13}Resources}{407}{section.14.13}%
\contentsline {chapter}{\numberline {15}Nephrology}{409}{chapter.15}%
\contentsline {section}{\numberline {15.1}Formulas}{409}{section.15.1}%
\contentsline {subsection}{\numberline {15.1.1}Modified Bedside Schwartz}{409}{subsection.15.1.1}%
\contentsline {subsection}{\numberline {15.1.2}Insensible Fluid Loss}{409}{subsection.15.1.2}%
\contentsline {subsection}{\numberline {15.1.3}Total Body Water}{409}{subsection.15.1.3}%
\contentsline {subsection}{\numberline {15.1.4}Free Water Deficit}{409}{subsection.15.1.4}%
\contentsline {subsection}{\numberline {15.1.5}Fractional Excretion Sodium}{410}{subsection.15.1.5}%
\contentsline {subsection}{\numberline {15.1.6}Fractional Excretion of Urea}{410}{subsection.15.1.6}%
\contentsline {subsection}{\numberline {15.1.7}Urine Protein/Cr Ratio}{410}{subsection.15.1.7}%
\contentsline {subsection}{\numberline {15.1.8}Transtubular Potassium Gradient}{410}{subsection.15.1.8}%
\contentsline {subsection}{\numberline {15.1.9}Tubular Reabsorption of Phosphate}{410}{subsection.15.1.9}%
\contentsline {subsection}{\numberline {15.1.10}Urine Calcium/Cr Ratio}{410}{subsection.15.1.10}%
\contentsline {subsection}{\numberline {15.1.11}Corrected Calcium}{411}{subsection.15.1.11}%
\contentsline {subsection}{\numberline {15.1.12}Calculated Serum Osmolality}{411}{subsection.15.1.12}%
\contentsline {subsection}{\numberline {15.1.13}Osmolar Gap}{411}{subsection.15.1.13}%
\contentsline {section}{\numberline {15.2}Fluid Management}{411}{section.15.2}%
\contentsline {subsection}{\numberline {15.2.1}Dehydration}{411}{subsection.15.2.1}%
\contentsline {subsection}{\numberline {15.2.2}Maintenance Fluid Therapy}{412}{subsection.15.2.2}%
\contentsline {subsection}{\numberline {15.2.3}Holliday-Segar Method}{412}{subsection.15.2.3}%
\contentsline {section}{\numberline {15.3}Acid/Base}{413}{section.15.3}%
\contentsline {subsection}{\numberline {15.3.1}Simple Acid/Base Disorders}{413}{subsection.15.3.1}%
\contentsline {subsection}{\numberline {15.3.2}Metabolic Acidosis}{414}{subsection.15.3.2}%
\contentsline {subsubsection}{\numberline {15.3.2.1}Renal Tubular Acidosis: Hyperchloremic Metabolic Acidosis w/ +Urine AG**}{415}{subsubsection.15.3.2.1}%
\contentsline {subsection}{\numberline {15.3.3}Metabolic Alkalosis}{415}{subsection.15.3.3}%
\contentsline {subsection}{\numberline {15.3.4}Respiratory Acidosis}{415}{subsection.15.3.4}%
\contentsline {subsection}{\numberline {15.3.5}Respiratory Alkalosis}{416}{subsection.15.3.5}%
\contentsline {section}{\numberline {15.4}Hyponatremia}{416}{section.15.4}%
\contentsline {section}{\numberline {15.5}Hypernatremia}{418}{section.15.5}%
\contentsline {section}{\numberline {15.6}Hypokalemia}{419}{section.15.6}%
\contentsline {section}{\numberline {15.7}Hyperkalemia}{420}{section.15.7}%
\contentsline {section}{\numberline {15.8}Proteinuria}{421}{section.15.8}%
\contentsline {section}{\numberline {15.9}Hematuria}{422}{section.15.9}%
\contentsline {section}{\numberline {15.10}Nephrotic Syndrome}{424}{section.15.10}%
\contentsline {section}{\numberline {15.11}Nephritic Syndrome}{425}{section.15.11}%
\contentsline {section}{\numberline {15.12}Acute Kidney Injury}{427}{section.15.12}%
\contentsline {section}{\numberline {15.13}Chronic Kidney Disease}{428}{section.15.13}%
\contentsline {section}{\numberline {15.14}Hemolytic-Uremic Syndrome}{430}{section.15.14}%
\contentsline {section}{\numberline {15.15}Hypertension}{432}{section.15.15}%
\contentsline {section}{\numberline {15.16}Urinary Tract Infections}{436}{section.15.16}%
\contentsline {section}{\numberline {15.17}Nephrolithiasis}{438}{section.15.17}%
\contentsline {section}{\numberline {15.18}References}{439}{section.15.18}%
\contentsline {chapter}{\numberline {16}Neurology}{441}{chapter.16}%
\contentsline {section}{\numberline {16.1}Neurologic Emergencies}{441}{section.16.1}%
\contentsline {subsection}{\numberline {16.1.1}Status Epilepticus}{441}{subsection.16.1.1}%
\contentsline {subsubsection}{\numberline {16.1.1.1}PowerPlan}{441}{subsubsection.16.1.1.1}%
\contentsline {subsubsection}{\numberline {16.1.1.2}Definition}{441}{subsubsection.16.1.1.2}%
\contentsline {subsubsection}{\numberline {16.1.1.3}Presentation}{441}{subsubsection.16.1.1.3}%
\contentsline {subsubsection}{\numberline {16.1.1.4}Differential}{441}{subsubsection.16.1.1.4}%
\contentsline {subsubsection}{\numberline {16.1.1.5}Red Flags}{441}{subsubsection.16.1.1.5}%
\contentsline {subsubsection}{\numberline {16.1.1.6}Work-up}{442}{subsubsection.16.1.1.6}%
\contentsline {subsubsection}{\numberline {16.1.1.7}Management}{442}{subsubsection.16.1.1.7}%
\contentsline {subsubsection}{\numberline {16.1.1.8}Complications}{442}{subsubsection.16.1.1.8}%
\contentsline {subsection}{\numberline {16.1.2}Increased Intracranial Pressure (ICP)}{442}{subsection.16.1.2}%
\contentsline {subsection}{\numberline {16.1.3}Stroke}{442}{subsection.16.1.3}%
\contentsline {subsubsection}{\numberline {16.1.3.1}PowerPlans, Order Sets \& Clinical Pathways}{442}{subsubsection.16.1.3.1}%
\contentsline {subsubsection}{\numberline {16.1.3.2}Pathophysiology}{443}{subsubsection.16.1.3.2}%
\contentsline {subsubsection}{\numberline {16.1.3.3}Presentation}{443}{subsubsection.16.1.3.3}%
\contentsline {subsubsection}{\numberline {16.1.3.4}Differential}{443}{subsubsection.16.1.3.4}%
\contentsline {subsubsection}{\numberline {16.1.3.5}Red Flags}{443}{subsubsection.16.1.3.5}%
\contentsline {subsubsection}{\numberline {16.1.3.6}Work-up}{443}{subsubsection.16.1.3.6}%
\contentsline {subsubsection}{\numberline {16.1.3.7}Management}{443}{subsubsection.16.1.3.7}%
\contentsline {subsubsection}{\numberline {16.1.3.8}Complications}{443}{subsubsection.16.1.3.8}%
\contentsline {section}{\numberline {16.2}Weakness}{443}{section.16.2}%
\contentsline {subsection}{\numberline {16.2.1}Guillain-Barr√© Syndorme (GBS)}{443}{subsection.16.2.1}%
\contentsline {subsubsection}{\numberline {16.2.1.1}Pathophysiology}{444}{subsubsection.16.2.1.1}%
\contentsline {subsubsection}{\numberline {16.2.1.2}Presentation}{444}{subsubsection.16.2.1.2}%
\contentsline {subsubsection}{\numberline {16.2.1.3}Differential}{444}{subsubsection.16.2.1.3}%
\contentsline {subsubsection}{\numberline {16.2.1.4}Red Flags}{444}{subsubsection.16.2.1.4}%
\contentsline {subsubsection}{\numberline {16.2.1.5}Work-up}{444}{subsubsection.16.2.1.5}%
\contentsline {subsubsection}{\numberline {16.2.1.6}Management}{444}{subsubsection.16.2.1.6}%
\contentsline {subsection}{\numberline {16.2.2}Miller-Fisher variant of Guillain-Barr√©}{444}{subsection.16.2.2}%
\contentsline {subsubsection}{\numberline {16.2.2.1}Pathophysiology}{444}{subsubsection.16.2.2.1}%
\contentsline {subsubsection}{\numberline {16.2.2.2}Presentation}{444}{subsubsection.16.2.2.2}%
\contentsline {subsubsection}{\numberline {16.2.2.3}Differential}{444}{subsubsection.16.2.2.3}%
\contentsline {subsubsection}{\numberline {16.2.2.4}Red Flags}{445}{subsubsection.16.2.2.4}%
\contentsline {subsubsection}{\numberline {16.2.2.5}Work-up}{445}{subsubsection.16.2.2.5}%
\contentsline {subsubsection}{\numberline {16.2.2.6}Management}{445}{subsubsection.16.2.2.6}%
\contentsline {subsection}{\numberline {16.2.3}Myasthenia Gravis}{445}{subsection.16.2.3}%
\contentsline {subsubsection}{\numberline {16.2.3.1}Pathophysiology}{445}{subsubsection.16.2.3.1}%
\contentsline {subsubsection}{\numberline {16.2.3.2}Presentation}{445}{subsubsection.16.2.3.2}%
\contentsline {subsubsection}{\numberline {16.2.3.3}Differential}{445}{subsubsection.16.2.3.3}%
\contentsline {subsubsection}{\numberline {16.2.3.4}Red Flags}{445}{subsubsection.16.2.3.4}%
\contentsline {subsubsection}{\numberline {16.2.3.5}Work-up}{445}{subsubsection.16.2.3.5}%
\contentsline {subsubsection}{\numberline {16.2.3.6}Management}{446}{subsubsection.16.2.3.6}%
\contentsline {subsubsection}{\numberline {16.2.3.7}Management}{446}{subsubsection.16.2.3.7}%
\contentsline {subsubsection}{\numberline {16.2.3.8}Complications}{446}{subsubsection.16.2.3.8}%
\contentsline {subsection}{\numberline {16.2.4}Bell's Palsy}{446}{subsection.16.2.4}%
\contentsline {subsubsection}{\numberline {16.2.4.1}PowerPlans, Order Sets \& Clinical Pathways}{446}{subsubsection.16.2.4.1}%
\contentsline {subsubsection}{\numberline {16.2.4.2}Pathophysiology}{446}{subsubsection.16.2.4.2}%
\contentsline {subsubsection}{\numberline {16.2.4.3}Presentation}{446}{subsubsection.16.2.4.3}%
\contentsline {subsubsection}{\numberline {16.2.4.4}Differential}{446}{subsubsection.16.2.4.4}%
\contentsline {subsubsection}{\numberline {16.2.4.5}Red Flags}{446}{subsubsection.16.2.4.5}%
\contentsline {subsubsection}{\numberline {16.2.4.6}Work-up}{446}{subsubsection.16.2.4.6}%
\contentsline {subsubsection}{\numberline {16.2.4.7}Management}{447}{subsubsection.16.2.4.7}%
\contentsline {subsubsection}{\numberline {16.2.4.8}Complications}{447}{subsubsection.16.2.4.8}%
\contentsline {subsection}{\numberline {16.2.5}Acute Flaccid Myelitis (AFM)}{447}{subsection.16.2.5}%
\contentsline {subsubsection}{\numberline {16.2.5.1}Pathophysiology}{447}{subsubsection.16.2.5.1}%
\contentsline {subsubsection}{\numberline {16.2.5.2}Presentation}{447}{subsubsection.16.2.5.2}%
\contentsline {subsubsection}{\numberline {16.2.5.3}Differential}{447}{subsubsection.16.2.5.3}%
\contentsline {subsubsection}{\numberline {16.2.5.4}Red Flags}{447}{subsubsection.16.2.5.4}%
\contentsline {subsubsection}{\numberline {16.2.5.5}Work-up}{447}{subsubsection.16.2.5.5}%
\contentsline {subsubsection}{\numberline {16.2.5.6}Management}{448}{subsubsection.16.2.5.6}%
\contentsline {subsubsection}{\numberline {16.2.5.7}Complications}{448}{subsubsection.16.2.5.7}%
\contentsline {section}{\numberline {16.3}Hypotonia}{448}{section.16.3}%
\contentsline {subsection}{\numberline {16.3.1}Approach to Neonatal Hypotonia}{448}{subsection.16.3.1}%
\contentsline {subsubsection}{\numberline {16.3.1.1}Pathophysiology}{448}{subsubsection.16.3.1.1}%
\contentsline {subsubsection}{\numberline {16.3.1.2}Presentation}{448}{subsubsection.16.3.1.2}%
\contentsline {subsubsection}{\numberline {16.3.1.3}Differential}{448}{subsubsection.16.3.1.3}%
\contentsline {subsubsection}{\numberline {16.3.1.4}Red Flags}{448}{subsubsection.16.3.1.4}%
\contentsline {subsubsection}{\numberline {16.3.1.5}Work-up}{448}{subsubsection.16.3.1.5}%
\contentsline {subsubsection}{\numberline {16.3.1.6}Management}{449}{subsubsection.16.3.1.6}%
\contentsline {subsubsection}{\numberline {16.3.1.7}Complications}{449}{subsubsection.16.3.1.7}%
\contentsline {subsection}{\numberline {16.3.2}Infantile Botulism}{449}{subsection.16.3.2}%
\contentsline {subsubsection}{\numberline {16.3.2.1}Pathophysiology}{449}{subsubsection.16.3.2.1}%
\contentsline {subsubsection}{\numberline {16.3.2.2}Presentation}{449}{subsubsection.16.3.2.2}%
\contentsline {subsubsection}{\numberline {16.3.2.3}Differential}{449}{subsubsection.16.3.2.3}%
\contentsline {subsubsection}{\numberline {16.3.2.4}Red Flags}{449}{subsubsection.16.3.2.4}%
\contentsline {subsubsection}{\numberline {16.3.2.5}Work-up}{449}{subsubsection.16.3.2.5}%
\contentsline {subsubsection}{\numberline {16.3.2.6}Management}{450}{subsubsection.16.3.2.6}%
\contentsline {subsubsection}{\numberline {16.3.2.7}Complications}{450}{subsubsection.16.3.2.7}%
\contentsline {section}{\numberline {16.4}Neuroimmunology}{450}{section.16.4}%
\contentsline {subsection}{\numberline {16.4.1}Multiple Sclerosis (MS)}{450}{subsection.16.4.1}%
\contentsline {subsubsection}{\numberline {16.4.1.1}Pathophysiology}{450}{subsubsection.16.4.1.1}%
\contentsline {subsubsection}{\numberline {16.4.1.2}Presentation}{450}{subsubsection.16.4.1.2}%
\contentsline {subsubsection}{\numberline {16.4.1.3}Differential}{450}{subsubsection.16.4.1.3}%
\contentsline {subsubsection}{\numberline {16.4.1.4}Red Flags}{450}{subsubsection.16.4.1.4}%
\contentsline {subsubsection}{\numberline {16.4.1.5}Work-up}{451}{subsubsection.16.4.1.5}%
\contentsline {subsubsection}{\numberline {16.4.1.6}Management}{451}{subsubsection.16.4.1.6}%
\contentsline {subsection}{\numberline {16.4.2}Acute Disseminated Encephalomyelitis (ADEM)}{451}{subsection.16.4.2}%
\contentsline {subsubsection}{\numberline {16.4.2.1}Pathophysiology}{451}{subsubsection.16.4.2.1}%
\contentsline {subsubsection}{\numberline {16.4.2.2}Presentation}{451}{subsubsection.16.4.2.2}%
\contentsline {subsubsection}{\numberline {16.4.2.3}Differential}{451}{subsubsection.16.4.2.3}%
\contentsline {subsubsection}{\numberline {16.4.2.4}Red Flags}{451}{subsubsection.16.4.2.4}%
\contentsline {subsubsection}{\numberline {16.4.2.5}Work-up}{451}{subsubsection.16.4.2.5}%
\contentsline {subsubsection}{\numberline {16.4.2.6}Management}{451}{subsubsection.16.4.2.6}%
\contentsline {subsubsection}{\numberline {16.4.2.7}Complications}{452}{subsubsection.16.4.2.7}%
\contentsline {subsection}{\numberline {16.4.3}Transverse Myelitis}{452}{subsection.16.4.3}%
\contentsline {subsubsection}{\numberline {16.4.3.1}Pathophysiology}{452}{subsubsection.16.4.3.1}%
\contentsline {subsubsection}{\numberline {16.4.3.2}Presentation}{452}{subsubsection.16.4.3.2}%
\contentsline {subsubsection}{\numberline {16.4.3.3}Differential}{452}{subsubsection.16.4.3.3}%
\contentsline {subsubsection}{\numberline {16.4.3.4}Red Flags}{452}{subsubsection.16.4.3.4}%
\contentsline {subsubsection}{\numberline {16.4.3.5}Work-up}{452}{subsubsection.16.4.3.5}%
\contentsline {subsubsection}{\numberline {16.4.3.6}Management}{453}{subsubsection.16.4.3.6}%
\contentsline {subsubsection}{\numberline {16.4.3.7}Complications}{453}{subsubsection.16.4.3.7}%
\contentsline {subsection}{\numberline {16.4.4}Autoimmune Encephalitis (NMDA Receptor Antibody Encephalopathy)}{453}{subsection.16.4.4}%
\contentsline {subsubsection}{\numberline {16.4.4.1}Pathophysiology}{453}{subsubsection.16.4.4.1}%
\contentsline {subsubsection}{\numberline {16.4.4.2}Presentation}{453}{subsubsection.16.4.4.2}%
\contentsline {subsubsection}{\numberline {16.4.4.3}Differential}{453}{subsubsection.16.4.4.3}%
\contentsline {subsubsection}{\numberline {16.4.4.4}Red Flags}{453}{subsubsection.16.4.4.4}%
\contentsline {subsubsection}{\numberline {16.4.4.5}Work-up}{453}{subsubsection.16.4.4.5}%
\contentsline {subsubsection}{\numberline {16.4.4.6}Management}{454}{subsubsection.16.4.4.6}%
\contentsline {subsubsection}{\numberline {16.4.4.7}Complications}{454}{subsubsection.16.4.4.7}%
\contentsline {section}{\numberline {16.5}Neuropsychiatric}{454}{section.16.5}%
\contentsline {subsection}{\numberline {16.5.1}Functional Neurologic Disorder}{454}{subsection.16.5.1}%
\contentsline {subsubsection}{\numberline {16.5.1.1}PowerPlans, Order Sets \& Clinical Pathways}{454}{subsubsection.16.5.1.1}%
\contentsline {subsubsection}{\numberline {16.5.1.2}Pathophysiology}{454}{subsubsection.16.5.1.2}%
\contentsline {subsubsection}{\numberline {16.5.1.3}Presentation}{454}{subsubsection.16.5.1.3}%
\contentsline {subsubsection}{\numberline {16.5.1.4}Differential}{454}{subsubsection.16.5.1.4}%
\contentsline {subsubsection}{\numberline {16.5.1.5}Red Flags}{454}{subsubsection.16.5.1.5}%
\contentsline {subsubsection}{\numberline {16.5.1.6}Work-up}{454}{subsubsection.16.5.1.6}%
\contentsline {subsubsection}{\numberline {16.5.1.7}Management}{456}{subsubsection.16.5.1.7}%
\contentsline {section}{\numberline {16.6}Headache}{456}{section.16.6}%
\contentsline {subsection}{\numberline {16.6.1}Migraine}{456}{subsection.16.6.1}%
\contentsline {subsubsection}{\numberline {16.6.1.1}PowerPlans, Order Sets \& Clinical Pathways}{456}{subsubsection.16.6.1.1}%
\contentsline {subsubsection}{\numberline {16.6.1.2}Pathophysiology}{456}{subsubsection.16.6.1.2}%
\contentsline {subsubsection}{\numberline {16.6.1.3}Presentation}{456}{subsubsection.16.6.1.3}%
\contentsline {subsubsection}{\numberline {16.6.1.4}Differential}{456}{subsubsection.16.6.1.4}%
\contentsline {subsubsection}{\numberline {16.6.1.5}Red Flags}{456}{subsubsection.16.6.1.5}%
\contentsline {subsubsection}{\numberline {16.6.1.6}Work-up}{456}{subsubsection.16.6.1.6}%
\contentsline {subsubsection}{\numberline {16.6.1.7}Management}{456}{subsubsection.16.6.1.7}%
\contentsline {subsection}{\numberline {16.6.2}Tension Headache}{457}{subsection.16.6.2}%
\contentsline {subsection}{\numberline {16.6.3}Concussion}{457}{subsection.16.6.3}%
\contentsline {subsection}{\numberline {16.6.4}Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)}{457}{subsection.16.6.4}%
\contentsline {subsubsection}{\numberline {16.6.4.1}Pathophysiology}{457}{subsubsection.16.6.4.1}%
\contentsline {subsubsection}{\numberline {16.6.4.2}Presentation}{457}{subsubsection.16.6.4.2}%
\contentsline {subsubsection}{\numberline {16.6.4.3}Differential}{457}{subsubsection.16.6.4.3}%
\contentsline {subsubsection}{\numberline {16.6.4.4}Work-up}{457}{subsubsection.16.6.4.4}%
\contentsline {subsubsection}{\numberline {16.6.4.5}Management}{457}{subsubsection.16.6.4.5}%
\contentsline {subsubsection}{\numberline {16.6.4.6}Complications}{457}{subsubsection.16.6.4.6}%
\contentsline {section}{\numberline {16.7}Seizures}{457}{section.16.7}%
\contentsline {subsection}{\numberline {16.7.1}Febrile Seizure}{457}{subsection.16.7.1}%
\contentsline {subsubsection}{\numberline {16.7.1.1}PowerPlans, Order Sets \& Clinical Pathways:}{457}{subsubsection.16.7.1.1}%
\contentsline {subsubsection}{\numberline {16.7.1.2}Pathophysiology}{458}{subsubsection.16.7.1.2}%
\contentsline {subsubsection}{\numberline {16.7.1.3}Presentation}{458}{subsubsection.16.7.1.3}%
\contentsline {subsubsection}{\numberline {16.7.1.4}Differential}{458}{subsubsection.16.7.1.4}%
\contentsline {subsubsection}{\numberline {16.7.1.5}Red Flags}{458}{subsubsection.16.7.1.5}%
\contentsline {subsubsection}{\numberline {16.7.1.6}Work-up}{458}{subsubsection.16.7.1.6}%
\contentsline {subsubsection}{\numberline {16.7.1.7}Management}{458}{subsubsection.16.7.1.7}%
\contentsline {subsubsection}{\numberline {16.7.1.8}Complications}{458}{subsubsection.16.7.1.8}%
\contentsline {subsection}{\numberline {16.7.2}First-time Unprovoked Seizure}{458}{subsection.16.7.2}%
\contentsline {subsubsection}{\numberline {16.7.2.1}Pathophysiology}{458}{subsubsection.16.7.2.1}%
\contentsline {subsubsection}{\numberline {16.7.2.2}Presentation}{458}{subsubsection.16.7.2.2}%
\contentsline {subsubsection}{\numberline {16.7.2.3}Differential}{459}{subsubsection.16.7.2.3}%
\contentsline {subsubsection}{\numberline {16.7.2.4}Red Flags}{459}{subsubsection.16.7.2.4}%
\contentsline {subsubsection}{\numberline {16.7.2.5}Work-up}{459}{subsubsection.16.7.2.5}%
\contentsline {subsubsection}{\numberline {16.7.2.6}Management}{459}{subsubsection.16.7.2.6}%
\contentsline {subsubsection}{\numberline {16.7.2.7}Complications}{459}{subsubsection.16.7.2.7}%
\contentsline {subsection}{\numberline {16.7.3}Breakthrough Seizure (in a patient w/ epilepsy)}{459}{subsection.16.7.3}%
\contentsline {subsubsection}{\numberline {16.7.3.1}Pathophysiology}{459}{subsubsection.16.7.3.1}%
\contentsline {subsubsection}{\numberline {16.7.3.2}Differential}{459}{subsubsection.16.7.3.2}%
\contentsline {subsubsection}{\numberline {16.7.3.3}Red Flags}{459}{subsubsection.16.7.3.3}%
\contentsline {subsubsection}{\numberline {16.7.3.4}Work-up}{460}{subsubsection.16.7.3.4}%
\contentsline {subsubsection}{\numberline {16.7.3.5}Management}{460}{subsubsection.16.7.3.5}%
\contentsline {subsection}{\numberline {16.7.4}Infantile Spasms}{460}{subsection.16.7.4}%
\contentsline {subsubsection}{\numberline {16.7.4.1}Pathophysiology}{460}{subsubsection.16.7.4.1}%
\contentsline {subsubsection}{\numberline {16.7.4.2}Presentation}{460}{subsubsection.16.7.4.2}%
\contentsline {subsubsection}{\numberline {16.7.4.3}Differential}{460}{subsubsection.16.7.4.3}%
\contentsline {subsubsection}{\numberline {16.7.4.4}Work-up}{460}{subsubsection.16.7.4.4}%
\contentsline {subsubsection}{\numberline {16.7.4.5}Management}{460}{subsubsection.16.7.4.5}%
\contentsline {subsubsection}{\numberline {16.7.4.6}Complications}{460}{subsubsection.16.7.4.6}%
\contentsline {section}{\numberline {16.8}Meningitis}{460}{section.16.8}%
\contentsline {subsection}{\numberline {16.8.1}Bacterial Meningitis}{461}{subsection.16.8.1}%
\contentsline {subsubsection}{\numberline {16.8.1.1}PowerPlans}{461}{subsubsection.16.8.1.1}%
\contentsline {subsubsection}{\numberline {16.8.1.2}Pathophysiology}{461}{subsubsection.16.8.1.2}%
\contentsline {subsubsection}{\numberline {16.8.1.3}Presentation}{461}{subsubsection.16.8.1.3}%
\contentsline {subsubsection}{\numberline {16.8.1.4}Differential}{461}{subsubsection.16.8.1.4}%
\contentsline {subsubsection}{\numberline {16.8.1.5}Red Flags}{461}{subsubsection.16.8.1.5}%
\contentsline {subsubsection}{\numberline {16.8.1.6}Work-up}{461}{subsubsection.16.8.1.6}%
\contentsline {subsubsection}{\numberline {16.8.1.7}Management}{461}{subsubsection.16.8.1.7}%
\contentsline {subsubsection}{\numberline {16.8.1.8}Complications}{461}{subsubsection.16.8.1.8}%
\contentsline {subsection}{\numberline {16.8.2}Viral Meningitis \& Encephalitis}{461}{subsection.16.8.2}%
\contentsline {subsubsection}{\numberline {16.8.2.1}Pathophysiology}{461}{subsubsection.16.8.2.1}%
\contentsline {subsubsection}{\numberline {16.8.2.2}Presentation}{462}{subsubsection.16.8.2.2}%
\contentsline {subsubsection}{\numberline {16.8.2.3}Differential}{462}{subsubsection.16.8.2.3}%
\contentsline {subsubsection}{\numberline {16.8.2.4}Red Flags}{462}{subsubsection.16.8.2.4}%
\contentsline {subsubsection}{\numberline {16.8.2.5}Work-up}{462}{subsubsection.16.8.2.5}%
\contentsline {subsubsection}{\numberline {16.8.2.6}Management}{462}{subsubsection.16.8.2.6}%
\contentsline {subsubsection}{\numberline {16.8.2.7}Complications}{462}{subsubsection.16.8.2.7}%
\contentsline {section}{\numberline {16.9}References}{463}{section.16.9}%
\contentsline {chapter}{\numberline {17}Newborn Nursery}{465}{chapter.17}%
\contentsline {section}{\numberline {17.1}Rotation Specific Entities}{465}{section.17.1}%
\contentsline {section}{\numberline {17.2}Gestational Age}{465}{section.17.2}%
\contentsline {section}{\numberline {17.3}Normal Infant Feeding}{465}{section.17.3}%
\contentsline {subsection}{\numberline {17.3.1}Breastfeeding}{466}{subsection.17.3.1}%
\contentsline {subsubsection}{\numberline {17.3.1.1}Breastfeeding Tips}{466}{subsubsection.17.3.1.1}%
\contentsline {subsubsection}{\numberline {17.3.1.2}Contraindications to breastfeeding}{466}{subsubsection.17.3.1.2}%
\contentsline {subsection}{\numberline {17.3.2}Formula Feeding}{467}{subsection.17.3.2}%
\contentsline {subsection}{\numberline {17.3.3}Tongue Ties}{467}{subsection.17.3.3}%
\contentsline {section}{\numberline {17.4}Newborn Behavior}{467}{section.17.4}%
\contentsline {section}{\numberline {17.5}Anticipatory Guidance / Discharge Teaching}{467}{section.17.5}%
\contentsline {subsection}{\numberline {17.5.1}Feeding}{467}{subsection.17.5.1}%
\contentsline {subsection}{\numberline {17.5.2}Normal Voiding / Stooling}{468}{subsection.17.5.2}%
\contentsline {subsection}{\numberline {17.5.3}Cord Care}{468}{subsection.17.5.3}%
\contentsline {subsection}{\numberline {17.5.4}Circumcision Care}{468}{subsection.17.5.4}%
\contentsline {subsection}{\numberline {17.5.5}Safe Sleep}{468}{subsection.17.5.5}%
\contentsline {subsection}{\numberline {17.5.6}Tummy Time}{468}{subsection.17.5.6}%
\contentsline {subsection}{\numberline {17.5.7}Consoling}{468}{subsection.17.5.7}%
\contentsline {subsection}{\numberline {17.5.8}Illness}{468}{subsection.17.5.8}%
\contentsline {section}{\numberline {17.6}Hyperbilirubinemia}{468}{section.17.6}%
\contentsline {subsection}{\numberline {17.6.1}Definition}{469}{subsection.17.6.1}%
\contentsline {subsection}{\numberline {17.6.2}Pathophysiology}{469}{subsection.17.6.2}%
\contentsline {subsection}{\numberline {17.6.3}Evaluation}{469}{subsection.17.6.3}%
\contentsline {subsection}{\numberline {17.6.4}Management}{470}{subsection.17.6.4}%
\contentsline {section}{\numberline {17.7}Infant of a Diabetic Mother (IDM)}{470}{section.17.7}%
\contentsline {subsection}{\numberline {17.7.1}Increased risks}{470}{subsection.17.7.1}%
\contentsline {subsection}{\numberline {17.7.2}Congenital anomalies}{470}{subsection.17.7.2}%
\contentsline {subsection}{\numberline {17.7.3}Management}{470}{subsection.17.7.3}%
\contentsline {subsection}{\numberline {17.7.4}Hypoglycemia}{470}{subsection.17.7.4}%
\contentsline {section}{\numberline {17.8}Neonatal Abstinence Syndrome (NAS)}{471}{section.17.8}%
\contentsline {subsection}{\numberline {17.8.1}Pathophysiology}{471}{subsection.17.8.1}%
\contentsline {subsection}{\numberline {17.8.2}Presentation}{471}{subsection.17.8.2}%
\contentsline {subsection}{\numberline {17.8.3}Management}{471}{subsection.17.8.3}%
\contentsline {section}{\numberline {17.9}Newborn ID}{472}{section.17.9}%
\contentsline {subsection}{\numberline {17.9.1}Early Onset Sepsis}{472}{subsection.17.9.1}%
\contentsline {subsubsection}{\numberline {17.9.1.1}Pathophysiology}{472}{subsubsection.17.9.1.1}%
\contentsline {subsubsection}{\numberline {17.9.1.2}Sepsis RFs}{472}{subsubsection.17.9.1.2}%
\contentsline {subsubsection}{\numberline {17.9.1.3}Treatment}{472}{subsubsection.17.9.1.3}%
\contentsline {subsection}{\numberline {17.9.2}Hepatitis B}{472}{subsection.17.9.2}%
\contentsline {subsection}{\numberline {17.9.3}HIV}{473}{subsection.17.9.3}%
\contentsline {subsubsection}{\numberline {17.9.3.1}Management}{473}{subsubsection.17.9.3.1}%
\contentsline {subsubsection}{\numberline {17.9.3.2}Treatment}{473}{subsubsection.17.9.3.2}%
\contentsline {subsection}{\numberline {17.9.4}HSV}{473}{subsection.17.9.4}%
\contentsline {subsubsection}{\numberline {17.9.4.1}Pathophysiology}{473}{subsubsection.17.9.4.1}%
\contentsline {subsubsection}{\numberline {17.9.4.2}Presentation}{473}{subsubsection.17.9.4.2}%
\contentsline {subsubsection}{\numberline {17.9.4.3}Workup}{473}{subsubsection.17.9.4.3}%
\contentsline {subsubsection}{\numberline {17.9.4.4}Treatment}{474}{subsubsection.17.9.4.4}%
\contentsline {chapter}{\numberline {18}Neonatology (NICU)}{475}{chapter.18}%
\contentsline {section}{\numberline {18.1}APGAR Scoring}{476}{section.18.1}%
\contentsline {section}{\numberline {18.2}Neonatal Respiratory Disorders \& Delivery Room Pathology}{477}{section.18.2}%
\contentsline {subsection}{\numberline {18.2.1}Choanal Atresia}{477}{subsection.18.2.1}%
\contentsline {subsubsection}{\numberline {18.2.1.1}History}{477}{subsubsection.18.2.1.1}%
\contentsline {subsubsection}{\numberline {18.2.1.2}Management}{477}{subsubsection.18.2.1.2}%
\contentsline {subsection}{\numberline {18.2.2}Pharyngeal Airway Malformation}{477}{subsection.18.2.2}%
\contentsline {subsubsection}{\numberline {18.2.2.1}History}{477}{subsubsection.18.2.2.1}%
\contentsline {subsubsection}{\numberline {18.2.2.2}Management}{477}{subsubsection.18.2.2.2}%
\contentsline {subsection}{\numberline {18.2.3}Congenital Diaphragmatic Hernia (CDH)}{477}{subsection.18.2.3}%
\contentsline {subsubsection}{\numberline {18.2.3.1}History}{477}{subsubsection.18.2.3.1}%
\contentsline {subsubsection}{\numberline {18.2.3.2}Diagnosis}{477}{subsubsection.18.2.3.2}%
\contentsline {subsubsection}{\numberline {18.2.3.3}Management}{477}{subsubsection.18.2.3.3}%
\contentsline {subsection}{\numberline {18.2.4}Pleural Effusion}{478}{subsection.18.2.4}%
\contentsline {subsubsection}{\numberline {18.2.4.1}History}{478}{subsubsection.18.2.4.1}%
\contentsline {subsubsection}{\numberline {18.2.4.2}Management}{478}{subsubsection.18.2.4.2}%
\contentsline {subsection}{\numberline {18.2.5}Pneumothorax}{478}{subsection.18.2.5}%
\contentsline {subsubsection}{\numberline {18.2.5.1}History}{478}{subsubsection.18.2.5.1}%
\contentsline {subsubsection}{\numberline {18.2.5.2}Diagnosis}{478}{subsubsection.18.2.5.2}%
\contentsline {subsubsection}{\numberline {18.2.5.3}Management}{478}{subsubsection.18.2.5.3}%
\contentsline {subsection}{\numberline {18.2.6}Meconium Aspiration}{478}{subsection.18.2.6}%
\contentsline {subsubsection}{\numberline {18.2.6.1}History}{478}{subsubsection.18.2.6.1}%
\contentsline {subsubsection}{\numberline {18.2.6.2}Diagnosis}{478}{subsubsection.18.2.6.2}%
\contentsline {subsubsection}{\numberline {18.2.6.3}Management}{478}{subsubsection.18.2.6.3}%
\contentsline {subsubsection}{\numberline {18.2.6.4}Complications}{478}{subsubsection.18.2.6.4}%
\contentsline {subsection}{\numberline {18.2.7}Persistent Pulmonay Hypertension (PPHN)}{479}{subsection.18.2.7}%
\contentsline {subsubsection}{\numberline {18.2.7.1}History}{479}{subsubsection.18.2.7.1}%
\contentsline {subsubsection}{\numberline {18.2.7.2}Clinical Manifestations}{479}{subsubsection.18.2.7.2}%
\contentsline {subsubsection}{\numberline {18.2.7.3}Diagnostics}{479}{subsubsection.18.2.7.3}%
\contentsline {subsubsection}{\numberline {18.2.7.4}Management}{479}{subsubsection.18.2.7.4}%
\contentsline {subsection}{\numberline {18.2.8}Respiratory Distress Syndrome (RDS)}{479}{subsection.18.2.8}%
\contentsline {subsubsection}{\numberline {18.2.8.1}Etiology}{479}{subsubsection.18.2.8.1}%
\contentsline {subsubsection}{\numberline {18.2.8.2}Symtpoms}{479}{subsubsection.18.2.8.2}%
\contentsline {subsubsection}{\numberline {18.2.8.3}Diagnostics}{479}{subsubsection.18.2.8.3}%
\contentsline {subsubsection}{\numberline {18.2.8.4}Management}{479}{subsubsection.18.2.8.4}%
\contentsline {subsection}{\numberline {18.2.9}Transient Tachypnea of the Newborn (TTN)}{479}{subsection.18.2.9}%
\contentsline {subsubsection}{\numberline {18.2.9.1}Etiology}{479}{subsubsection.18.2.9.1}%
\contentsline {subsubsection}{\numberline {18.2.9.2}History}{480}{subsubsection.18.2.9.2}%
\contentsline {subsubsection}{\numberline {18.2.9.3}Clinical Manifestations}{480}{subsubsection.18.2.9.3}%
\contentsline {subsubsection}{\numberline {18.2.9.4}Diagnosis}{480}{subsubsection.18.2.9.4}%
\contentsline {subsubsection}{\numberline {18.2.9.5}Management}{480}{subsubsection.18.2.9.5}%
\contentsline {section}{\numberline {18.3}Neonatal Cardiology}{480}{section.18.3}%
\contentsline {subsection}{\numberline {18.3.1}Blood Pressure for Premature Infants}{480}{subsection.18.3.1}%
\contentsline {subsection}{\numberline {18.3.2}Patent Ductus Arteriosus (PDA)}{480}{subsection.18.3.2}%
\contentsline {subsubsection}{\numberline {18.3.2.1}Etiology}{480}{subsubsection.18.3.2.1}%
\contentsline {subsubsection}{\numberline {18.3.2.2}Clinical Manifestations}{480}{subsubsection.18.3.2.2}%
\contentsline {subsubsection}{\numberline {18.3.2.3}Diagnosis}{481}{subsubsection.18.3.2.3}%
\contentsline {subsubsection}{\numberline {18.3.2.4}Management}{481}{subsubsection.18.3.2.4}%
\contentsline {section}{\numberline {18.4}Neonatal Hematology}{481}{section.18.4}%
\contentsline {subsection}{\numberline {18.4.1}Anemia}{481}{subsection.18.4.1}%
\contentsline {subsubsection}{\numberline {18.4.1.1}Definition}{481}{subsubsection.18.4.1.1}%
\contentsline {subsubsection}{\numberline {18.4.1.2}Differential}{481}{subsubsection.18.4.1.2}%
\contentsline {subsubsection}{\numberline {18.4.1.3}Work-up}{481}{subsubsection.18.4.1.3}%
\contentsline {subsubsection}{\numberline {18.4.1.4}Management}{481}{subsubsection.18.4.1.4}%
\contentsline {subsection}{\numberline {18.4.2}Polycythemia}{482}{subsection.18.4.2}%
\contentsline {subsubsection}{\numberline {18.4.2.1}Definition}{482}{subsubsection.18.4.2.1}%
\contentsline {subsubsection}{\numberline {18.4.2.2}Differential}{482}{subsubsection.18.4.2.2}%
\contentsline {subsubsection}{\numberline {18.4.2.3}Work-up}{482}{subsubsection.18.4.2.3}%
\contentsline {subsubsection}{\numberline {18.4.2.4}Management}{482}{subsubsection.18.4.2.4}%
\contentsline {subsection}{\numberline {18.4.3}Thrombocytopenia}{482}{subsection.18.4.3}%
\contentsline {subsubsection}{\numberline {18.4.3.1}Definition}{482}{subsubsection.18.4.3.1}%
\contentsline {subsubsection}{\numberline {18.4.3.2}Differential}{482}{subsubsection.18.4.3.2}%
\contentsline {subsubsection}{\numberline {18.4.3.3}Work-up}{482}{subsubsection.18.4.3.3}%
\contentsline {subsubsection}{\numberline {18.4.3.4}Management}{482}{subsubsection.18.4.3.4}%
\contentsline {section}{\numberline {18.5}Neonatal Neurology}{483}{section.18.5}%
\contentsline {subsection}{\numberline {18.5.1}Interventricular Hemorrhage (IVH)}{483}{subsection.18.5.1}%
\contentsline {subsubsection}{\numberline {18.5.1.1}Pathophygiolosy}{483}{subsubsection.18.5.1.1}%
\contentsline {subsubsection}{\numberline {18.5.1.2}Screening}{483}{subsubsection.18.5.1.2}%
\contentsline {subsubsection}{\numberline {18.5.1.3}IVH Grading}{483}{subsubsection.18.5.1.3}%
\contentsline {subsection}{\numberline {18.5.2}Therapeutic Cooling}{483}{subsection.18.5.2}%
\contentsline {subsubsection}{\numberline {18.5.2.1}BWH Protocol}{483}{subsubsection.18.5.2.1}%
\contentsline {subsubsection}{\numberline {18.5.2.2}Management}{484}{subsubsection.18.5.2.2}%
\contentsline {section}{\numberline {18.6}Neonatal Infectious Disease}{484}{section.18.6}%
\contentsline {subsection}{\numberline {18.6.1}Sepsis}{485}{subsection.18.6.1}%
\contentsline {subsection}{\numberline {18.6.2}TORCH infections}{485}{subsection.18.6.2}%
\contentsline {subsection}{\numberline {18.6.3}Vertical Transmission}{485}{subsection.18.6.3}%
\contentsline {subsubsection}{\numberline {18.6.3.1}Hep B}{485}{subsubsection.18.6.3.1}%
\contentsline {subsubsection}{\numberline {18.6.3.2}HIV}{485}{subsubsection.18.6.3.2}%
\contentsline {section}{\numberline {18.7}Neonatal Endocrinology}{485}{section.18.7}%
\contentsline {subsection}{\numberline {18.7.1}Hypoglycemia}{485}{subsection.18.7.1}%
\contentsline {subsubsection}{\numberline {18.7.1.1}Definition}{485}{subsubsection.18.7.1.1}%
\contentsline {subsubsection}{\numberline {18.7.1.2}Risk factors}{485}{subsubsection.18.7.1.2}%
\contentsline {subsubsection}{\numberline {18.7.1.3}Management}{486}{subsubsection.18.7.1.3}%
\contentsline {section}{\numberline {18.8}Neonatal Gastroenterology}{486}{section.18.8}%
\contentsline {subsection}{\numberline {18.8.1}Emesis in an Infant}{486}{subsection.18.8.1}%
\contentsline {subsubsection}{\numberline {18.8.1.1}Differential}{486}{subsubsection.18.8.1.1}%
\contentsline {subsubsection}{\numberline {18.8.1.2}Work-up}{486}{subsubsection.18.8.1.2}%
\contentsline {subsection}{\numberline {18.8.2}Acute Abdomen in the Neonate}{487}{subsection.18.8.2}%
\contentsline {subsection}{\numberline {18.8.3}Indirect Hyperbilirubinemia}{487}{subsection.18.8.3}%
\contentsline {subsection}{\numberline {18.8.4}Neonatal Entercolitis (NEC)}{488}{subsection.18.8.4}%
\contentsline {subsubsection}{\numberline {18.8.4.1}Etiology}{488}{subsubsection.18.8.4.1}%
\contentsline {subsubsection}{\numberline {18.8.4.2}Clinical Manifestations}{488}{subsubsection.18.8.4.2}%
\contentsline {subsubsection}{\numberline {18.8.4.3}Work-up}{488}{subsubsection.18.8.4.3}%
\contentsline {subsubsection}{\numberline {18.8.4.4}Management}{488}{subsubsection.18.8.4.4}%
\contentsline {subsection}{\numberline {18.8.5}Malrotation (+/- Mid Gut Volvulus)}{488}{subsection.18.8.5}%
\contentsline {subsubsection}{\numberline {18.8.5.1}Etiology}{488}{subsubsection.18.8.5.1}%
\contentsline {subsubsection}{\numberline {18.8.5.2}Clinical Manifestations}{489}{subsubsection.18.8.5.2}%
\contentsline {subsubsection}{\numberline {18.8.5.3}Work-up}{489}{subsubsection.18.8.5.3}%
\contentsline {subsubsection}{\numberline {18.8.5.4}Management}{489}{subsubsection.18.8.5.4}%
\contentsline {subsection}{\numberline {18.8.6}Duodenal Atresia}{489}{subsection.18.8.6}%
\contentsline {subsubsection}{\numberline {18.8.6.1}Etiology}{489}{subsubsection.18.8.6.1}%
\contentsline {subsubsection}{\numberline {18.8.6.2}Clinical Manifestations}{489}{subsubsection.18.8.6.2}%
\contentsline {subsubsection}{\numberline {18.8.6.3}Work-up}{489}{subsubsection.18.8.6.3}%
\contentsline {subsubsection}{\numberline {18.8.6.4}Management}{489}{subsubsection.18.8.6.4}%
\contentsline {subsection}{\numberline {18.8.7}Jujonoileal Atresia}{489}{subsection.18.8.7}%
\contentsline {subsubsection}{\numberline {18.8.7.1}Etiology}{489}{subsubsection.18.8.7.1}%
\contentsline {subsubsection}{\numberline {18.8.7.2}Clinical Manifestations}{490}{subsubsection.18.8.7.2}%
\contentsline {subsubsection}{\numberline {18.8.7.3}Work-up}{490}{subsubsection.18.8.7.3}%
\contentsline {subsubsection}{\numberline {18.8.7.4}Management}{490}{subsubsection.18.8.7.4}%
\contentsline {subsection}{\numberline {18.8.8}Meconium ileus}{490}{subsection.18.8.8}%
\contentsline {subsubsection}{\numberline {18.8.8.1}Etiology}{490}{subsubsection.18.8.8.1}%
\contentsline {subsubsection}{\numberline {18.8.8.2}Clinical Manifestations}{490}{subsubsection.18.8.8.2}%
\contentsline {subsubsection}{\numberline {18.8.8.3}Work-up}{490}{subsubsection.18.8.8.3}%
\contentsline {subsubsection}{\numberline {18.8.8.4}Management}{490}{subsubsection.18.8.8.4}%
\contentsline {chapter}{\numberline {19}Oncology}{491}{chapter.19}%
\contentsline {section}{\numberline {19.1}Order Sets \& PowerPlans}{491}{section.19.1}%
\contentsline {section}{\numberline {19.2}Common Pediatric Cancers}{491}{section.19.2}%
\contentsline {subsection}{\numberline {19.2.1}Hematologic Cancers}{491}{subsection.19.2.1}%
\contentsline {subsubsection}{\numberline {19.2.1.1}B-ALL}{491}{subsubsection.19.2.1.1}%
\contentsline {paragraph}{\numberline {19.2.1.1.1}Presentation}{491}{paragraph.19.2.1.1.1}%
\contentsline {paragraph}{\numberline {19.2.1.1.2}Epidemiology}{491}{paragraph.19.2.1.1.2}%
\contentsline {paragraph}{\numberline {19.2.1.1.3}Key Early Diagnostics}{492}{paragraph.19.2.1.1.3}%
\contentsline {paragraph}{\numberline {19.2.1.1.4}Risk Stratification (DFCI 16-001)}{492}{paragraph.19.2.1.1.4}%
\contentsline {paragraph}{\numberline {19.2.1.1.5}Standard Treatment}{492}{paragraph.19.2.1.1.5}%
\contentsline {subsubsection}{\numberline {19.2.1.2}T-ALL}{492}{subsubsection.19.2.1.2}%
\contentsline {paragraph}{\numberline {19.2.1.2.1}Presentation}{492}{paragraph.19.2.1.2.1}%
\contentsline {paragraph}{\numberline {19.2.1.2.2}Epidemiology}{493}{paragraph.19.2.1.2.2}%
\contentsline {paragraph}{\numberline {19.2.1.2.3}Diagnostics}{493}{paragraph.19.2.1.2.3}%
\contentsline {paragraph}{\numberline {19.2.1.2.4}Risk Stratification}{493}{paragraph.19.2.1.2.4}%
\contentsline {paragraph}{\numberline {19.2.1.2.5}Treatment}{493}{paragraph.19.2.1.2.5}%
\contentsline {paragraph}{\numberline {19.2.1.2.6}Outcomes/Prognosis}{493}{paragraph.19.2.1.2.6}%
\contentsline {subsubsection}{\numberline {19.2.1.3}AML}{493}{subsubsection.19.2.1.3}%
\contentsline {paragraph}{\numberline {19.2.1.3.1}Presentation}{493}{paragraph.19.2.1.3.1}%
\contentsline {paragraph}{\numberline {19.2.1.3.2}Epidemiology}{493}{paragraph.19.2.1.3.2}%
\contentsline {paragraph}{\numberline {19.2.1.3.3}Diagnostics}{493}{paragraph.19.2.1.3.3}%
\contentsline {paragraph}{\numberline {19.2.1.3.4}Risk Stratification}{493}{paragraph.19.2.1.3.4}%
\contentsline {paragraph}{\numberline {19.2.1.3.5}Treatment}{494}{paragraph.19.2.1.3.5}%
\contentsline {paragraph}{\numberline {19.2.1.3.6}Outcomes/Prognosis}{494}{paragraph.19.2.1.3.6}%
\contentsline {subsubsection}{\numberline {19.2.1.4}Hodgkin's Lymphoma}{494}{subsubsection.19.2.1.4}%
\contentsline {paragraph}{\numberline {19.2.1.4.1}Presentation}{494}{paragraph.19.2.1.4.1}%
\contentsline {paragraph}{\numberline {19.2.1.4.2}Epidemiology}{494}{paragraph.19.2.1.4.2}%
\contentsline {paragraph}{\numberline {19.2.1.4.3}Risk Stratigication \& Staging}{494}{paragraph.19.2.1.4.3}%
\contentsline {paragraph}{\numberline {19.2.1.4.4}Treatment}{494}{paragraph.19.2.1.4.4}%
\contentsline {paragraph}{\numberline {19.2.1.4.5}Outcomes/Prognosis}{494}{paragraph.19.2.1.4.5}%
\contentsline {subsubsection}{\numberline {19.2.1.5}Non-Hodgkin's Lymphoma}{495}{subsubsection.19.2.1.5}%
\contentsline {paragraph}{\numberline {19.2.1.5.1}Presentation}{495}{paragraph.19.2.1.5.1}%
\contentsline {paragraph}{\numberline {19.2.1.5.2}Epidemiology}{495}{paragraph.19.2.1.5.2}%
\contentsline {paragraph}{\numberline {19.2.1.5.3}Notes about Grouping, Staging, or Potential Prognostic Features}{495}{paragraph.19.2.1.5.3}%
\contentsline {subsection}{\numberline {19.2.2}Musculoskeletal Tumors}{495}{subsection.19.2.2}%
\contentsline {subsubsection}{\numberline {19.2.2.1}Rhabdomyosarcoma}{495}{subsubsection.19.2.2.1}%
\contentsline {paragraph}{\numberline {19.2.2.1.1}Presentation}{495}{paragraph.19.2.2.1.1}%
\contentsline {paragraph}{\numberline {19.2.2.1.2}Epidemiology}{495}{paragraph.19.2.2.1.2}%
\contentsline {paragraph}{\numberline {19.2.2.1.3}Types \& Outcomes/Prognosis}{495}{paragraph.19.2.2.1.3}%
\contentsline {paragraph}{\numberline {19.2.2.1.4}Treatment}{496}{paragraph.19.2.2.1.4}%
\contentsline {subsubsection}{\numberline {19.2.2.2}Osteosarcoma}{496}{subsubsection.19.2.2.2}%
\contentsline {paragraph}{\numberline {19.2.2.2.1}Presentation}{496}{paragraph.19.2.2.2.1}%
\contentsline {paragraph}{\numberline {19.2.2.2.2}Epidemiology}{496}{paragraph.19.2.2.2.2}%
\contentsline {paragraph}{\numberline {19.2.2.2.3}Risk Factors}{496}{paragraph.19.2.2.2.3}%
\contentsline {paragraph}{\numberline {19.2.2.2.4}Treatment}{496}{paragraph.19.2.2.2.4}%
\contentsline {paragraph}{\numberline {19.2.2.2.5}Outcomes/Prognosis}{496}{paragraph.19.2.2.2.5}%
\contentsline {subsubsection}{\numberline {19.2.2.3}Ewing Sarcoma}{496}{subsubsection.19.2.2.3}%
\contentsline {paragraph}{\numberline {19.2.2.3.1}Presentation}{496}{paragraph.19.2.2.3.1}%
\contentsline {paragraph}{\numberline {19.2.2.3.2}Epidemiology}{496}{paragraph.19.2.2.3.2}%
\contentsline {paragraph}{\numberline {19.2.2.3.3}Treatment}{497}{paragraph.19.2.2.3.3}%
\contentsline {paragraph}{\numberline {19.2.2.3.4}Outcomes/Prognosis}{497}{paragraph.19.2.2.3.4}%
\contentsline {subsection}{\numberline {19.2.3}Nervous System Tumors, managed by Neuro-Oncologists}{497}{subsection.19.2.3}%
\contentsline {subsubsection}{\numberline {19.2.3.1}Medulloblastoma}{497}{subsubsection.19.2.3.1}%
\contentsline {paragraph}{\numberline {19.2.3.1.1}Presentation}{497}{paragraph.19.2.3.1.1}%
\contentsline {paragraph}{\numberline {19.2.3.1.2}Epidemiology}{497}{paragraph.19.2.3.1.2}%
\contentsline {paragraph}{\numberline {19.2.3.1.3}Risk Stratification \& Outcomes/Prognosis}{497}{paragraph.19.2.3.1.3}%
\contentsline {subsubsection}{\numberline {19.2.3.2}Gliomas}{497}{subsubsection.19.2.3.2}%
\contentsline {paragraph}{\numberline {19.2.3.2.1}Presentation}{497}{paragraph.19.2.3.2.1}%
\contentsline {paragraph}{\numberline {19.2.3.2.2}Epidemiology}{497}{paragraph.19.2.3.2.2}%
\contentsline {paragraph}{\numberline {19.2.3.2.3}Risk Stratification \& Outcomes/Prognosis}{497}{paragraph.19.2.3.2.3}%
\contentsline {subsection}{\numberline {19.2.4}Nervous System Tumors, managed by Non-Neuro Oncologists}{497}{subsection.19.2.4}%
\contentsline {subsubsection}{\numberline {19.2.4.1}Neuroblastoma}{498}{subsubsection.19.2.4.1}%
\contentsline {paragraph}{\numberline {19.2.4.1.1}Presentation}{498}{paragraph.19.2.4.1.1}%
\contentsline {paragraph}{\numberline {19.2.4.1.2}Epidemiology}{498}{paragraph.19.2.4.1.2}%
\contentsline {paragraph}{\numberline {19.2.4.1.3}Risk Stratification \& Outcomes/Prognosis}{498}{paragraph.19.2.4.1.3}%
\contentsline {paragraph}{\numberline {19.2.4.1.4}Diagnostics}{498}{paragraph.19.2.4.1.4}%
\contentsline {paragraph}{\numberline {19.2.4.1.5}Treatment}{498}{paragraph.19.2.4.1.5}%
\contentsline {subsubsection}{\numberline {19.2.4.2}Retinoblastoma}{498}{subsubsection.19.2.4.2}%
\contentsline {paragraph}{\numberline {19.2.4.2.1}Presentation}{498}{paragraph.19.2.4.2.1}%
\contentsline {paragraph}{\numberline {19.2.4.2.2}Epidemiology}{498}{paragraph.19.2.4.2.2}%
\contentsline {paragraph}{\numberline {19.2.4.2.3}Risk Stratification \& Outcomes/Prognosis}{498}{paragraph.19.2.4.2.3}%
\contentsline {subsection}{\numberline {19.2.5}Kidney Tumors}{498}{subsection.19.2.5}%
\contentsline {subsubsection}{\numberline {19.2.5.1}Wilm's Tumor}{498}{subsubsection.19.2.5.1}%
\contentsline {paragraph}{\numberline {19.2.5.1.1}Presentation}{498}{paragraph.19.2.5.1.1}%
\contentsline {paragraph}{\numberline {19.2.5.1.2}Epidemiology}{499}{paragraph.19.2.5.1.2}%
\contentsline {paragraph}{\numberline {19.2.5.1.3}Risk Stratification \& Outcomes/Prognosis}{499}{paragraph.19.2.5.1.3}%
\contentsline {subsection}{\numberline {19.2.6}Liver Tumors}{499}{subsection.19.2.6}%
\contentsline {subsubsection}{\numberline {19.2.6.1}Hepatoblastoma}{499}{subsubsection.19.2.6.1}%
\contentsline {paragraph}{\numberline {19.2.6.1.1}Presentation}{499}{paragraph.19.2.6.1.1}%
\contentsline {paragraph}{\numberline {19.2.6.1.2}Epidemiology}{499}{paragraph.19.2.6.1.2}%
\contentsline {paragraph}{\numberline {19.2.6.1.3}Risk Stratification \& Outcomes/Prognosis}{499}{paragraph.19.2.6.1.3}%
\contentsline {subsubsection}{\numberline {19.2.6.2}Hepatocellular Carcinoma}{499}{subsubsection.19.2.6.2}%
\contentsline {paragraph}{\numberline {19.2.6.2.1}Presentation}{499}{paragraph.19.2.6.2.1}%
\contentsline {paragraph}{\numberline {19.2.6.2.2}Epidemiology}{499}{paragraph.19.2.6.2.2}%
\contentsline {paragraph}{\numberline {19.2.6.2.3}Risk Stratification \& Outcomes/Prognisis}{499}{paragraph.19.2.6.2.3}%
\contentsline {subsection}{\numberline {19.2.7}Germ Cell Tumors}{500}{subsection.19.2.7}%
\contentsline {subsubsection}{\numberline {19.2.7.1}Teratoma}{500}{subsubsection.19.2.7.1}%
\contentsline {paragraph}{\numberline {19.2.7.1.1}Presentation}{500}{paragraph.19.2.7.1.1}%
\contentsline {paragraph}{\numberline {19.2.7.1.2}Epidemiology}{500}{paragraph.19.2.7.1.2}%
\contentsline {paragraph}{\numberline {19.2.7.1.3}Risk Stratification \& Outcomes/Prognosis}{500}{paragraph.19.2.7.1.3}%
\contentsline {paragraph}{\numberline {19.2.7.1.4}Diagnostics (shared among all GCTs)}{500}{paragraph.19.2.7.1.4}%
\contentsline {subsubsection}{\numberline {19.2.7.2}Yolk Sac Tumor}{500}{subsubsection.19.2.7.2}%
\contentsline {paragraph}{\numberline {19.2.7.2.1}Presentation}{500}{paragraph.19.2.7.2.1}%
\contentsline {paragraph}{\numberline {19.2.7.2.2}Epidemiology}{500}{paragraph.19.2.7.2.2}%
\contentsline {subsubsection}{\numberline {19.2.7.3}Germinoma (Neuro-Onc)}{500}{subsubsection.19.2.7.3}%
\contentsline {paragraph}{\numberline {19.2.7.3.1}Presentation}{500}{paragraph.19.2.7.3.1}%
\contentsline {paragraph}{\numberline {19.2.7.3.2}Epidemiology}{501}{paragraph.19.2.7.3.2}%
\contentsline {paragraph}{\numberline {19.2.7.3.3}Risk Stratification \& Outcomes/Prognosis}{501}{paragraph.19.2.7.3.3}%
\contentsline {section}{\numberline {19.3}Common Chemotherapies}{501}{section.19.3}%
\contentsline {section}{\numberline {19.4}Common Targeted Therapies}{501}{section.19.4}%
\contentsline {section}{\numberline {19.5}Oncologic Emergencies}{503}{section.19.5}%
\contentsline {subsection}{\numberline {19.5.1}Tumor Lysis Syndrome (TLS)}{503}{subsection.19.5.1}%
\contentsline {subsubsection}{\numberline {19.5.1.1}Definition}{503}{subsubsection.19.5.1.1}%
\contentsline {subsubsection}{\numberline {19.5.1.2}Pathogenesis}{503}{subsubsection.19.5.1.2}%
\contentsline {subsubsection}{\numberline {19.5.1.3}Clinical Manifestation}{504}{subsubsection.19.5.1.3}%
\contentsline {subsubsection}{\numberline {19.5.1.4}Diagnostic Studies}{504}{subsubsection.19.5.1.4}%
\contentsline {subsubsection}{\numberline {19.5.1.5}Treatment}{504}{subsubsection.19.5.1.5}%
\contentsline {subsection}{\numberline {19.5.2}Fever and Neutropenia}{505}{subsection.19.5.2}%
\contentsline {subsubsection}{\numberline {19.5.2.1}Definition}{505}{subsubsection.19.5.2.1}%
\contentsline {subsubsection}{\numberline {19.5.2.2}Risk Stratification}{505}{subsubsection.19.5.2.2}%
\contentsline {subsubsection}{\numberline {19.5.2.3}Pathogenesis}{505}{subsubsection.19.5.2.3}%
\contentsline {subsubsection}{\numberline {19.5.2.4}Microbiology}{505}{subsubsection.19.5.2.4}%
\contentsline {subsubsection}{\numberline {19.5.2.5}Clinical Manifestations}{506}{subsubsection.19.5.2.5}%
\contentsline {subsubsection}{\numberline {19.5.2.6}Diagnostic Studies}{506}{subsubsection.19.5.2.6}%
\contentsline {subsubsection}{\numberline {19.5.2.7}Treatment}{506}{subsubsection.19.5.2.7}%
\contentsline {paragraph}{\numberline {19.5.2.7.1}High-Risk Patient w/ Fever}{507}{paragraph.19.5.2.7.1}%
\contentsline {paragraph}{\numberline {19.5.2.7.2}Standard-Risk Patient w/ Fever}{507}{paragraph.19.5.2.7.2}%
\contentsline {subsubsection}{\numberline {19.5.2.8}Prophylaxis}{508}{subsubsection.19.5.2.8}%
\contentsline {paragraph}{\numberline {19.5.2.8.1}Antimicrobial}{508}{paragraph.19.5.2.8.1}%
\contentsline {paragraph}{\numberline {19.5.2.8.2}Antifungal}{508}{paragraph.19.5.2.8.2}%
\contentsline {paragraph}{\numberline {19.5.2.8.3}PJP Prophylaxis}{509}{paragraph.19.5.2.8.3}%
\contentsline {paragraph}{\numberline {19.5.2.8.4}Antiviral}{509}{paragraph.19.5.2.8.4}%
\contentsline {subsection}{\numberline {19.5.3}Anterior Mediastinal Mass \& Superior Vena Cava Syndrome}{509}{subsection.19.5.3}%
\contentsline {subsubsection}{\numberline {19.5.3.1}Pathogenesis}{509}{subsubsection.19.5.3.1}%
\contentsline {subsubsection}{\numberline {19.5.3.2}Differential}{509}{subsubsection.19.5.3.2}%
\contentsline {subsubsection}{\numberline {19.5.3.3}Clinical Manifestations}{509}{subsubsection.19.5.3.3}%
\contentsline {subsubsection}{\numberline {19.5.3.4}Diagnostic Studies}{509}{subsubsection.19.5.3.4}%
\contentsline {subsubsection}{\numberline {19.5.3.5}Management}{510}{subsubsection.19.5.3.5}%
\contentsline {subsection}{\numberline {19.5.4}Spinal Cord Compression}{510}{subsection.19.5.4}%
\contentsline {subsubsection}{\numberline {19.5.4.1}Pathogenesis}{510}{subsubsection.19.5.4.1}%
\contentsline {subsubsection}{\numberline {19.5.4.2}Clinical Manifestations}{510}{subsubsection.19.5.4.2}%
\contentsline {subsubsection}{\numberline {19.5.4.3}Physical Exam}{510}{subsubsection.19.5.4.3}%
\contentsline {subsubsection}{\numberline {19.5.4.4}Diagnostic Studies}{511}{subsubsection.19.5.4.4}%
\contentsline {subsubsection}{\numberline {19.5.4.5}Treatment}{511}{subsubsection.19.5.4.5}%
\contentsline {subsection}{\numberline {19.5.5}Hyperleukocytosis \& Leukostasis}{511}{subsection.19.5.5}%
\contentsline {subsubsection}{\numberline {19.5.5.1}Definition}{511}{subsubsection.19.5.5.1}%
\contentsline {subsubsection}{\numberline {19.5.5.2}Pathogenesis}{511}{subsubsection.19.5.5.2}%
\contentsline {subsubsection}{\numberline {19.5.5.3}Clinical Manifestations}{511}{subsubsection.19.5.5.3}%
\contentsline {subsubsection}{\numberline {19.5.5.4}Physical Exam}{512}{subsubsection.19.5.5.4}%
\contentsline {subsubsection}{\numberline {19.5.5.5}Diagnostic Studies}{512}{subsubsection.19.5.5.5}%
\contentsline {subsubsection}{\numberline {19.5.5.6}Treatment}{512}{subsubsection.19.5.5.6}%
\contentsline {subsection}{\numberline {19.5.6}Increased ICP}{512}{subsection.19.5.6}%
\contentsline {subsubsection}{\numberline {19.5.6.1}Definition}{513}{subsubsection.19.5.6.1}%
\contentsline {subsubsection}{\numberline {19.5.6.2}Pathogenesis}{513}{subsubsection.19.5.6.2}%
\contentsline {subsubsection}{\numberline {19.5.6.3}Clinical Manifestations}{513}{subsubsection.19.5.6.3}%
\contentsline {subsubsection}{\numberline {19.5.6.4}Physical Exam}{513}{subsubsection.19.5.6.4}%
\contentsline {subsubsection}{\numberline {19.5.6.5}Diagnostic Studies}{513}{subsubsection.19.5.6.5}%
\contentsline {subsubsection}{\numberline {19.5.6.6}Treatment}{513}{subsubsection.19.5.6.6}%
\contentsline {chapter}{\numberline {20}Pain}{515}{chapter.20}%
\contentsline {section}{\numberline {20.1}Chronic Pain}{515}{section.20.1}%
\contentsline {subsection}{\numberline {20.1.1}Complex Regional Pain Syndrome (CRPS)}{515}{subsection.20.1.1}%
\contentsline {subsubsection}{\numberline {20.1.1.1}Management}{515}{subsubsection.20.1.1.1}%
\contentsline {subsection}{\numberline {20.1.2}Sickle Cell Disease}{515}{subsection.20.1.2}%
\contentsline {subsubsection}{\numberline {20.1.2.1}Management}{515}{subsubsection.20.1.2.1}%
\contentsline {subsection}{\numberline {20.1.3}Adjunct Pain Medications Often Used in Chronic Pain}{516}{subsection.20.1.3}%
\contentsline {section}{\numberline {20.2}Acute Pain}{516}{section.20.2}%
\contentsline {subsection}{\numberline {20.2.1}Post-Surgical Pain}{516}{subsection.20.2.1}%
\contentsline {subsection}{\numberline {20.2.2}Acute Infectious Pain}{516}{subsection.20.2.2}%
\contentsline {subsection}{\numberline {20.2.3}Acute Sickle Cell Pain}{516}{subsection.20.2.3}%
\contentsline {section}{\numberline {20.3}Cancer Pain Management}{516}{section.20.3}%
\contentsline {subsection}{\numberline {20.3.1}Patient-Controlled Analgesia (PCA)}{516}{subsection.20.3.1}%
\contentsline {subsubsection}{\numberline {20.3.1.1}PCA Notation}{517}{subsubsection.20.3.1.1}%
\contentsline {subsubsection}{\numberline {20.3.1.2}PCA Dosing}{517}{subsubsection.20.3.1.2}%
\contentsline {subsection}{\numberline {20.3.2}Neuraxial Catheters with Pump}{517}{subsection.20.3.2}%
\contentsline {subsubsection}{\numberline {20.3.2.1}\textbf {Intrathecal} vs.\nobreakspace {}\textbf {epidural} catheters:}{517}{subsubsection.20.3.2.1}%
\contentsline {subsubsection}{\numberline {20.3.2.2}How to check a level}{517}{subsubsection.20.3.2.2}%
\contentsline {subsubsection}{\numberline {20.3.2.3}Notation for patient- or nurse-controlled epidural anesthesia}{518}{subsubsection.20.3.2.3}%
\contentsline {subsubsection}{\numberline {20.3.2.4}Common neuraxial questions from nursing}{518}{subsubsection.20.3.2.4}%
\contentsline {chapter}{\numberline {21}Pediatric Advanced Care Team (PACT) ``CODE CARD''}{519}{chapter.21}%
\contentsline {section}{\numberline {21.1}Pediatric Palliative Care (PPC)}{519}{section.21.1}%
\contentsline {section}{\numberline {21.2}Specialty PPC at BCH}{519}{section.21.2}%
\contentsline {subsection}{\numberline {21.2.1}PACT Teams}{519}{subsection.21.2.1}%
\contentsline {subsection}{\numberline {21.2.2}Requesting a PACT Consult}{519}{subsection.21.2.2}%
\contentsline {subsection}{\numberline {21.2.3}Introducing PACT to Families: Sample Language}{520}{subsection.21.2.3}%
\contentsline {section}{\numberline {21.3}Primary PPC: Skills for All Clinicians}{520}{section.21.3}%
\contentsline {subsection}{\numberline {21.3.1}Promoting Child Wellbeing}{520}{subsection.21.3.1}%
\contentsline {subsubsection}{\numberline {21.3.1.1}Quality of Life}{520}{subsubsection.21.3.1.1}%
\contentsline {subsubsection}{\numberline {21.3.1.2}Symptoms: Non-Pharmacologic Approaches}{520}{subsubsection.21.3.1.2}%
\contentsline {subsubsection}{\numberline {21.3.1.3}Pain: Pharmacologic Approaches}{520}{subsubsection.21.3.1.3}%
\contentsline {subsubsection}{\numberline {21.3.1.4}KEY TIPS: Prescribing Opioids}{521}{subsubsection.21.3.1.4}%
\contentsline {subsubsection}{\numberline {21.3.1.5}KEY TIPS: Breakthrough Pain (BTP)}{521}{subsubsection.21.3.1.5}%
\contentsline {subsubsection}{\numberline {21.3.1.6}Sample Opioid Calculations}{522}{subsubsection.21.3.1.6}%
\contentsline {subsubsection}{\numberline {21.3.1.7}Proper Use of Naloxone}{522}{subsubsection.21.3.1.7}%
\contentsline {subsubsection}{\numberline {21.3.1.8}Adjuvant Agents:}{523}{subsubsection.21.3.1.8}%
\contentsline {subsection}{\numberline {21.3.2}COMMUNICATING EFFECTIVELY}{523}{subsection.21.3.2}%
\contentsline {subsubsection}{\numberline {21.3.2.1}KEY TIPS: Language}{523}{subsubsection.21.3.2.1}%
\contentsline {subsubsection}{\numberline {21.3.2.2}Managing Emotion (NURSE mnemonic)}{524}{subsubsection.21.3.2.2}%
\contentsline {subsubsection}{\numberline {21.3.2.3}Discussing Goals of Care}{524}{subsubsection.21.3.2.3}%
\contentsline {subsubsection}{\numberline {21.3.2.4}Sharing Difficult News}{524}{subsubsection.21.3.2.4}%
\contentsline {subsubsection}{\numberline {21.3.2.5}Discussing Life-Sustaining Therapies (LST)}{524}{subsubsection.21.3.2.5}%
\contentsline {subsection}{\numberline {21.3.3}CARING FOR A CHILD FACING END OF LIFE}{525}{subsection.21.3.3}%
\contentsline {subsubsection}{\numberline {21.3.3.1}BEFORE the Child's Death:}{525}{subsubsection.21.3.3.1}%
\contentsline {subsubsection}{\numberline {21.3.3.2}KEY TIPS: Organ Donation}{525}{subsubsection.21.3.3.2}%
\contentsline {subsubsection}{\numberline {21.3.3.3}AT the Time of Death:}{525}{subsubsection.21.3.3.3}%
\contentsline {subsubsection}{\numberline {21.3.3.4}AFTER the Child's Death:}{526}{subsubsection.21.3.3.4}%
\contentsline {subsubsection}{\numberline {21.3.3.5}Writing a Condolence Note}{526}{subsubsection.21.3.3.5}%
\contentsline {chapter}{\numberline {22}Primary Care}{529}{chapter.22}%
\contentsline {section}{\numberline {22.1}Developmental Milestones}{529}{section.22.1}%
\contentsline {section}{\numberline {22.2}Red Flags}{532}{section.22.2}%
\contentsline {section}{\numberline {22.3}Newborn Visit}{533}{section.22.3}%
\contentsline {subsection}{\numberline {22.3.1}HPI}{533}{subsection.22.3.1}%
\contentsline {subsubsection}{\numberline {22.3.1.1}BIRTH/PREGNANCY HISTORY}{533}{subsubsection.22.3.1.1}%
\contentsline {subsubsection}{\numberline {22.3.1.2}IN/OUTs}{534}{subsubsection.22.3.1.2}%
\contentsline {subsubsection}{\numberline {22.3.1.3}SLEEP}{534}{subsubsection.22.3.1.3}%
\contentsline {subsubsection}{\numberline {22.3.1.4}DEVELOPMENT}{534}{subsubsection.22.3.1.4}%
\contentsline {subsubsection}{\numberline {22.3.1.5}SOCIAL}{534}{subsubsection.22.3.1.5}%
\contentsline {subsection}{\numberline {22.3.2}Exam}{534}{subsection.22.3.2}%
\contentsline {subsection}{\numberline {22.3.3}A/P}{534}{subsection.22.3.3}%
\contentsline {subsubsection}{\numberline {22.3.3.1}Immunizations/Supplements}{534}{subsubsection.22.3.3.1}%
\contentsline {subsubsection}{\numberline {22.3.3.2}Anticipatory Guidance}{535}{subsubsection.22.3.3.2}%
\contentsline {subsubsection}{\numberline {22.3.3.3}Follow Up}{535}{subsubsection.22.3.3.3}%
\contentsline {section}{\numberline {22.4}2 Month WCC}{535}{section.22.4}%
\contentsline {subsection}{\numberline {22.4.1}HPI}{535}{subsection.22.4.1}%
\contentsline {subsubsection}{\numberline {22.4.1.1}IN/OUTs}{535}{subsubsection.22.4.1.1}%
\contentsline {subsubsection}{\numberline {22.4.1.2}SLEEP}{535}{subsubsection.22.4.1.2}%
\contentsline {subsubsection}{\numberline {22.4.1.3}DEVELOPMENT}{536}{subsubsection.22.4.1.3}%
\contentsline {subsubsection}{\numberline {22.4.1.4}SOCIAL}{536}{subsubsection.22.4.1.4}%
\contentsline {subsection}{\numberline {22.4.2}Exam}{536}{subsection.22.4.2}%
\contentsline {subsection}{\numberline {22.4.3}A/P}{536}{subsection.22.4.3}%
\contentsline {subsubsection}{\numberline {22.4.3.1}Immunizations/Supplements}{536}{subsubsection.22.4.3.1}%
\contentsline {subsubsection}{\numberline {22.4.3.2}Anticipatory Guidance}{536}{subsubsection.22.4.3.2}%
\contentsline {subsubsection}{\numberline {22.4.3.3}Follow Up}{536}{subsubsection.22.4.3.3}%
\contentsline {section}{\numberline {22.5}4 Month WCC}{536}{section.22.5}%
\contentsline {subsection}{\numberline {22.5.1}HPI}{536}{subsection.22.5.1}%
\contentsline {subsubsection}{\numberline {22.5.1.1}IN/OUTs}{537}{subsubsection.22.5.1.1}%
\contentsline {subsubsection}{\numberline {22.5.1.2}SLEEP}{537}{subsubsection.22.5.1.2}%
\contentsline {subsubsection}{\numberline {22.5.1.3}DEVELOPMENT}{537}{subsubsection.22.5.1.3}%
\contentsline {subsubsection}{\numberline {22.5.1.4}SOCIAL}{537}{subsubsection.22.5.1.4}%
\contentsline {subsection}{\numberline {22.5.2}Exam}{537}{subsection.22.5.2}%
\contentsline {subsection}{\numberline {22.5.3}A/P}{537}{subsection.22.5.3}%
\contentsline {subsubsection}{\numberline {22.5.3.1}Vaccines/Supplements}{537}{subsubsection.22.5.3.1}%
\contentsline {subsubsection}{\numberline {22.5.3.2}Anticipatory Guidance}{537}{subsubsection.22.5.3.2}%
\contentsline {subsubsection}{\numberline {22.5.3.3}Follow Up}{538}{subsubsection.22.5.3.3}%
\contentsline {section}{\numberline {22.6}6 Month WCC}{538}{section.22.6}%
\contentsline {subsection}{\numberline {22.6.1}HPI}{538}{subsection.22.6.1}%
\contentsline {subsubsection}{\numberline {22.6.1.1}IN/OUTs}{538}{subsubsection.22.6.1.1}%
\contentsline {subsubsection}{\numberline {22.6.1.2}SLEEP}{538}{subsubsection.22.6.1.2}%
\contentsline {subsubsection}{\numberline {22.6.1.3}DEVELOPMENT}{538}{subsubsection.22.6.1.3}%
\contentsline {subsubsection}{\numberline {22.6.1.4}SOCIAL}{538}{subsubsection.22.6.1.4}%
\contentsline {subsection}{\numberline {22.6.2}Exam}{538}{subsection.22.6.2}%
\contentsline {subsection}{\numberline {22.6.3}A/P}{539}{subsection.22.6.3}%
\contentsline {subsubsection}{\numberline {22.6.3.1}Vaccines/Supplements}{539}{subsubsection.22.6.3.1}%
\contentsline {subsubsection}{\numberline {22.6.3.2}Anticipatory Guidance}{539}{subsubsection.22.6.3.2}%
\contentsline {subsubsection}{\numberline {22.6.3.3}Follow Up}{539}{subsubsection.22.6.3.3}%
\contentsline {section}{\numberline {22.7}9 Month WCC}{539}{section.22.7}%
\contentsline {subsection}{\numberline {22.7.1}HPI}{539}{subsection.22.7.1}%
\contentsline {subsubsection}{\numberline {22.7.1.1}IN/OUTs}{539}{subsubsection.22.7.1.1}%
\contentsline {subsubsection}{\numberline {22.7.1.2}DEVELOPMENT}{540}{subsubsection.22.7.1.2}%
\contentsline {subsection}{\numberline {22.7.2}Exam}{540}{subsection.22.7.2}%
\contentsline {subsection}{\numberline {22.7.3}A/P}{540}{subsection.22.7.3}%
\contentsline {subsubsection}{\numberline {22.7.3.1}Vaccines/Supplements/Screenings}{540}{subsubsection.22.7.3.1}%
\contentsline {subsubsection}{\numberline {22.7.3.2}Anticipatory Guidance}{540}{subsubsection.22.7.3.2}%
\contentsline {subsubsection}{\numberline {22.7.3.3}Follow Up}{540}{subsubsection.22.7.3.3}%
\contentsline {section}{\numberline {22.8}12 Month WCC}{541}{section.22.8}%
\contentsline {subsection}{\numberline {22.8.1}HPI}{541}{subsection.22.8.1}%
\contentsline {subsubsection}{\numberline {22.8.1.1}IN/OUTs}{541}{subsubsection.22.8.1.1}%
\contentsline {subsubsection}{\numberline {22.8.1.2}DEVELOPMENT}{541}{subsubsection.22.8.1.2}%
\contentsline {subsection}{\numberline {22.8.2}Exam}{541}{subsection.22.8.2}%
\contentsline {subsection}{\numberline {22.8.3}A/P}{541}{subsection.22.8.3}%
\contentsline {subsubsection}{\numberline {22.8.3.1}Vaccines/Supplements/Screenings}{541}{subsubsection.22.8.3.1}%
\contentsline {subsubsection}{\numberline {22.8.3.2}Anticipatory Guidance}{541}{subsubsection.22.8.3.2}%
\contentsline {subsubsection}{\numberline {22.8.3.3}Follow Up}{542}{subsubsection.22.8.3.3}%
\contentsline {section}{\numberline {22.9}15 Month WCC}{542}{section.22.9}%
\contentsline {subsection}{\numberline {22.9.1}HPI}{542}{subsection.22.9.1}%
\contentsline {subsubsection}{\numberline {22.9.1.1}IN/OUTs}{542}{subsubsection.22.9.1.1}%
\contentsline {subsubsection}{\numberline {22.9.1.2}DEVELOPMENT}{542}{subsubsection.22.9.1.2}%
\contentsline {subsection}{\numberline {22.9.2}Exam}{542}{subsection.22.9.2}%
\contentsline {subsection}{\numberline {22.9.3}A/P}{542}{subsection.22.9.3}%
\contentsline {subsubsection}{\numberline {22.9.3.1}Vaccines}{542}{subsubsection.22.9.3.1}%
\contentsline {subsubsection}{\numberline {22.9.3.2}Anticipatory Guidance}{543}{subsubsection.22.9.3.2}%
\contentsline {subsubsection}{\numberline {22.9.3.3}Follow up}{543}{subsubsection.22.9.3.3}%
\contentsline {section}{\numberline {22.10}18 Month WCC}{543}{section.22.10}%
\contentsline {subsection}{\numberline {22.10.1}HPI}{543}{subsection.22.10.1}%
\contentsline {subsubsection}{\numberline {22.10.1.1}IN/OUTs}{543}{subsubsection.22.10.1.1}%
\contentsline {subsubsection}{\numberline {22.10.1.2}DEVELOPMENT}{543}{subsubsection.22.10.1.2}%
\contentsline {subsection}{\numberline {22.10.2}Exam}{544}{subsection.22.10.2}%
\contentsline {subsection}{\numberline {22.10.3}A/P}{544}{subsection.22.10.3}%
\contentsline {subsubsection}{\numberline {22.10.3.1}Vaccines/Screenings}{544}{subsubsection.22.10.3.1}%
\contentsline {subsubsection}{\numberline {22.10.3.2}Anticipatory Guidance}{544}{subsubsection.22.10.3.2}%
\contentsline {subsubsection}{\numberline {22.10.3.3}Follow up}{544}{subsubsection.22.10.3.3}%
\contentsline {section}{\numberline {22.11}2 Year Old WCC}{544}{section.22.11}%
\contentsline {subsection}{\numberline {22.11.1}HPI}{544}{subsection.22.11.1}%
\contentsline {subsubsection}{\numberline {22.11.1.1}IN/OUTs}{544}{subsubsection.22.11.1.1}%
\contentsline {subsubsection}{\numberline {22.11.1.2}DEVELOPMENT}{545}{subsubsection.22.11.1.2}%
\contentsline {subsection}{\numberline {22.11.2}Exam}{545}{subsection.22.11.2}%
\contentsline {subsection}{\numberline {22.11.3}A/P}{545}{subsection.22.11.3}%
\contentsline {subsubsection}{\numberline {22.11.3.1}Vaccines/Screenings}{545}{subsubsection.22.11.3.1}%
\contentsline {subsubsection}{\numberline {22.11.3.2}Anticipatory Guidance}{545}{subsubsection.22.11.3.2}%
\contentsline {subsubsection}{\numberline {22.11.3.3}Follow up}{546}{subsubsection.22.11.3.3}%
\contentsline {section}{\numberline {22.12}3 Year Old WCC}{546}{section.22.12}%
\contentsline {subsection}{\numberline {22.12.1}HPI}{546}{subsection.22.12.1}%
\contentsline {subsubsection}{\numberline {22.12.1.1}IN/OUTs}{546}{subsubsection.22.12.1.1}%
\contentsline {subsubsection}{\numberline {22.12.1.2}DEVELOPMENT}{546}{subsubsection.22.12.1.2}%
\contentsline {subsection}{\numberline {22.12.2}Exam}{546}{subsection.22.12.2}%
\contentsline {subsection}{\numberline {22.12.3}A/P}{546}{subsection.22.12.3}%
\contentsline {subsubsection}{\numberline {22.12.3.1}Vaccines/Screenings}{546}{subsubsection.22.12.3.1}%
\contentsline {subsubsection}{\numberline {22.12.3.2}Anticipatory Guidance}{546}{subsubsection.22.12.3.2}%
\contentsline {subsubsection}{\numberline {22.12.3.3}Follow up}{547}{subsubsection.22.12.3.3}%
\contentsline {section}{\numberline {22.13}4 Year Old WCC}{547}{section.22.13}%
\contentsline {subsection}{\numberline {22.13.1}HPI}{547}{subsection.22.13.1}%
\contentsline {subsubsection}{\numberline {22.13.1.1}IN/OUTs}{547}{subsubsection.22.13.1.1}%
\contentsline {subsubsection}{\numberline {22.13.1.2}DEVELOPMENT}{547}{subsubsection.22.13.1.2}%
\contentsline {subsection}{\numberline {22.13.2}Exam}{547}{subsection.22.13.2}%
\contentsline {subsection}{\numberline {22.13.3}A/P}{547}{subsection.22.13.3}%
\contentsline {subsubsection}{\numberline {22.13.3.1}Vaccines/Screenings}{547}{subsubsection.22.13.3.1}%
\contentsline {subsubsection}{\numberline {22.13.3.2}Anticipatory Guidance}{548}{subsubsection.22.13.3.2}%
\contentsline {subsubsection}{\numberline {22.13.3.3}Follow up}{548}{subsubsection.22.13.3.3}%
\contentsline {section}{\numberline {22.14}School Age (\textasciitilde 5-10)}{548}{section.22.14}%
\contentsline {subsection}{\numberline {22.14.1}HPI}{548}{subsection.22.14.1}%
\contentsline {subsubsection}{\numberline {22.14.1.1}IN/OUTs}{548}{subsubsection.22.14.1.1}%
\contentsline {subsubsection}{\numberline {22.14.1.2}DEVELOPMENT}{548}{subsubsection.22.14.1.2}%
\contentsline {subsection}{\numberline {22.14.2}Exam}{549}{subsection.22.14.2}%
\contentsline {subsection}{\numberline {22.14.3}A/P}{549}{subsection.22.14.3}%
\contentsline {subsubsection}{\numberline {22.14.3.1}Vaccines/Screenings}{549}{subsubsection.22.14.3.1}%
\contentsline {subsubsection}{\numberline {22.14.3.2}Anticipatory Guidance}{549}{subsubsection.22.14.3.2}%
\contentsline {subsubsection}{\numberline {22.14.3.3}Follow up}{549}{subsubsection.22.14.3.3}%
\contentsline {section}{\numberline {22.15}Middle School (\textasciitilde 11-13)}{549}{section.22.15}%
\contentsline {subsection}{\numberline {22.15.1}HPI}{549}{subsection.22.15.1}%
\contentsline {subsubsection}{\numberline {22.15.1.1}IN/OUTs}{549}{subsubsection.22.15.1.1}%
\contentsline {subsubsection}{\numberline {22.15.1.2}DEVELOPMENT}{550}{subsubsection.22.15.1.2}%
\contentsline {subsection}{\numberline {22.15.2}Exam}{550}{subsection.22.15.2}%
\contentsline {subsection}{\numberline {22.15.3}A/P}{550}{subsection.22.15.3}%
\contentsline {subsubsection}{\numberline {22.15.3.1}Vaccines/Screenings}{550}{subsubsection.22.15.3.1}%
\contentsline {subsubsection}{\numberline {22.15.3.2}Anticipatory Guidance}{550}{subsubsection.22.15.3.2}%
\contentsline {subsubsection}{\numberline {22.15.3.3}Follow up}{550}{subsubsection.22.15.3.3}%
\contentsline {section}{\numberline {22.16}Adolescence (\textasciitilde 13-18)}{550}{section.22.16}%
\contentsline {subsection}{\numberline {22.16.1}HPI}{550}{subsection.22.16.1}%
\contentsline {subsubsection}{\numberline {22.16.1.1}IN/OUTs}{551}{subsubsection.22.16.1.1}%
\contentsline {subsubsection}{\numberline {22.16.1.2}DEVELOPMENT}{551}{subsubsection.22.16.1.2}%
\contentsline {subsection}{\numberline {22.16.2}Exam}{551}{subsection.22.16.2}%
\contentsline {subsection}{\numberline {22.16.3}A/P}{551}{subsection.22.16.3}%
\contentsline {subsubsection}{\numberline {22.16.3.1}Vaccines/Screenings}{551}{subsubsection.22.16.3.1}%
\contentsline {subsubsection}{\numberline {22.16.3.2}Anticipatory Guidance}{551}{subsubsection.22.16.3.2}%
\contentsline {subsubsection}{\numberline {22.16.3.3}Follow up}{552}{subsubsection.22.16.3.3}%
\contentsline {section}{\numberline {22.17}Vaccine Schedule (Birth to 18 years)}{552}{section.22.17}%
\contentsline {section}{\numberline {22.18}CHPCC Vaccine Schedule}{552}{section.22.18}%
\contentsline {section}{\numberline {22.19}CHPCC Screening Schedule}{554}{section.22.19}%
\contentsline {section}{\numberline {22.20}BMC Clinic Screening Questionnaire Schedule}{554}{section.22.20}%
\contentsline {section}{\numberline {22.21}Autism Management in Primary Care Clinic (**CHOP EBG)}{554}{section.22.21}%
\contentsline {subsection}{\numberline {22.21.1}Who to Screen}{554}{subsection.22.21.1}%
\contentsline {subsection}{\numberline {22.21.2}How to Screen}{555}{subsection.22.21.2}%
\contentsline {subsection}{\numberline {22.21.3}Developmental Red Flags}{555}{subsection.22.21.3}%
\contentsline {subsection}{\numberline {22.21.4}Positive screening - what now?}{555}{subsection.22.21.4}%
\contentsline {subsection}{\numberline {22.21.5}Follow up}{555}{subsection.22.21.5}%
\contentsline {section}{\numberline {22.22}ADHD}{555}{section.22.22}%
\contentsline {subsection}{\numberline {22.22.1}EBGs}{555}{subsection.22.22.1}%
\contentsline {subsection}{\numberline {22.22.2}ADHD Definition}{556}{subsection.22.22.2}%
\contentsline {subsection}{\numberline {22.22.3}How to Screen}{556}{subsection.22.22.3}%
\contentsline {subsection}{\numberline {22.22.4}Common Coexisting Disorders}{556}{subsection.22.22.4}%
\contentsline {subsection}{\numberline {22.22.5}Additional Evaluation PRN}{556}{subsection.22.22.5}%
\contentsline {subsection}{\numberline {22.22.6}Considerations Prior to Initiating Pharmacotherapy}{556}{subsection.22.22.6}%
\contentsline {subsection}{\numberline {22.22.7}Follow Up}{557}{subsection.22.22.7}%
\contentsline {subsection}{\numberline {22.22.8}General Prescribing Principles}{557}{subsection.22.22.8}%
\contentsline {subsection}{\numberline {22.22.9}Stimulants}{558}{subsection.22.22.9}%
\contentsline {subsubsection}{\numberline {22.22.9.1}Methylphenidates}{558}{subsubsection.22.22.9.1}%
\contentsline {subsubsection}{\numberline {22.22.9.2}Amphetamines}{558}{subsubsection.22.22.9.2}%
\contentsline {subsubsection}{\numberline {22.22.9.3}Non-Stimulants}{559}{subsubsection.22.22.9.3}%
\contentsline {paragraph}{\numberline {22.22.9.3.1}Norepinephrine Reuptake Inhibitors}{559}{paragraph.22.22.9.3.1}%
\contentsline {paragraph}{\numberline {22.22.9.3.2}Alpha Agonists}{559}{paragraph.22.22.9.3.2}%
\contentsline {section}{\numberline {22.23}Anxiety}{560}{section.22.23}%
\contentsline {subsection}{\numberline {22.23.1}Types of Anxiety Disorders}{560}{subsection.22.23.1}%
\contentsline {subsection}{\numberline {22.23.2}How to Screen}{560}{subsection.22.23.2}%
\contentsline {subsection}{\numberline {22.23.3}Positive Screening}{560}{subsection.22.23.3}%
\contentsline {subsection}{\numberline {22.23.4}Initial treatment (school aged)}{561}{subsection.22.23.4}%
\contentsline {section}{\numberline {22.24}Depression}{561}{section.22.24}%
\contentsline {subsection}{\numberline {22.24.1}Background}{561}{subsection.22.24.1}%
\contentsline {subsection}{\numberline {22.24.2}Neurovegetative Symptoms (SIGECAPS)}{561}{subsection.22.24.2}%
\contentsline {subsection}{\numberline {22.24.3}How to Screen}{561}{subsection.22.24.3}%
\contentsline {subsection}{\numberline {22.24.4}Therapy}{562}{subsection.22.24.4}%
\contentsline {subsection}{\numberline {22.24.5}Follow Up}{562}{subsection.22.24.5}%
\contentsline {section}{\numberline {22.25}Medication Management: Anxiety and Depression}{562}{section.22.25}%
\contentsline {subsection}{\numberline {22.25.1}Side Effects/Precautions with SSRI use (see chart below for medication recs)}{562}{subsection.22.25.1}%
\contentsline {subsection}{\numberline {22.25.2}Anxiety}{563}{subsection.22.25.2}%
\contentsline {subsection}{\numberline {22.25.3}Depression}{564}{subsection.22.25.3}%
\contentsline {section}{\numberline {22.26}BMC Primary Care Clinic Resources}{565}{section.22.26}%
\contentsline {subsection}{\numberline {22.26.1}Asthma Education}{565}{subsection.22.26.1}%
\contentsline {subsection}{\numberline {22.26.2}Reach out and Read (ROR)}{565}{subsection.22.26.2}%
\contentsline {subsection}{\numberline {22.26.3}Lactation Resources}{565}{subsection.22.26.3}%
\contentsline {subsection}{\numberline {22.26.4}Food Pantry}{565}{subsection.22.26.4}%
\contentsline {subsection}{\numberline {22.26.5}Street Cred}{566}{subsection.22.26.5}%
\contentsline {subsection}{\numberline {22.26.6}Child Witness to Violence Project}{566}{subsection.22.26.6}%
\contentsline {section}{\numberline {22.27}BMC Pediatrics Specialty Outpatient Clinics}{566}{section.22.27}%
\contentsline {subsection}{\numberline {22.27.1}CCP Clinic}{566}{subsection.22.27.1}%
\contentsline {subsection}{\numberline {22.27.2}GROW Clinic}{566}{subsection.22.27.2}%
\contentsline {subsection}{\numberline {22.27.3}Baby Steps Clinic}{567}{subsection.22.27.3}%
\contentsline {section}{\numberline {22.28}SoFAR Clinic}{567}{section.22.28}%
\contentsline {subsection}{\numberline {22.28.1}Teen and Tot Clinic}{567}{subsection.22.28.1}%
\contentsline {subsection}{\numberline {22.28.2}IEP Clinic}{567}{subsection.22.28.2}%
\contentsline {subsection}{\numberline {22.28.3}Family Planning Services}{568}{subsection.22.28.3}%
\contentsline {subsection}{\numberline {22.28.4}Pain Clinic}{568}{subsection.22.28.4}%
\contentsline {subsection}{\numberline {22.28.5}CATALYST Clinic}{568}{subsection.22.28.5}%
\contentsline {subsection}{\numberline {22.28.6}Menstrual Disorders Clinic}{568}{subsection.22.28.6}%
\contentsline {subsection}{\numberline {22.28.7}Lead Clinic}{568}{subsection.22.28.7}%
\contentsline {subsection}{\numberline {22.28.8}CATCH Clinic}{568}{subsection.22.28.8}%
\contentsline {subsection}{\numberline {22.28.9}Embedded Child Psychiatrist}{568}{subsection.22.28.9}%
\contentsline {section}{\numberline {22.29}BMC Indications for Social Work Consult}{568}{section.22.29}%
\contentsline {section}{\numberline {22.30}BMC Clinic Tips}{569}{section.22.30}%
\contentsline {section}{\numberline {22.31}CHPCC Co-Located ``Specialty'' Clinics}{569}{section.22.31}%
\contentsline {subsection}{\numberline {22.31.1}Asthma Clinic}{569}{subsection.22.31.1}%
\contentsline {subsection}{\numberline {22.31.2}Advocating Success for Kids (ASK)}{569}{subsection.22.31.2}%
\contentsline {subsection}{\numberline {22.31.3}Rainbow}{570}{subsection.22.31.3}%
\contentsline {subsection}{\numberline {22.31.4}RASH}{570}{subsection.22.31.4}%
\contentsline {subsection}{\numberline {22.31.5}Young Parents Program (YPP)}{570}{subsection.22.31.5}%
\contentsline {section}{\numberline {22.32}CHPCC Contacts}{570}{section.22.32}%
\contentsline {chapter}{\numberline {23}Psychiatry}{571}{chapter.23}%
\contentsline {section}{\numberline {23.1}Consulting Psych}{571}{section.23.1}%
\contentsline {section}{\numberline {23.2}A/P Template for Patients Awaiting Inpatient Psych Placement}{571}{section.23.2}%
\contentsline {section}{\numberline {23.3}Agitation}{572}{section.23.3}%
\contentsline {subsection}{\numberline {23.3.1}Identifying Agitation}{572}{subsection.23.3.1}%
\contentsline {subsection}{\numberline {23.3.2}Non-Pharm Management}{572}{subsection.23.3.2}%
\contentsline {subsubsection}{\numberline {23.3.2.1}Prevention}{572}{subsubsection.23.3.2.1}%
\contentsline {subsubsection}{\numberline {23.3.2.2}Ways to respond}{572}{subsubsection.23.3.2.2}%
\contentsline {subsubsection}{\numberline {23.3.2.3}Managing the situation}{573}{subsubsection.23.3.2.3}%
\contentsline {subsection}{\numberline {23.3.3}Restraints}{574}{subsection.23.3.3}%
\contentsline {subsection}{\numberline {23.3.4}Pharmacologic Management}{574}{subsection.23.3.4}%
\contentsline {subsubsection}{\numberline {23.3.4.1}Medication Recommendations - Moderate Agitation}{574}{subsubsection.23.3.4.1}%
\contentsline {subsubsection}{\numberline {23.3.4.2}Medication Recommendations - Severe Agitation}{575}{subsubsection.23.3.4.2}%
\contentsline {section}{\numberline {23.4}Medications That Cause Psychiatric Side Effects}{576}{section.23.4}%
\contentsline {subsection}{\numberline {23.4.1}Selected Meds}{576}{subsection.23.4.1}%
\contentsline {subsection}{\numberline {23.4.2}Psychosis}{577}{subsection.23.4.2}%
\contentsline {subsection}{\numberline {23.4.3}Agitation/Confusion/Delirium}{577}{subsection.23.4.3}%
\contentsline {subsection}{\numberline {23.4.4}Depression}{577}{subsection.23.4.4}%
\contentsline {subsection}{\numberline {23.4.5}Anxiety}{577}{subsection.23.4.5}%
\contentsline {subsection}{\numberline {23.4.6}Sedation/Poor concentration}{577}{subsection.23.4.6}%
\contentsline {section}{\numberline {23.5}Capacity Assessment}{577}{section.23.5}%
\contentsline {section}{\numberline {23.6}Depression \& Anxiety}{578}{section.23.6}%
\contentsline {subsection}{\numberline {23.6.1}Diagnosis}{578}{subsection.23.6.1}%
\contentsline {subsection}{\numberline {23.6.2}Management}{578}{subsection.23.6.2}%
\contentsline {section}{\numberline {23.7}Suicide}{578}{section.23.7}%
\contentsline {section}{\numberline {23.8}Antidepressants}{579}{section.23.8}%
\contentsline {subsection}{\numberline {23.8.1}Selective Serotonin Reuptake Inhibitors (SSRIs)}{579}{subsection.23.8.1}%
\contentsline {subsubsection}{\numberline {23.8.1.1}Mechanism of Action}{579}{subsubsection.23.8.1.1}%
\contentsline {subsubsection}{\numberline {23.8.1.2}Use}{579}{subsubsection.23.8.1.2}%
\contentsline {subsubsection}{\numberline {23.8.1.3}Side Effects}{579}{subsubsection.23.8.1.3}%
\contentsline {subsection}{\numberline {23.8.2}Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)}{579}{subsection.23.8.2}%
\contentsline {subsubsection}{\numberline {23.8.2.1}Mechanism of Action}{579}{subsubsection.23.8.2.1}%
\contentsline {subsubsection}{\numberline {23.8.2.2}Use}{580}{subsubsection.23.8.2.2}%
\contentsline {subsubsection}{\numberline {23.8.2.3}Examples}{580}{subsubsection.23.8.2.3}%
\contentsline {subsubsection}{\numberline {23.8.2.4}Side Effects}{580}{subsubsection.23.8.2.4}%
\contentsline {subsection}{\numberline {23.8.3}Tricyclic Antidepressants (TCAs)}{580}{subsection.23.8.3}%
\contentsline {subsubsection}{\numberline {23.8.3.1}Mechanism of Action}{580}{subsubsection.23.8.3.1}%
\contentsline {subsubsection}{\numberline {23.8.3.2}Use}{580}{subsubsection.23.8.3.2}%
\contentsline {subsubsection}{\numberline {23.8.3.3}Examples}{580}{subsubsection.23.8.3.3}%
\contentsline {subsubsection}{\numberline {23.8.3.4}Side Effects}{580}{subsubsection.23.8.3.4}%
\contentsline {subsection}{\numberline {23.8.4}Monoamine Oxidase Inhibitors (MAOIs)}{580}{subsection.23.8.4}%
\contentsline {subsubsection}{\numberline {23.8.4.1}Mechanism of Action}{581}{subsubsection.23.8.4.1}%
\contentsline {subsubsection}{\numberline {23.8.4.2}Use}{581}{subsubsection.23.8.4.2}%
\contentsline {subsubsection}{\numberline {23.8.4.3}Examples}{581}{subsubsection.23.8.4.3}%
\contentsline {subsubsection}{\numberline {23.8.4.4}Side Effects}{581}{subsubsection.23.8.4.4}%
\contentsline {subsection}{\numberline {23.8.5}Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)}{581}{subsection.23.8.5}%
\contentsline {subsubsection}{\numberline {23.8.5.1}Mechanism of Action}{581}{subsubsection.23.8.5.1}%
\contentsline {subsubsection}{\numberline {23.8.5.2}Use}{581}{subsubsection.23.8.5.2}%
\contentsline {subsubsection}{\numberline {23.8.5.3}Examples}{581}{subsubsection.23.8.5.3}%
\contentsline {subsubsection}{\numberline {23.8.5.4}Side Effects}{581}{subsubsection.23.8.5.4}%
\contentsline {subsection}{\numberline {23.8.6}Alpha2-Adrenergic Receptor Antagonists}{582}{subsection.23.8.6}%
\contentsline {subsubsection}{\numberline {23.8.6.1}Mechanism of Action}{582}{subsubsection.23.8.6.1}%
\contentsline {subsubsection}{\numberline {23.8.6.2}Use}{582}{subsubsection.23.8.6.2}%
\contentsline {subsubsection}{\numberline {23.8.6.3}Examples}{582}{subsubsection.23.8.6.3}%
\contentsline {subsubsection}{\numberline {23.8.6.4}Side Effects}{582}{subsubsection.23.8.6.4}%
\contentsline {subsubsection}{\numberline {23.8.6.5}Notes}{582}{subsubsection.23.8.6.5}%
\contentsline {subsection}{\numberline {23.8.7}Serotonin Receptor Antagonists and Agonists}{582}{subsection.23.8.7}%
\contentsline {subsubsection}{\numberline {23.8.7.1}Mechanism of Action}{582}{subsubsection.23.8.7.1}%
\contentsline {subsubsection}{\numberline {23.8.7.2}Use}{582}{subsubsection.23.8.7.2}%
\contentsline {subsubsection}{\numberline {23.8.7.3}Examples}{582}{subsubsection.23.8.7.3}%
\contentsline {subsubsection}{\numberline {23.8.7.4}Side Effects}{582}{subsubsection.23.8.7.4}%
\contentsline {subsection}{\numberline {23.8.8}Nicotinic ACh Receptor Partial Agonist}{583}{subsection.23.8.8}%
\contentsline {subsubsection}{\numberline {23.8.8.1}Use}{583}{subsubsection.23.8.8.1}%
\contentsline {subsubsection}{\numberline {23.8.8.2}Examples}{583}{subsubsection.23.8.8.2}%
\contentsline {subsubsection}{\numberline {23.8.8.3}Side Effects}{583}{subsubsection.23.8.8.3}%
\contentsline {section}{\numberline {23.9}Antipsychotics}{583}{section.23.9}%
\contentsline {subsection}{\numberline {23.9.1}Typical Antipsychotics (1st Generation)}{583}{subsection.23.9.1}%
\contentsline {subsubsection}{\numberline {23.9.1.1}Mechanism of Action}{583}{subsubsection.23.9.1.1}%
\contentsline {subsubsection}{\numberline {23.9.1.2}Use}{583}{subsubsection.23.9.1.2}%
\contentsline {subsubsection}{\numberline {23.9.1.3}Low Potency}{583}{subsubsection.23.9.1.3}%
\contentsline {subsubsection}{\numberline {23.9.1.4}High Potency}{583}{subsubsection.23.9.1.4}%
\contentsline {subsubsection}{\numberline {23.9.1.5}Notes}{584}{subsubsection.23.9.1.5}%
\contentsline {subsection}{\numberline {23.9.2}Atypical Antipsychotics (2nd Generation)}{584}{subsection.23.9.2}%
\contentsline {subsubsection}{\numberline {23.9.2.1}Mechanism of Action}{584}{subsubsection.23.9.2.1}%
\contentsline {subsubsection}{\numberline {23.9.2.2}Use}{584}{subsubsection.23.9.2.2}%
\contentsline {subsubsection}{\numberline {23.9.2.3}Side Effects}{584}{subsubsection.23.9.2.3}%
\contentsline {section}{\numberline {23.10}Mood Stabilizers}{585}{section.23.10}%
\contentsline {subsection}{\numberline {23.10.1}Lithium}{585}{subsection.23.10.1}%
\contentsline {subsubsection}{\numberline {23.10.1.1}Mechanism of Action}{585}{subsubsection.23.10.1.1}%
\contentsline {subsubsection}{\numberline {23.10.1.2}Use}{585}{subsubsection.23.10.1.2}%
\contentsline {subsubsection}{\numberline {23.10.1.3}Side Effects}{585}{subsubsection.23.10.1.3}%
\contentsline {subsection}{\numberline {23.10.2}Valproic Acid (Depakote)}{586}{subsection.23.10.2}%
\contentsline {subsubsection}{\numberline {23.10.2.1}Mechanism of Action}{586}{subsubsection.23.10.2.1}%
\contentsline {subsubsection}{\numberline {23.10.2.2}Use}{586}{subsubsection.23.10.2.2}%
\contentsline {subsubsection}{\numberline {23.10.2.3}Side Effects}{586}{subsubsection.23.10.2.3}%
\contentsline {subsection}{\numberline {23.10.3}Carbamazepine (Tegretol)}{586}{subsection.23.10.3}%
\contentsline {subsubsection}{\numberline {23.10.3.1}Mechanism of Action}{586}{subsubsection.23.10.3.1}%
\contentsline {subsubsection}{\numberline {23.10.3.2}Use}{586}{subsubsection.23.10.3.2}%
\contentsline {subsubsection}{\numberline {23.10.3.3}Side Effects}{586}{subsubsection.23.10.3.3}%
\contentsline {subsection}{\numberline {23.10.4}Buspirone (BuSpar)}{586}{subsection.23.10.4}%
\contentsline {subsubsection}{\numberline {23.10.4.1}Mechanism of Action}{586}{subsubsection.23.10.4.1}%
\contentsline {subsubsection}{\numberline {23.10.4.2}Use}{586}{subsubsection.23.10.4.2}%
\contentsline {subsubsection}{\numberline {23.10.4.3}Side Effects}{586}{subsubsection.23.10.4.3}%
\contentsline {subsection}{\numberline {23.10.5}Benzodiazepines}{587}{subsection.23.10.5}%
\contentsline {subsubsection}{\numberline {23.10.5.1}Mechanism of Action}{587}{subsubsection.23.10.5.1}%
\contentsline {subsubsection}{\numberline {23.10.5.2}Use}{587}{subsubsection.23.10.5.2}%
\contentsline {subsubsection}{\numberline {23.10.5.3}Examples}{587}{subsubsection.23.10.5.3}%
\contentsline {subsubsection}{\numberline {23.10.5.4}Side Effects}{587}{subsubsection.23.10.5.4}%
\contentsline {subsection}{\numberline {23.10.6}Barbiturates}{587}{subsection.23.10.6}%
\contentsline {subsubsection}{\numberline {23.10.6.1}Mechanism of Action}{587}{subsubsection.23.10.6.1}%
\contentsline {subsubsection}{\numberline {23.10.6.2}Use}{587}{subsubsection.23.10.6.2}%
\contentsline {subsubsection}{\numberline {23.10.6.3}Examples}{587}{subsubsection.23.10.6.3}%
\contentsline {subsubsection}{\numberline {23.10.6.4}Side Effects}{588}{subsubsection.23.10.6.4}%
\contentsline {subsection}{\numberline {23.10.7}Non-Benzodiazepine Hypnotics}{588}{subsection.23.10.7}%
\contentsline {subsubsection}{\numberline {23.10.7.1}Mechanism of Action}{588}{subsubsection.23.10.7.1}%
\contentsline {subsubsection}{\numberline {23.10.7.2}Use}{588}{subsubsection.23.10.7.2}%
\contentsline {subsubsection}{\numberline {23.10.7.3}Examples}{588}{subsubsection.23.10.7.3}%
\contentsline {subsubsection}{\numberline {23.10.7.4}Side Effects}{588}{subsubsection.23.10.7.4}%
\contentsline {section}{\numberline {23.11}Other Psychotropic Medications}{588}{section.23.11}%
\contentsline {subsection}{\numberline {23.11.1}Stimulants}{588}{subsection.23.11.1}%
\contentsline {subsubsection}{\numberline {23.11.1.1}Mechanism of Action}{588}{subsubsection.23.11.1.1}%
\contentsline {subsubsection}{\numberline {23.11.1.2}Use}{588}{subsubsection.23.11.1.2}%
\contentsline {subsubsection}{\numberline {23.11.1.3}Examples}{588}{subsubsection.23.11.1.3}%
\contentsline {subsubsection}{\numberline {23.11.1.4}Side Effects}{589}{subsubsection.23.11.1.4}%
\contentsline {subsection}{\numberline {23.11.2}Acetylcholinesterase Inhibitors}{589}{subsection.23.11.2}%
\contentsline {subsubsection}{\numberline {23.11.2.1}Mechanism of Action}{589}{subsubsection.23.11.2.1}%
\contentsline {subsubsection}{\numberline {23.11.2.2}Use}{589}{subsubsection.23.11.2.2}%
\contentsline {subsubsection}{\numberline {23.11.2.3}Examples}{589}{subsubsection.23.11.2.3}%
\contentsline {subsection}{\numberline {23.11.3}NMDA (Glutamate) Receptor Antagonist}{589}{subsection.23.11.3}%
\contentsline {subsubsection}{\numberline {23.11.3.1}Mechanism of Action}{589}{subsubsection.23.11.3.1}%
\contentsline {subsubsection}{\numberline {23.11.3.2}Use}{589}{subsubsection.23.11.3.2}%
\contentsline {subsubsection}{\numberline {23.11.3.3}Examples}{589}{subsubsection.23.11.3.3}%
\contentsline {section}{\numberline {23.12}Electroconvulsive Therapy (ECT)}{589}{section.23.12}%
\contentsline {subsection}{\numberline {23.12.1}Definition}{589}{subsection.23.12.1}%
\contentsline {subsection}{\numberline {23.12.2}Indications}{589}{subsection.23.12.2}%
\contentsline {subsection}{\numberline {23.12.3}Safety}{590}{subsection.23.12.3}%
\contentsline {subsection}{\numberline {23.12.4}Side Effects}{590}{subsection.23.12.4}%
\contentsline {section}{\numberline {23.13}Psychotherapy}{590}{section.23.13}%
\contentsline {chapter}{\numberline {24}Pulmonology}{591}{chapter.24}%
\contentsline {section}{\numberline {24.1}Asthma -- ED/Inpatient: EBG}{591}{section.24.1}%
\contentsline {subsection}{\numberline {24.1.1}History to Elicit}{591}{subsection.24.1.1}%
\contentsline {subsection}{\numberline {24.1.2}Exam}{591}{subsection.24.1.2}%
\contentsline {subsection}{\numberline {24.1.3}Etiology}{591}{subsection.24.1.3}%
\contentsline {subsection}{\numberline {24.1.4}Work-up}{591}{subsection.24.1.4}%
\contentsline {subsection}{\numberline {24.1.5}Order Sets}{592}{subsection.24.1.5}%
\contentsline {subsection}{\numberline {24.1.6}Treatment}{592}{subsection.24.1.6}%
\contentsline {subsection}{\numberline {24.1.7}Discharge Criteria}{592}{subsection.24.1.7}%
\contentsline {section}{\numberline {24.2}Asthma -- Outpatient:}{593}{section.24.2}%
\contentsline {subsection}{\numberline {24.2.1}History to Elicit}{593}{subsection.24.2.1}%
\contentsline {subsection}{\numberline {24.2.2}Presentation}{593}{subsection.24.2.2}%
\contentsline {subsection}{\numberline {24.2.3}Etiology}{593}{subsection.24.2.3}%
\contentsline {subsection}{\numberline {24.2.4}Workup}{593}{subsection.24.2.4}%
\contentsline {subsection}{\numberline {24.2.5}Severity Classification}{593}{subsection.24.2.5}%
\contentsline {subsection}{\numberline {24.2.6}Stepwise Approach to Asthma Treatment}{594}{subsection.24.2.6}%
\contentsline {section}{\numberline {24.3}Bronchiolitis: EBG}{595}{section.24.3}%
\contentsline {subsection}{\numberline {24.3.1}Presentation}{595}{subsection.24.3.1}%
\contentsline {subsection}{\numberline {24.3.2}Differential}{595}{subsection.24.3.2}%
\contentsline {subsection}{\numberline {24.3.3}Workup}{595}{subsection.24.3.3}%
\contentsline {subsection}{\numberline {24.3.4}Treatment}{595}{subsection.24.3.4}%
\contentsline {subsection}{\numberline {24.3.5}Prevention}{596}{subsection.24.3.5}%
\contentsline {section}{\numberline {24.4}Approach to Cough}{596}{section.24.4}%
\contentsline {subsection}{\numberline {24.4.1}Definition}{596}{subsection.24.4.1}%
\contentsline {subsection}{\numberline {24.4.2}History to Elicit}{596}{subsection.24.4.2}%
\contentsline {subsection}{\numberline {24.4.3}Exam}{596}{subsection.24.4.3}%
\contentsline {subsection}{\numberline {24.4.4}Differential Diagnosis}{596}{subsection.24.4.4}%
\contentsline {section}{\numberline {24.5}Cystic Fibrosis: EBG}{598}{section.24.5}%
\contentsline {subsection}{\numberline {24.5.1}Clinical Manifestations}{598}{subsection.24.5.1}%
\contentsline {subsection}{\numberline {24.5.2}Diagnosis}{598}{subsection.24.5.2}%
\contentsline {subsection}{\numberline {24.5.3}Pulmonary Exacerbations}{598}{subsection.24.5.3}%
\contentsline {subsection}{\numberline {24.5.4}Chronic Pulmonary Treatment}{598}{subsection.24.5.4}%
\contentsline {subsection}{\numberline {24.5.5}Treatment CF Exacerbations}{599}{subsection.24.5.5}%
\contentsline {subsection}{\numberline {24.5.6}Admission Labs}{599}{subsection.24.5.6}%
\contentsline {subsection}{\numberline {24.5.7}Lab monitoring:}{599}{subsection.24.5.7}%
\contentsline {subsection}{\numberline {24.5.8}Antibiotics:}{599}{subsection.24.5.8}%
\contentsline {subsection}{\numberline {24.5.9}Pulmonary Clearance:}{601}{subsection.24.5.9}%
\contentsline {subsection}{\numberline {24.5.10}Bowel Regimen}{601}{subsection.24.5.10}%
\contentsline {section}{\numberline {24.6}Hemoptysis (CF)}{601}{section.24.6}%
\contentsline {subsection}{\numberline {24.6.1}Definition}{601}{subsection.24.6.1}%
\contentsline {subsection}{\numberline {24.6.2}Management}{601}{subsection.24.6.2}%
\contentsline {subsection}{\numberline {24.6.3}Clinically stable patient with hemoptysis}{602}{subsection.24.6.3}%
\contentsline {section}{\numberline {24.7}Pneumothorax}{602}{section.24.7}%
\contentsline {subsection}{\numberline {24.7.1}Types}{602}{subsection.24.7.1}%
\contentsline {subsection}{\numberline {24.7.2}Presentation}{602}{subsection.24.7.2}%
\contentsline {subsection}{\numberline {24.7.3}Workup}{603}{subsection.24.7.3}%
\contentsline {subsection}{\numberline {24.7.4}Management}{603}{subsection.24.7.4}%
\contentsline {section}{\numberline {24.8}Pneumonia: EBG}{603}{section.24.8}%
\contentsline {subsection}{\numberline {24.8.1}Presentation}{603}{subsection.24.8.1}%
\contentsline {subsection}{\numberline {24.8.2}Etiology}{603}{subsection.24.8.2}%
\contentsline {subsection}{\numberline {24.8.3}Differential}{603}{subsection.24.8.3}%
\contentsline {subsection}{\numberline {24.8.4}Workup}{603}{subsection.24.8.4}%
\contentsline {subsection}{\numberline {24.8.5}When to Hospitalize}{603}{subsection.24.8.5}%
\contentsline {subsection}{\numberline {24.8.6}Treatment}{603}{subsection.24.8.6}%
\contentsline {section}{\numberline {24.9}Pleural Effusions}{604}{section.24.9}%
\contentsline {subsection}{\numberline {24.9.1}Presentation}{604}{subsection.24.9.1}%
\contentsline {subsection}{\numberline {24.9.2}Differential}{604}{subsection.24.9.2}%
\contentsline {subsection}{\numberline {24.9.3}Workup}{604}{subsection.24.9.3}%
\contentsline {subsection}{\numberline {24.9.4}Treatment}{604}{subsection.24.9.4}%
\contentsline {section}{\numberline {24.10}Obstructive Sleep Apnea}{604}{section.24.10}%
\contentsline {subsection}{\numberline {24.10.1}Presentation}{604}{subsection.24.10.1}%
\contentsline {subsection}{\numberline {24.10.2}Differential}{605}{subsection.24.10.2}%
\contentsline {subsection}{\numberline {24.10.3}Workup}{605}{subsection.24.10.3}%
\contentsline {subsection}{\numberline {24.10.4}Treatment}{605}{subsection.24.10.4}%
\contentsline {section}{\numberline {24.11}Tuberculosis}{605}{section.24.11}%
\contentsline {subsection}{\numberline {24.11.1}Symptoms}{605}{subsection.24.11.1}%
\contentsline {subsection}{\numberline {24.11.2}Workup}{605}{subsection.24.11.2}%
\contentsline {subsection}{\numberline {24.11.3}Treatment}{606}{subsection.24.11.3}%
\contentsline {section}{\numberline {24.12}Pulmonary Function Tests}{606}{section.24.12}%
\contentsline {subsection}{\numberline {24.12.1}Definitions}{606}{subsection.24.12.1}%
\contentsline {subsubsection}{\numberline {24.12.1.1}Forced vital capacity (FVC)}{606}{subsubsection.24.12.1.1}%
\contentsline {subsubsection}{\numberline {24.12.1.2}Forced expiratory volume 1 (FEV1)}{606}{subsubsection.24.12.1.2}%
\contentsline {subsubsection}{\numberline {24.12.1.3}Forced expiratory flow 25\% to 75\%}{606}{subsubsection.24.12.1.3}%
\contentsline {subsubsection}{\numberline {24.12.1.4}Peak expiratory flow (PEF):}{606}{subsubsection.24.12.1.4}%
\contentsline {subsubsection}{\numberline {24.12.1.5}Total lung capacity (TLC)}{606}{subsubsection.24.12.1.5}%
\contentsline {subsubsection}{\numberline {24.12.1.6}Functional residual capacity (FRC)}{607}{subsubsection.24.12.1.6}%
\contentsline {subsubsection}{\numberline {24.12.1.7}Expiratory reserve volume (ERV)}{607}{subsubsection.24.12.1.7}%
\contentsline {section}{\numberline {24.13}Obstructive vs.\nobreakspace {}Restrictive Lung Disease}{607}{section.24.13}%
\contentsline {section}{\numberline {24.14}Bronchodilator/Bronchoprovocation Testing in Asthma}{608}{section.24.14}%
\contentsline {section}{\numberline {24.15}EVALI (E-Cigarette and Vaping Associated Lung Injury)}{608}{section.24.15}%
\contentsline {subsection}{\numberline {24.15.1}Presentation}{608}{subsection.24.15.1}%
\contentsline {subsection}{\numberline {24.15.2}Etiology/Pathophysiology}{608}{subsection.24.15.2}%
\contentsline {subsection}{\numberline {24.15.3}Differential}{608}{subsection.24.15.3}%
\contentsline {subsection}{\numberline {24.15.4}Proposed Criteria for Diagnosis}{609}{subsection.24.15.4}%
\contentsline {subsection}{\numberline {24.15.5}Workup}{609}{subsection.24.15.5}%
\contentsline {subsection}{\numberline {24.15.6}Consults}{609}{subsection.24.15.6}%
\contentsline {subsection}{\numberline {24.15.7}Treatment}{609}{subsection.24.15.7}%
\contentsline {chapter}{\numberline {25}Rheumatology}{611}{chapter.25}%
\contentsline {section}{\numberline {25.1}Pediatric approach to rheumatic disease}{611}{section.25.1}%
\contentsline {section}{\numberline {25.2}Inflammatory markers and autoantibodies}{611}{section.25.2}%
\contentsline {section}{\numberline {25.3}Childhood Vasculitides}{614}{section.25.3}%
\contentsline {section}{\numberline {25.4}Henoch-Schonlein Purpura (IgA vasculitis)}{616}{section.25.4}%
\contentsline {section}{\numberline {25.5}Kawasaki Disease}{617}{section.25.5}%
\contentsline {subsubsection}{\numberline {25.5.0.1}\textbf {Complete KD}:}{617}{subsubsection.25.5.0.1}%
\contentsline {subsubsection}{\numberline {25.5.0.2}\textbf {Incomplete (Atypical) KD}:}{617}{subsubsection.25.5.0.2}%
\contentsline {section}{\numberline {25.6}Polyarteritis Nodosa}{618}{section.25.6}%
\contentsline {section}{\numberline {25.7}Connective Tissue Disorders}{620}{section.25.7}%
\contentsline {subsection}{\numberline {25.7.1}\emph {SLE}}{620}{subsection.25.7.1}%
\contentsline {subsection}{\numberline {25.7.2}\emph {Juvenile Polymyositis}}{620}{subsection.25.7.2}%
\contentsline {subsection}{\numberline {25.7.3}\emph {Juvenile Dermatomyositis}}{620}{subsection.25.7.3}%
\contentsline {subsection}{\numberline {25.7.4}\emph {Sjogren's}}{621}{subsection.25.7.4}%
\contentsline {subsection}{\numberline {25.7.5}\emph {Scleroderma}}{621}{subsection.25.7.5}%
\contentsline {subsection}{\numberline {25.7.6}\emph {CREST}}{621}{subsection.25.7.6}%
\contentsline {subsection}{\numberline {25.7.7}\emph {Mixed Connective Tissue Disease}}{622}{subsection.25.7.7}%
\contentsline {section}{\numberline {25.8}Systemic Lupus Erythematosus}{622}{section.25.8}%
\contentsline {section}{\numberline {25.9}Inflammatory Myopathies}{624}{section.25.9}%
\contentsline {section}{\numberline {25.10}Sjogren Syndrome}{625}{section.25.10}%
\contentsline {section}{\numberline {25.11}Pediatric arthritides: Approach to Joint Disease}{625}{section.25.11}%
\contentsline {section}{\numberline {25.12}Juvenile Idiopathic Arthritis}{626}{section.25.12}%
\contentsline {section}{\numberline {25.13}Systemic JIA (Still's disease)}{628}{section.25.13}%
\contentsline {section}{\numberline {25.14}Macrophage Activation Syndrome (MAS)}{628}{section.25.14}%
\contentsline {section}{\numberline {25.15}Fever of Unknown Origin}{629}{section.25.15}%
\contentsline {section}{\numberline {25.16}Autoinflammatory Diseases}{630}{section.25.16}%
\contentsline {subsection}{\numberline {25.16.1}Periodic Fever Syndromes}{630}{subsection.25.16.1}%
\contentsline {subsection}{\numberline {25.16.2}Autoinflammatory Disorders without Periodic Fever}{632}{subsection.25.16.2}%
\contentsline {section}{\numberline {25.17}Common Rheumatology Medications}{632}{section.25.17}%
\contentsline {chapter}{\numberline {26}Sports Medicine}{635}{chapter.26}%
\contentsline {section}{\numberline {26.1}General Approach to the MSK Exam}{635}{section.26.1}%
\contentsline {section}{\numberline {26.2}Fractures}{636}{section.26.2}%
\contentsline {subsection}{\numberline {26.2.1}Salter-Harris Classification for Physeal Fractures}{636}{subsection.26.2.1}%
\contentsline {section}{\numberline {26.3}Pre-Participation Physical}{637}{section.26.3}%
\contentsline {subsubsection}{\numberline {26.3.0.1}History}{637}{subsubsection.26.3.0.1}%
\contentsline {subsubsection}{\numberline {26.3.0.2}Physical Exam}{637}{subsubsection.26.3.0.2}%
\contentsline {subsubsection}{\numberline {26.3.0.3}Cardiac Testing}{637}{subsubsection.26.3.0.3}%
\contentsline {subsubsection}{\numberline {26.3.0.4}Clearance}{638}{subsubsection.26.3.0.4}%
\contentsline {section}{\numberline {26.4}Upper Extremity: Elbow, Forearm \& Wrist}{638}{section.26.4}%
\contentsline {subsection}{\numberline {26.4.1}Anatomy}{639}{subsection.26.4.1}%
\contentsline {subsection}{\numberline {26.4.2}Exam Pearls}{639}{subsection.26.4.2}%
\contentsline {subsection}{\numberline {26.4.3}Supracondylar Fracture}{639}{subsection.26.4.3}%
\contentsline {subsubsection}{\numberline {26.4.3.1}Description/Mechanism}{640}{subsubsection.26.4.3.1}%
\contentsline {subsubsection}{\numberline {26.4.3.2}Diagnosis}{642}{subsubsection.26.4.3.2}%
\contentsline {subsubsection}{\numberline {26.4.3.3}Management}{642}{subsubsection.26.4.3.3}%
\contentsline {subsection}{\numberline {26.4.4}Nursemaid's Elbow (Subluxation of Radial Head)}{642}{subsection.26.4.4}%
\contentsline {subsubsection}{\numberline {26.4.4.1}Description/Mechanism}{642}{subsubsection.26.4.4.1}%
\contentsline {subsubsection}{\numberline {26.4.4.2}Diagnosis}{642}{subsubsection.26.4.4.2}%
\contentsline {subsubsection}{\numberline {26.4.4.3}Management}{642}{subsubsection.26.4.4.3}%
\contentsline {subsection}{\numberline {26.4.5}Distal Radius Fracture}{642}{subsection.26.4.5}%
\contentsline {subsubsection}{\numberline {26.4.5.1}Description/Mechanism}{642}{subsubsection.26.4.5.1}%
\contentsline {subsubsection}{\numberline {26.4.5.2}Diagnosis}{642}{subsubsection.26.4.5.2}%
\contentsline {subsubsection}{\numberline {26.4.5.3}Management}{642}{subsubsection.26.4.5.3}%
\contentsline {section}{\numberline {26.5}Upper Extremity: Shoulder}{643}{section.26.5}%
\contentsline {subsection}{\numberline {26.5.1}Anatomy}{643}{subsection.26.5.1}%
\contentsline {subsection}{\numberline {26.5.2}Exam Pearls \& Special Tests}{643}{subsection.26.5.2}%
\contentsline {subsubsection}{\numberline {26.5.2.1}Common Associations}{644}{subsubsection.26.5.2.1}%
\contentsline {subsection}{\numberline {26.5.3}Proximal Humeral Fracture}{644}{subsection.26.5.3}%
\contentsline {subsubsection}{\numberline {26.5.3.1}Description/Mechanism}{644}{subsubsection.26.5.3.1}%
\contentsline {subsubsection}{\numberline {26.5.3.2}Signs \& Symptoms}{645}{subsubsection.26.5.3.2}%
\contentsline {subsubsection}{\numberline {26.5.3.3}Diagnosis}{645}{subsubsection.26.5.3.3}%
\contentsline {subsubsection}{\numberline {26.5.3.4}Management}{645}{subsubsection.26.5.3.4}%
\contentsline {subsection}{\numberline {26.5.4}Dislocation}{645}{subsection.26.5.4}%
\contentsline {subsubsection}{\numberline {26.5.4.1}Description/Mechanism}{645}{subsubsection.26.5.4.1}%
\contentsline {subsubsection}{\numberline {26.5.4.2}Diagnosis}{645}{subsubsection.26.5.4.2}%
\contentsline {subsubsection}{\numberline {26.5.4.3}Management}{645}{subsubsection.26.5.4.3}%
\contentsline {subsection}{\numberline {26.5.5}Rotator Cuff Injury}{645}{subsection.26.5.5}%
\contentsline {subsubsection}{\numberline {26.5.5.1}Description/Mechanism}{645}{subsubsection.26.5.5.1}%
\contentsline {subsubsection}{\numberline {26.5.5.2}Signs \& Symptoms}{646}{subsubsection.26.5.5.2}%
\contentsline {subsubsection}{\numberline {26.5.5.3}Diagnosis}{646}{subsubsection.26.5.5.3}%
\contentsline {subsubsection}{\numberline {26.5.5.4}Management}{646}{subsubsection.26.5.5.4}%
\contentsline {subsection}{\numberline {26.5.6}Little Leage Shoulder (Proximal Humeral Epiphysiolysis)}{646}{subsection.26.5.6}%
\contentsline {subsubsection}{\numberline {26.5.6.1}Description/Mechanism}{646}{subsubsection.26.5.6.1}%
\contentsline {subsubsection}{\numberline {26.5.6.2}Signs \& Symptoms}{646}{subsubsection.26.5.6.2}%
\contentsline {subsubsection}{\numberline {26.5.6.3}Diagnosis}{646}{subsubsection.26.5.6.3}%
\contentsline {subsubsection}{\numberline {26.5.6.4}Management}{646}{subsubsection.26.5.6.4}%
\contentsline {subsection}{\numberline {26.5.7}Acromioclavicular (AC) Joint Injury}{646}{subsection.26.5.7}%
\contentsline {subsubsection}{\numberline {26.5.7.1}Description/Mechanism}{646}{subsubsection.26.5.7.1}%
\contentsline {subsubsection}{\numberline {26.5.7.2}Diagnosis}{647}{subsubsection.26.5.7.2}%
\contentsline {subsubsection}{\numberline {26.5.7.3}Management}{647}{subsubsection.26.5.7.3}%
\contentsline {subsection}{\numberline {26.5.8}Clavicular Fracture}{647}{subsection.26.5.8}%
\contentsline {subsubsection}{\numberline {26.5.8.1}Description/Mechanism}{647}{subsubsection.26.5.8.1}%
\contentsline {subsubsection}{\numberline {26.5.8.2}Diagnosis}{647}{subsubsection.26.5.8.2}%
\contentsline {subsubsection}{\numberline {26.5.8.3}Management}{647}{subsubsection.26.5.8.3}%
\contentsline {section}{\numberline {26.6}Lower Extremity: Hip}{647}{section.26.6}%
\contentsline {subsection}{\numberline {26.6.1}Anatomy}{648}{subsection.26.6.1}%
\contentsline {subsection}{\numberline {26.6.2}Exam Pearls \& Special Tests}{648}{subsection.26.6.2}%
\contentsline {subsection}{\numberline {26.6.3}Legg-Calve-Parthes Disease}{649}{subsection.26.6.3}%
\contentsline {subsubsection}{\numberline {26.6.3.1}Description/Mechanism}{649}{subsubsection.26.6.3.1}%
\contentsline {subsubsection}{\numberline {26.6.3.2}Signs \& Symptoms}{649}{subsubsection.26.6.3.2}%
\contentsline {subsubsection}{\numberline {26.6.3.3}Diagnosis}{649}{subsubsection.26.6.3.3}%
\contentsline {subsubsection}{\numberline {26.6.3.4}Management}{650}{subsubsection.26.6.3.4}%
\contentsline {subsection}{\numberline {26.6.4}Slipped Capital Femoral Epiphysis (SCFE)}{650}{subsection.26.6.4}%
\contentsline {subsubsection}{\numberline {26.6.4.1}Description/Mechanism}{650}{subsubsection.26.6.4.1}%
\contentsline {subsubsection}{\numberline {26.6.4.2}Signs \& Symptoms}{650}{subsubsection.26.6.4.2}%
\contentsline {subsubsection}{\numberline {26.6.4.3}Diagnosis}{650}{subsubsection.26.6.4.3}%
\contentsline {subsection}{\numberline {26.6.5}Developmental Dysplasia of the Hip (DDH)}{651}{subsection.26.6.5}%
\contentsline {subsubsection}{\numberline {26.6.5.1}Description/Mechanism}{651}{subsubsection.26.6.5.1}%
\contentsline {subsubsection}{\numberline {26.6.5.2}Diagnosis}{651}{subsubsection.26.6.5.2}%
\contentsline {subsubsection}{\numberline {26.6.5.3}Management}{651}{subsubsection.26.6.5.3}%
\contentsline {subsection}{\numberline {26.6.6}Femoroacetabular Impingement (FAI)}{651}{subsection.26.6.6}%
\contentsline {subsubsection}{\numberline {26.6.6.1}Description/Mechanism}{651}{subsubsection.26.6.6.1}%
\contentsline {subsubsection}{\numberline {26.6.6.2}Diagnosis}{651}{subsubsection.26.6.6.2}%
\contentsline {subsubsection}{\numberline {26.6.6.3}Management}{652}{subsubsection.26.6.6.3}%
\contentsline {section}{\numberline {26.7}Lower Extremity: Knee}{652}{section.26.7}%
\contentsline {subsection}{\numberline {26.7.1}Anatomy}{652}{subsection.26.7.1}%
\contentsline {subsection}{\numberline {26.7.2}Exam Pearls \& Special Tests}{652}{subsection.26.7.2}%
\contentsline {subsection}{\numberline {26.7.3}Osgood-Schlatter Disease}{653}{subsection.26.7.3}%
\contentsline {subsubsection}{\numberline {26.7.3.1}Description/Mechanism}{653}{subsubsection.26.7.3.1}%
\contentsline {subsubsection}{\numberline {26.7.3.2}Signs \& Symptoms}{653}{subsubsection.26.7.3.2}%
\contentsline {subsubsection}{\numberline {26.7.3.3}Diagnosis}{653}{subsubsection.26.7.3.3}%
\contentsline {subsubsection}{\numberline {26.7.3.4}Management}{654}{subsubsection.26.7.3.4}%
\contentsline {subsection}{\numberline {26.7.4}Patellofemoral Pain Syndrome (PFPS)}{654}{subsection.26.7.4}%
\contentsline {subsubsection}{\numberline {26.7.4.1}Description/Mechanism}{654}{subsubsection.26.7.4.1}%
\contentsline {subsubsection}{\numberline {26.7.4.2}Signs \& Symptoms}{654}{subsubsection.26.7.4.2}%
\contentsline {subsubsection}{\numberline {26.7.4.3}Diagnosis}{654}{subsubsection.26.7.4.3}%
\contentsline {subsubsection}{\numberline {26.7.4.4}Management}{654}{subsubsection.26.7.4.4}%
\contentsline {subsection}{\numberline {26.7.5}Anterior Cruciate Ligament (ACL) Injuries}{654}{subsection.26.7.5}%
\contentsline {subsubsection}{\numberline {26.7.5.1}Description/Mechanism}{654}{subsubsection.26.7.5.1}%
\contentsline {subsubsection}{\numberline {26.7.5.2}Signs \& Symptoms}{654}{subsubsection.26.7.5.2}%
\contentsline {subsubsection}{\numberline {26.7.5.3}Diagnosis}{654}{subsubsection.26.7.5.3}%
\contentsline {subsubsection}{\numberline {26.7.5.4}Management}{655}{subsubsection.26.7.5.4}%
\contentsline {subsection}{\numberline {26.7.6}Meniscus Injuries}{655}{subsection.26.7.6}%
\contentsline {subsubsection}{\numberline {26.7.6.1}Description/Mechanism}{655}{subsubsection.26.7.6.1}%
\contentsline {subsubsection}{\numberline {26.7.6.2}Signs \& Symptoms}{655}{subsubsection.26.7.6.2}%
\contentsline {subsubsection}{\numberline {26.7.6.3}Diagnosis}{655}{subsubsection.26.7.6.3}%
\contentsline {subsubsection}{\numberline {26.7.6.4}Management}{655}{subsubsection.26.7.6.4}%
\contentsline {subsection}{\numberline {26.7.7}Iliotibial (IT) Band Syndrome}{655}{subsection.26.7.7}%
\contentsline {subsubsection}{\numberline {26.7.7.1}Description/Mechanism}{655}{subsubsection.26.7.7.1}%
\contentsline {subsubsection}{\numberline {26.7.7.2}Signs \& Symptoms}{655}{subsubsection.26.7.7.2}%
\contentsline {subsubsection}{\numberline {26.7.7.3}Diagnosis}{655}{subsubsection.26.7.7.3}%
\contentsline {subsubsection}{\numberline {26.7.7.4}Management}{656}{subsubsection.26.7.7.4}%
\contentsline {subsection}{\numberline {26.7.8}Osteochondritis Dissecans}{656}{subsection.26.7.8}%
\contentsline {subsubsection}{\numberline {26.7.8.1}Description/Mechanism}{656}{subsubsection.26.7.8.1}%
\contentsline {subsubsection}{\numberline {26.7.8.2}Signs \& Symptoms}{656}{subsubsection.26.7.8.2}%
\contentsline {subsubsection}{\numberline {26.7.8.3}Diagnosis}{656}{subsubsection.26.7.8.3}%
\contentsline {subsubsection}{\numberline {26.7.8.4}Management}{656}{subsubsection.26.7.8.4}%
\contentsline {section}{\numberline {26.8}Lower Extremity: Ankle/Foot}{656}{section.26.8}%
\contentsline {subsection}{\numberline {26.8.1}Anatomy}{657}{subsection.26.8.1}%
\contentsline {subsection}{\numberline {26.8.2}Exam Pearls \& Special Tests}{657}{subsection.26.8.2}%
\contentsline {subsection}{\numberline {26.8.3}Ankle Sprain}{658}{subsection.26.8.3}%
\contentsline {subsubsection}{\numberline {26.8.3.1}Description/Mechanism}{658}{subsubsection.26.8.3.1}%
\contentsline {subsubsection}{\numberline {26.8.3.2}Signs \& Symptoms}{658}{subsubsection.26.8.3.2}%
\contentsline {subsubsection}{\numberline {26.8.3.3}Diagnosis}{658}{subsubsection.26.8.3.3}%
\contentsline {subsubsection}{\numberline {26.8.3.4}Management}{659}{subsubsection.26.8.3.4}%
\contentsline {subsection}{\numberline {26.8.4}Sever's Disease}{659}{subsection.26.8.4}%
\contentsline {subsubsection}{\numberline {26.8.4.1}Description/Mechanism}{659}{subsubsection.26.8.4.1}%
\contentsline {subsubsection}{\numberline {26.8.4.2}Signs \& Symptoms}{659}{subsubsection.26.8.4.2}%
\contentsline {subsubsection}{\numberline {26.8.4.3}Diagnosis}{659}{subsubsection.26.8.4.3}%
\contentsline {subsubsection}{\numberline {26.8.4.4}Management}{659}{subsubsection.26.8.4.4}%
\contentsline {subsection}{\numberline {26.8.5}Spiral/Oblique Fracture}{659}{subsection.26.8.5}%
\contentsline {subsubsection}{\numberline {26.8.5.1}Description/Mechanism}{659}{subsubsection.26.8.5.1}%
\contentsline {subsubsection}{\numberline {26.8.5.2}Signs \& Symptoms}{659}{subsubsection.26.8.5.2}%
\contentsline {subsubsection}{\numberline {26.8.5.3}Diagnosis}{660}{subsubsection.26.8.5.3}%
\contentsline {subsubsection}{\numberline {26.8.5.4}Management}{660}{subsubsection.26.8.5.4}%
\contentsline {subsection}{\numberline {26.8.6}Congenital Clubfoot}{660}{subsection.26.8.6}%
\contentsline {subsubsection}{\numberline {26.8.6.1}Description/Mechanism}{660}{subsubsection.26.8.6.1}%
\contentsline {subsubsection}{\numberline {26.8.6.2}Diagnosis}{660}{subsubsection.26.8.6.2}%
\contentsline {subsubsection}{\numberline {26.8.6.3}Management}{660}{subsubsection.26.8.6.3}%
\contentsline {section}{\numberline {26.9}Spine}{660}{section.26.9}%
\contentsline {subsection}{\numberline {26.9.1}Anatomy}{661}{subsection.26.9.1}%
\contentsline {subsection}{\numberline {26.9.2}Exam Pearls \& Special Tests}{661}{subsection.26.9.2}%
\contentsline {subsection}{\numberline {26.9.3}Scoliosis}{662}{subsection.26.9.3}%
\contentsline {subsubsection}{\numberline {26.9.3.1}Description/Mechanism}{662}{subsubsection.26.9.3.1}%
\contentsline {subsubsection}{\numberline {26.9.3.2}Diagnosis}{662}{subsubsection.26.9.3.2}%
\contentsline {subsubsection}{\numberline {26.9.3.3}Management}{663}{subsubsection.26.9.3.3}%
\contentsline {subsection}{\numberline {26.9.4}Spondylolysis \& Spondylolisthesis}{663}{subsection.26.9.4}%
\contentsline {subsubsection}{\numberline {26.9.4.1}Description/Mechanism}{663}{subsubsection.26.9.4.1}%
\contentsline {subsubsection}{\numberline {26.9.4.2}Signs \& Symptoms}{664}{subsubsection.26.9.4.2}%
\contentsline {subsubsection}{\numberline {26.9.4.3}Diagnosis}{664}{subsubsection.26.9.4.3}%
\contentsline {subsubsection}{\numberline {26.9.4.4}Management}{664}{subsubsection.26.9.4.4}%
\contentsline {subsection}{\numberline {26.9.5}Spondyloarthropathies}{664}{subsection.26.9.5}%
\contentsline {subsubsection}{\numberline {26.9.5.1}Signs \& Symptoms}{664}{subsubsection.26.9.5.1}%
\contentsline {section}{\numberline {26.10}Head}{665}{section.26.10}%
\contentsline {subsection}{\numberline {26.10.1}Mild Traumatic Brain Injury (TBI) (Concussion)}{665}{subsection.26.10.1}%
\contentsline {chapter}{\numberline {27}Toxicology}{667}{chapter.27}%
\contentsline {section}{\numberline {27.1}Key Resources}{667}{section.27.1}%
\contentsline {section}{\numberline {27.2}Approach to Poisoned Patient}{667}{section.27.2}%
\contentsline {subsection}{\numberline {27.2.1}Stabilization}{667}{subsection.27.2.1}%
\contentsline {subsection}{\numberline {27.2.2}Physical Exam}{667}{subsection.27.2.2}%
\contentsline {subsection}{\numberline {27.2.3}History}{667}{subsection.27.2.3}%
\contentsline {subsection}{\numberline {27.2.4}Basic Labs}{668}{subsection.27.2.4}%
\contentsline {subsection}{\numberline {27.2.5}Tox Screens}{668}{subsection.27.2.5}%
\contentsline {subsection}{\numberline {27.2.6}Management}{668}{subsection.27.2.6}%
\contentsline {section}{\numberline {27.3}Toxidromes}{668}{section.27.3}%
\contentsline {section}{\numberline {27.4}Differential Diagnosis (non-exhaustive)}{668}{section.27.4}%
\contentsline {subsection}{\numberline {27.4.1}Temperature}{670}{subsection.27.4.1}%
\contentsline {subsection}{\numberline {27.4.2}Heart Rate}{670}{subsection.27.4.2}%
\contentsline {subsection}{\numberline {27.4.3}Blood Pressure}{670}{subsection.27.4.3}%
\contentsline {subsection}{\numberline {27.4.4}Respiratory Rate}{670}{subsection.27.4.4}%
\contentsline {subsection}{\numberline {27.4.5}Blood Glucose}{670}{subsection.27.4.5}%
\contentsline {section}{\numberline {27.5}Acetaminophen Overdose}{671}{section.27.5}%
\contentsline {subsection}{\numberline {27.5.1}Toxic Dose}{671}{subsection.27.5.1}%
\contentsline {subsection}{\numberline {27.5.2}Pathophysiology}{671}{subsection.27.5.2}%
\contentsline {subsection}{\numberline {27.5.3}Symptoms}{671}{subsection.27.5.3}%
\contentsline {subsection}{\numberline {27.5.4}Evaluation}{671}{subsection.27.5.4}%
\contentsline {subsection}{\numberline {27.5.5}Management}{671}{subsection.27.5.5}%
\contentsline {subsection}{\numberline {27.5.6}Rule of 150}{672}{subsection.27.5.6}%
\contentsline {section}{\numberline {27.6}Aspirin Overdose}{672}{section.27.6}%
\contentsline {subsection}{\numberline {27.6.1}Toxic Dose}{672}{subsection.27.6.1}%
\contentsline {subsection}{\numberline {27.6.2}Pathophysiology}{673}{subsection.27.6.2}%
\contentsline {subsection}{\numberline {27.6.3}Symptoms}{673}{subsection.27.6.3}%
\contentsline {subsection}{\numberline {27.6.4}Evaluation}{673}{subsection.27.6.4}%
\contentsline {subsection}{\numberline {27.6.5}Management}{673}{subsection.27.6.5}%
\contentsline {section}{\numberline {27.7}Beta-Blocker Overdose}{673}{section.27.7}%
\contentsline {subsection}{\numberline {27.7.1}Toxic Dose}{673}{subsection.27.7.1}%
\contentsline {subsection}{\numberline {27.7.2}Pathophysiology}{673}{subsection.27.7.2}%
\contentsline {subsection}{\numberline {27.7.3}Symptoms}{674}{subsection.27.7.3}%
\contentsline {subsection}{\numberline {27.7.4}Evaluation}{674}{subsection.27.7.4}%
\contentsline {subsection}{\numberline {27.7.5}Management}{674}{subsection.27.7.5}%
\contentsline {section}{\numberline {27.8}Calcium Channel Blocker Overdose}{674}{section.27.8}%
\contentsline {subsection}{\numberline {27.8.1}Toxic Dose}{674}{subsection.27.8.1}%
\contentsline {subsection}{\numberline {27.8.2}Pathophysiology}{674}{subsection.27.8.2}%
\contentsline {subsection}{\numberline {27.8.3}Symptoms}{674}{subsection.27.8.3}%
\contentsline {subsection}{\numberline {27.8.4}Evaluation}{674}{subsection.27.8.4}%
\contentsline {subsection}{\numberline {27.8.5}Management}{674}{subsection.27.8.5}%
\contentsline {section}{\numberline {27.9}Antidepressants: SSRIs and SNRIs}{675}{section.27.9}%
\contentsline {subsection}{\numberline {27.9.1}Toxicity}{675}{subsection.27.9.1}%
\contentsline {subsection}{\numberline {27.9.2}Pathophysiology}{675}{subsection.27.9.2}%
\contentsline {subsection}{\numberline {27.9.3}Symptoms}{675}{subsection.27.9.3}%
\contentsline {subsection}{\numberline {27.9.4}Evaluation}{675}{subsection.27.9.4}%
\contentsline {subsection}{\numberline {27.9.5}Management}{675}{subsection.27.9.5}%
\contentsline {section}{\numberline {27.10}Antidepressants: TCAs}{675}{section.27.10}%
\contentsline {subsection}{\numberline {27.10.1}Toxic Dose}{675}{subsection.27.10.1}%
\contentsline {subsection}{\numberline {27.10.2}Pathophysiology}{675}{subsection.27.10.2}%
\contentsline {subsection}{\numberline {27.10.3}Symptoms}{676}{subsection.27.10.3}%
\contentsline {subsection}{\numberline {27.10.4}Evaluation}{676}{subsection.27.10.4}%
\contentsline {subsection}{\numberline {27.10.5}Management}{676}{subsection.27.10.5}%
\contentsline {section}{\numberline {27.11}Antidepressants: Buproprion}{676}{section.27.11}%
\contentsline {subsection}{\numberline {27.11.1}Toxic Dose}{676}{subsection.27.11.1}%
\contentsline {subsection}{\numberline {27.11.2}Pathophysiology}{676}{subsection.27.11.2}%
\contentsline {subsection}{\numberline {27.11.3}Symptoms}{676}{subsection.27.11.3}%
\contentsline {subsection}{\numberline {27.11.4}Evaluation}{676}{subsection.27.11.4}%
\contentsline {subsection}{\numberline {27.11.5}Management}{677}{subsection.27.11.5}%
\contentsline {section}{\numberline {27.12}Iron}{677}{section.27.12}%
\contentsline {subsection}{\numberline {27.12.1}Toxic Dose}{677}{subsection.27.12.1}%
\contentsline {subsection}{\numberline {27.12.2}Pathophysiology}{677}{subsection.27.12.2}%
\contentsline {subsection}{\numberline {27.12.3}Symptoms}{677}{subsection.27.12.3}%
\contentsline {subsection}{\numberline {27.12.4}Evaluation}{678}{subsection.27.12.4}%
\contentsline {subsection}{\numberline {27.12.5}Management}{678}{subsection.27.12.5}%
\contentsline {section}{\numberline {27.13}Lead}{678}{section.27.13}%
\contentsline {subsection}{\numberline {27.13.1}Toxic Dose}{678}{subsection.27.13.1}%
\contentsline {subsection}{\numberline {27.13.2}Pathophysiology}{678}{subsection.27.13.2}%
\contentsline {subsection}{\numberline {27.13.3}Symptoms}{678}{subsection.27.13.3}%
\contentsline {subsection}{\numberline {27.13.4}Evaluation}{679}{subsection.27.13.4}%
\contentsline {subsection}{\numberline {27.13.5}Management}{679}{subsection.27.13.5}%
\contentsline {section}{\numberline {27.14}Drugs of Abuse}{679}{section.27.14}%
\contentsline {subsection}{\numberline {27.14.1}Ethanol}{679}{subsection.27.14.1}%
\contentsline {subsubsection}{\numberline {27.14.1.1}Hx/PE}{679}{subsubsection.27.14.1.1}%
\contentsline {subsubsection}{\numberline {27.14.1.2}Dx}{679}{subsubsection.27.14.1.2}%
\contentsline {subsubsection}{\numberline {27.14.1.3}Management}{679}{subsubsection.27.14.1.3}%
\contentsline {subsection}{\numberline {27.14.2}Marijuana}{679}{subsection.27.14.2}%
\contentsline {subsubsection}{\numberline {27.14.2.1}Hx/PE}{679}{subsubsection.27.14.2.1}%
\contentsline {subsubsection}{\numberline {27.14.2.2}Dx}{680}{subsubsection.27.14.2.2}%
\contentsline {subsubsection}{\numberline {27.14.2.3}Management}{680}{subsubsection.27.14.2.3}%
\contentsline {subsection}{\numberline {27.14.3}Stimulants (Amphetamines, Cocaine, Ecstasy/MDMA, ``Bath Salts'')}{680}{subsection.27.14.3}%
\contentsline {subsubsection}{\numberline {27.14.3.1}Hx/PE}{680}{subsubsection.27.14.3.1}%
\contentsline {subsubsection}{\numberline {27.14.3.2}Dx}{680}{subsubsection.27.14.3.2}%
\contentsline {subsubsection}{\numberline {27.14.3.3}Management}{680}{subsubsection.27.14.3.3}%
\contentsline {subsection}{\numberline {27.14.4}Opioids}{680}{subsection.27.14.4}%
\contentsline {subsubsection}{\numberline {27.14.4.1}Hx/PE}{680}{subsubsection.27.14.4.1}%
\contentsline {subsubsection}{\numberline {27.14.4.2}Dx}{680}{subsubsection.27.14.4.2}%
\contentsline {subsubsection}{\numberline {27.14.4.3}Management}{680}{subsubsection.27.14.4.3}%
\contentsline {subsubsection}{\numberline {27.14.4.4}Notes}{680}{subsubsection.27.14.4.4}%
